

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 December 2005 (15.12.2005)

PCT

(10) International Publication Number
WO 2005/118642 A2

(51) International Patent Classification⁷: **C07K 16/00**
(21) International Application Number:
PCT/GB2005/002163

(22) International Filing Date: 31 May 2005 (31.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/576,271 1 June 2004 (01.06.2004) US
60/632,361 2 December 2004 (02.12.2004) US

(71) Applicant (for all designated States except US): **DOMAN-
TIS LIMITED** [GB/GB]; 315 Cambridge Science Park,
Cambridge CB4 0WG (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOLT, Lucy, J.**
[GB/GB]; 53 Great Eastern Street, Cambridge CB1 3AB
(GB). **TOMLINSON, Ian, M.** [GB/GB]; 13 Tunwells
Lane, Great Shelford, Cambridge CB2 5LJ (GB).

(74) Agents: **LOCK, Graham, James et al.**; Fry Heath &
Spence LLP, The Gables, Massetts Road, Horley, Surrey
RH6 7DQ (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AI, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DRUG COMPOSITIONS, FUSIONS AND CONJUGATES

(57) Abstract: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer *in vivo* half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.

WO 2005/118642 A2

- 1 -

DRUG COMPOSITIONS, FUSIONS AND CONJUGATES

RELATED APPLICATIONS


This application claims the benefit of U.S. Provisional Patent Application No. 60/632,361, filed on December 2, 2004 and the benefit of U.S. Provisional Patent Application No. 60/576,271, filed on June 1, 2004. The entire teachings of the above applications are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Many drugs that possess activities that could be useful for therapeutic and/or diagnostic purposes have limited value because they are rapidly eliminated from the body when administered. For example, many polypeptides that have therapeutically useful activities are rapidly cleared from the circulation via the kidney. Accordingly, a large dose must be administered in order to achieve a desired therapeutic effect. A need exists for improved therapeutic and diagnostic agents that have improved pharmacokinetic properties. Polypeptides that bind serum albumin are known in the art. (See, *e.g.*, EP 0486525 B1 (Cemu Bioteknik AB); US 6,267,964 B1 (Nygren *et al.*); WO 04/001064 A2 (Dyax, Corp.); WO 02/076489 A1 (Dyax, Corp.); WO 01/45746 (Genentech, Inc.).)

SUMMARY OF THE INVENTION

The invention relates to drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) that have improved serum half-lives. In one aspect, the invention is a drug fusion, wherein the drug fusion is a continuous polypeptide chain having the formula:



wherein

X is a polypeptide drug that has binding specificity for a first target;

CONFIRMATION COPY

- 2 -

Y is an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin;

Z is a polypeptide drug that has binding specificity for a second target;

5 a, b, c and d are each independently absent or one to about 100 amino acid residues;

n1 is one to about 10;

n2 is one to about 10; and

n3 is zero to about 10,

10 with the proviso that when n1 and n2 are both one and n3 is zero, X does not comprise an antibody chain or a fragment of an antibody chain.

In some embodiments, Y comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ
15 ID NO:26, or an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In particular embodiments, X is IL-1ra or a functional variant of IL-1ra.

In another aspect, the drug fusion comprises a continuous polypeptide chain,
20 said chain comprising moieties X' and Y', wherein

X' is a polypeptide drug, with the proviso that X' does not comprise an antibody chain or a fragment of an antibody chain; and

Y' is an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain
25 (V_L) that has binding specificity for serum albumin. In some embodiments, Y' comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, or an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17,
30 SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22
~~and SEQ ID NO:23. In particular embodiments, X' is IL-1ra or a functional variant~~
of IL-1ra.

- 3 -

In another aspect, the invention is a drug conjugate comprising an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin, and a drug that is covalently bonded to said V_H or V_L . In some embodiments, the immunoglobulin heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, or an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In particular embodiments, the drug is IL-1ra or a functional variant of IL-1ra.

In another aspect, the invention is a noncovalent drug conjugate comprising an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin, and a drug that is noncovalently bonded to said V_H or V_L . In some embodiments, the immunoglobulin heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, or an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

The invention also provides recombinant nucleic acids and constructs that encode the drug fusions described herein, and host cells that comprise the recombinant nucleic acids and/or constructs. The invention further provides a method for producing a drug fusion comprising maintaining a host cell that comprises a recombinant nucleic acid and/or construct that encodes a drug fusion described herein under conditions suitable for expression of said recombinant nucleic acid, whereby a drug fusion is produced.

~~The invention also provides compositions (e.g., pharmaceutical~~
compositions) comprising a drug composition (e.g., drug conjugate, noncovalent

- 4 -

drug conjugate, drug fusion) of the invention. The invention also provides a method for treating an individual having a disease or disorder, such as those described herein, comprising administering to said individual a therapeutically effective amount of a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) of the invention. In some embodiments, the disease or disorder is an inflammatory disease, such as arthritis (*e.g.*, rheumatoid arthritis). The invention also provides for use of a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) of the invention for the manufacture of a medicament for treatment of a disease or disorder, such as an inflammatory disease (*e.g.*, arthritis (*e.g.*, rheumatoid arthritis)). The invention also relates to a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) as described herein for use in therapy, diagnosis or prophylaxis.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is an alignment of the amino acid sequences of three V_Ks selected by binding to mouse serum albumin (MSA). The aligned amino acid sequences are from V_Ks designated MSA16, which is also referred to as DOM7m-16 (SEQ ID NO:1), MSA 12, which is also referred to as DOM7m-12 (SEQ ID NO:2), and MSA 26, which is also referred to as DOM7m-26 (SEQ ID NO:3).

FIG. 1B is an alignment of the amino acid sequences of six V_Ks selected by binding to rat serum albumin (RSA). The aligned amino acid sequences are from V_Ks designated DOM7r-1 (SEQ ID NO:4), DOM7r-3 (SEQ ID NO:5), DOM7r-4 (SEQ ID NO:6), DOM7r-5 (SEQ ID NO:7), DOM7r-7 (SEQ ID NO:8), and DOM7r-8 (SEQ ID NO:9).

FIG. 1C is an alignment of the amino acid sequences of six V_Ks selected by binding to human serum albumin (HSA). The aligned amino acid sequences are from V_Ks designated DOM7h-2 (SEQ ID NO:10), DOM7h-3 (SEQ ID NO:11), DOM7h-4 (SEQ ID NO:12), DOM7h-6 (SEQ ID NO:13), DOM7h-1 (SEQ ID NO:14), and DOM7h-7 (SEQ ID NO:15).

FIG. 1D is an alignment of the amino acid sequences of seven V_Hs selected by binding to human serum albumin and a consensus sequence (SEQ ID NO:23).

The aligned sequences are from V_Hs designated DOM7h-22 (SEQ ID NO:16),

- 5 -

DOM7h-23 (SEQ ID NO:17), DOM7h-24 (SEQ ID NO:18), DOM7h-25 (SEQ ID NO:19), DOM7h-26 (SEQ ID NO:20), DOM7h-21 (SEQ ID NO:21), and DOM7h-27 (SEQ ID NO:22).

FIG. 1E is an alignment of the amino acid sequences of three V_κs selected by binding to human serum albumin and rat serum albumin. The aligned amino acid sequences are from V_κs designated DOM7h-8 (SEQ ID NO:24), DOM7r-13 (SEQ ID NO:25), and DOM7r-14 (SEQ ID NO:26).

FIG. 2A and 2B are schematics maps of the vectors used to express the MSA16IL-1ra (also referred to as DOM7m-16/IL-1ra) and IL-1raMSA16 (also referred to as IL-1ra/DOM7m-16) fusions, respectively.

FIG. 2C-2D is an illustration of the nucleotide sequence (SEQ ID NO:27) encoding the IL-1raMSA16 fusion (also referred to as IL-1ra/DOM7m-16) and of the amino acid sequence (SEQ ID NO:28) of the fusion.

FIG. 2E-2F is an illustration of the nucleotide sequence (SEQ ID NO:29) encoding the MSA16IL-1ra fusion (also referred to as DOM7m-16/IL-1ra) and of the amino acid sequence (SEQ ID NO:30) of the fusion.

FIG. 2G-2H is an illustration of the nucleotide sequence (SEQ ID NO:31) encoding the DummyIL-1ra fusion that did not bind serum albumin, and of the amino acid sequence (SEQ ID NO:32) of the fusion.

FIG. 3A is an illustration showing that IL-1 induces the production of IL-8 by HeLa cells, and showing the mechanism by which IL-8 is detected in an ELISA assay.

FIG. 3B is a graph showing that IL-1ra (, labeled "R&D"), MSA16IL-1ra () and IL-1raMSA16 () each inhibited IL-1-induced secretion of IL-8 by cultured MRC-5 cells. The observed inhibition was dose dependent for IL-1ra, MSA16IL-1ra and IL-1raMSA16.

FIGS. 4A-4C are graphs showing that IL-1ra () and MSA16IL-1ra () both inhibited IL-1-induced secretion of IL-8 by cultured MRC-5 cells in assays that included no mouse serum albumin (4A), 5% mouse serum albumin (4B) or 10% mouse serum albumin (4C). The observed inhibition was dose dependent for IL-1ra and MSA16IL-1ra under all conditions tested.

- 6 -

FIG. 5 is a schematic presentation of the results of an ELISA demonstrating that the MSA16IL1-ra fusion and the IL-1raMSA16 fusion both bound serum albumin, but the dummyIL1-ra fusion did not.

FIGS. 6A-6C are sensograms and tables showing BIAcore affinity data for clone DOM7h-1 binding to human serum albumin (HSA) (6A), DOM7h-7 binding to HSA (6B) and DOM7r-1 binding to rat serum albumin (RSA) (6C).

FIG. 7 is a table showing the affinities of DOM7h-1, DOM7r-1, DOM7h-2, DOM7r-3, DOM7h-7, DOM7h-8, DOM7r-8, DOM7r-13, DOM7r-14, DOM7m-16, DOM7h-22, DOM7h-23, DOM7h-26, DOM7r-16, DOM7m-26, DOM7r-27 and DOM7R-31 for the serum albumins that they bind. DOM7h-8 also binds porcine serum albumin with an affinity (KD) of 60 nM.

FIG. 8A is an illustration of the nucleotide sequence (SEQ ID NO:33) of a nucleic acid encoding human interleukin 1 receptor antagonist (IL-1ra) deposited in GenBank under accession number NM_173842. The nucleic acid has an open reading frame starting at position 65.

FIG. 8B is an illustration of the amino acid sequence of human IL-1ra (SEQ ID NO:34) encoded by the nucleic acid shown in FIG. 8A (SEQ ID NO:33). The mature protein consists of 152 amino acid residues (amino acid residues 26-177 of SEQ ID NO:34).

FIG. 9 is a graph showing the concentration ($\mu\text{g/mL}$) of MSA binding dAb/HA epitope tag fusion protein in mouse serum following a single intravenous (i.v.) injection (dose was about 1.5 mg/kg) into CD1 strain male animals over time (days). Serum concentration was determined by ELISA using goat anti-HA (Abcam, UK) capture and protein L-HRP (Invitrogen, USA) detection reagents. Standard curves of known concentrations of MSA binding dAb/HA fusion were set up in the presence of 1x mouse serum to ensure comparability with the test samples. Modelling with a 1 compartment model (WinNonlin Software, Pharsight Corp., USA) showed the MSA binding dAb/HA epitope tag fusion protein had a terminal phase $t_{1/2}$ of 29.1 hours and an area under the curve of 559 hr $\mu\text{g/mL}$.

FIG. 10 is an illustration of the amino acid sequences of Vks selected by binding to rat serum albumin (RSA). The illustrated sequences are from Vks

-7-

designated DOM7r-15 (SEQ ID NO:37), DOM7r-16 (SEQ ID NO:38), DOM7r-17 (SEQ ID NO:39), DOM7r-18 (SEQ ID NO:40), DOM7r-19 (SEQ ID NO:41).

FIG. 11A-11B is an illustration of the amino acid sequences of the amino acid sequences of V_{HS} that bind rat serum albumin (RSA). The illustrated sequences are from V_{HS} designated DOM7r-20 (SEQ ID NO:42), DOM7r-21 (SEQ ID NO:43), DOM7r-22 (SEQ ID NO:44), DOM7r-23 (SEQ ID NO:45), DOM7r-24 (SEQ ID NO:46), DOM7r-25 (SEQ ID NO:47), DOM7r-26 (SEQ ID NO:48), DOM7r-27 (SEQ ID NO:49), DOM7r-28 (SEQ ID NO:50), DOM7r-29 (SEQ ID NO:51), DOM7r-30 (SEQ ID NO:52), DOM7r-31 (SEQ ID NO:53), DOM7r-32 (SEQ ID NO:54), and DOM7r-33 (SEQ ID NO:55).

FIG. 12 is a graph showing the concentration (% initial dose) of DOM7m-16, DOM7m-26 or a control dAb that does not bind MSA, each of which contained an HA epitope tag, in mouse serum following a single intravenous (i.v.) injection (dose was about 1.5 mg/kg) into CD1 strain male animals over time. Serum concentration was determined by ELISA using goat anti-HA (Abcam, UK) capture and protein L-HRP (Invitrogen, USA) detection reagents. Standard curves of known concentrations of MSA binding dAb/HA fusion were set up in the presence of 1x mouse serum to ensure comparability with the test samples. Modelling with a 1 compartment model (WinNonlin Software, Pharsight Corp., USA) showed control dAb had a terminal phase t_{1/2β} of 20 minutes, while DOM7m-16, DOM7m-26 persisted in serum significantly longer.

FIG. 13 is a graph showing that DOM7m-16/IL-1ra was more effective than IL-1ra or ENBREL® (entarecept; Immunex Corporation) in treating arthritis in a mouse collagen-induced arthritis (CIA) model. Arthritis was induced and, beginning on day 21, mice were treated with Dexamethasone at 0.4 mg/Kg (Steroid), DOM7m-16/IL-1ra at 1 mg/Kg (IL-1ra/anti-SA 1mg/kg) or 10 mg/Kg (IL-1ra/anti-SA 10 mg/kg), IL-1ra at 1 mg/Kg or 10 mg/Kg, ENBREL® (entarecept; Immunex Corporation) at 5 mg/Kg, or saline. The results show that DOM7m-16/IL-1ra was more effective than IL-1ra or ENBREL® (entarecept; Immunex Corporation) in this study. The response to IL-1ra was dose dependent, as expected, and that the response to DOM7m-16/IL-1ra was also dose dependent. The average scores for treatment with DOM7m-16/IL-1ra at 1 mg/Kg were consistently lower than the

average scores obtained by treatment with IL-1ra at 10 mg/kg. The results indicate that treatment with DOM7m-16/IL-1ra was 10 times more effective than IL-1ra in this study.

FIGS. 14A-14G illustrate the amino acid sequences of saporin polypeptides.

- 5 FIG. 14A illustrates the amino acid sequence of saporin-2 precursor deposited as Swissprot Accession Number P27559 (SEQ ID NO:60). The signal peptide is amino acids 1-24 of SEQ ID NO:60. FIG. 14B illustrates the amino acid sequence of saporin-3 deposited as Swissprot Accession Number P27560 (SEQ ID NO:61). FIG. 14C illustrates the amino acid sequence of saporin-4 precursor deposited as
- 10 Swissprot Accession Number P27561 (SEQ ID NO:62). The signal peptide is amino acids 1-24 of SEQ ID NO:62. FIG. 14D illustrates the amino acid sequence of saporin-5 deposited as Swissprot Accession Number Q41389 (SEQ ID NO:63). FIG. 14E illustrates the amino acid sequence of saporin-6 precursor deposited as Swissprot Accession Number P20656 (SEQ ID NO:64). The signal peptide is
- 15 amino acids 1-24 of SEQ ID NO:64, and a potential propeptide is amino acids 278-299 of SEQ ID NO:64. The mature polypeptide is amino acids 25-277 of SEQ ID NO:64 (SEQ ID NO:65). FIG. 14F illustrates the amino acid sequence of saporin-7 deposited as Swissprot Accession Number Q41391 (SEQ ID NO:66). FIG. 14G illustrates a consensus amino acid sequence encompassing several variants and
- 20 isoforms of saporin-6 (SEQ ID NO:67).

- FIG. 15 illustrates the amino acid sequences of several *Camelid* V_{HHS} that bind mouse serum albumin that are disclosed in WO 2004/041862. Sequence A (SEQ ID NO:72), Sequence B (SEQ ID NO:73), Sequence C (SEQ ID NO:74), Sequence D (SEQ ID NO:75), Sequence E (SEQ ID NO:76), Sequence F (SEQ ID
- 25 NO:77), Sequence G (SEQ ID NO:78), Sequence H (SEQ ID NO:79), Sequence I (SEQ ID NO:80), Sequence J (SEQ ID NO:81), Sequence K (SEQ ID NO:82), Sequence L (SEQ ID NO:83), Sequence M (SEQ ID NO:84), Sequence N (SEQ ID NO:85), Sequence O (SEQ ID NO:86), Sequence P (SEQ ID NO:87), Sequence Q (SEQ ID NO:88).

- 9 -

DETAILED DESCRIPTION OF THE INVENTION

Within this specification embodiments have been described in a way which enables a clear and concise specification to be written, but it is intended and will be appreciated that embodiments may be variously combined or separated without
5 parting from the invention.

Known compositions of matter having a structural formula identical to any one of the embodiments of the invention are explicitly disclaimed per se. In contrast, novel compositions of matter, novel combinations of the known compositions, novel uses of the known compositions or novel methods involving the
10 known compositions are not disclaimed.

As used herein, "drug" refers to any compound (*e.g.*, small organic molecule, nucleic acid, polypeptide) that can be administered to an individual to produce a beneficial therapeutic or diagnostic effect through binding to and/or altering the function of a biological target molecule in the individual. The target molecule can
15 be an endogenous target molecule encoded by the individual's genome (*e.g.*, an enzyme, receptor, growth factor, cytokine encoded by the individual's genome) or an exogenous target molecule encoded by the genome of a pathogen (*e.g.*, an enzyme encoded by the genome of a virus, bacterium, fungus, nematode or other pathogen).

As used herein, "drug composition" refers to a composition comprising a drug that is covalently or noncovalently bonded to a polypeptide binding moiety, wherein the polypeptide binding moiety contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. The drug composition can be a conjugate wherein the drug is covalently
25 or noncovalently bonded to the polypeptide binding moiety. The drug can be covalently or noncovalently bonded to the polypeptide binding moiety directly or indirectly (*e.g.*, through a suitable linker and/or noncovalent binding of complementary binding partners (*e.g.*, biotin and avidin)). When complementary binding partners are employed, one of the binding partners can be covalently bonded
30 to the drug directly or through a suitable linker moiety, and the complementary binding partner can be covalently bonded to the polypeptide binding moiety directly or through a suitable linker moiety. When the drug is a polypeptide or peptide, the

drug composition can be a fusion protein, wherein the polypeptide or peptide drug and the polypeptide binding moiety are discrete parts (moieties) of a continuous polypeptide chain.

As used herein "conjugate" refers to a composition comprising an antigen-binding fragment of an antibody that binds serum albumin that is bonded to a drug. Such conjugates include "drug conjugates," which comprise an antigen-binding fragment of an antibody that binds serum albumin to which a drug is covalently bonded, and "noncovalent drug conjugates," which comprise an antigen-binding fragment of an antibody that binds serum albumin to which a drug is noncovalently bonded.

As used herein, "drug conjugate" refers to a composition comprising an antigen-binding fragment of an antibody that binds serum albumin to which a drug is covalently bonded. The drug can be covalently bonded to the antigen-binding fragment directly or indirectly through a suitable linker moiety. The drug can be bonded to the antigen-binding fragment at any suitable position, such as the amino-terminus, the carboxyl-terminus or through suitable amino acid side chains (*e.g.*, the ϵ amino group of lysine).

As used herein, "noncovalent drug conjugate" refers to a composition comprising an antigen-binding fragment of an antibody that binds serum albumin to which a drug is noncovalently bonded. The drug can be noncovalently bonded to the antigen-binding fragment directly (*e.g.*, electrostatic interaction, hydrophobic interaction) or indirectly (*e.g.*, through noncovalent binding of complementary binding partners (*e.g.*, biotin and avidin), wherein one partner is covalently bonded to drug and the complementary binding partner is covalently bonded to the antigen-binding fragment). When complementary binding partners are employed, one of the binding partners can be covalently bonded to the drug directly or through a suitable linker moiety, and the complementary binding partner can be covalently bonded to the antigen-binding fragment of an antibody that binds serum albumin directly or through a suitable linker moiety.

As used herein, "drug fusion" refers to a fusion protein that comprises an ~~antigen-binding fragment of an antibody that binds serum albumin and a polypeptide~~ drug. The antigen-binding fragment of an antibody that binds serum albumin and

the polypeptide drug are present as discrete parts (moieties) of a single continuous polypeptide chain.

As used herein the term “drug basis” refers to activities of drug compositions and drugs that are normalized based on the amount of drug (or drug moiety) used to assess, measure or determine activity. Generally, the drug compositions of the invention (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) have a larger molecular weight than the drug they contain. Thus, equivalent amounts of drug composition and drug, by weight, will contain different amounts of drug on a molecular or molar basis. For example, if a drug composition of the invention has a molecular weight that is twice the molecular weight of the drug it comprises, activities can be determined on a “drug basis” using 2 μg of drug composition and 1 μg of drug, because these quantities would contain the same amount of drug (as free drug or as part of the drug composition). Activities can be normalized and expressed on a “drug basis” using appropriate calculations, for example, by expressing activity on a per target binding site basis or, for enzyme drugs, on a per active site basis.

As used herein “interleukin 1 receptor antagonist” (IL-1ra) refers to naturally occurring or endogenous mammalian IL-1ra proteins and to proteins having an amino acid sequence which is the same as that of a naturally occurring or endogenous corresponding mammalian IL-1ra protein (*e.g.*, recombinant proteins, synthetic proteins (*i.e.*, produced using the methods of synthetic organic chemistry)). Accordingly, as defined herein, the term includes mature protein, polymorphic or allelic variants, and other isoforms of a IL-1ra (*e.g.*, produced by alternative splicing or other cellular processes), and modified or unmodified forms of the foregoing (*e.g.*, lipidated, glycosylated, PEGylated). Naturally occurring or endogenous IL-1ra include wild type proteins such as mature IL-1ra, polymorphic or allelic variants and other isoforms which occur naturally in mammals (*e.g.*, humans, non-human primates). Such proteins can be recovered or isolated from a source which naturally produces IL-1ra, for example. These proteins and IL-1ra proteins having the same amino acid sequence as a naturally occurring or endogenous corresponding IL-1ra, ~~are referred to by the name of the corresponding mammal. For example, where the~~ corresponding mammal is a human, the protein is designated as a human IL-1ra.

"Functional variants" of IL-1ra include functional fragments, functional mutant proteins, and/or functional fusion proteins which can be produced using suitable methods (e.g., mutagenesis (e.g., chemical mutagenesis, radiation mutagenesis), recombinant DNA techniques). A "functional variant" antagonizes interleukin-1 type 1 receptor. Generally, fragments or portions of IL-1ra include those having a deletion and/or addition (i.e., one or more amino acid deletions and/or additions) of an amino acid (i.e., one or more amino acids) relative to the mature IL-1ra (such as N-terminal, C-terminal or internal deletions). Fragments or portions in which only contiguous amino acids have been deleted or in which non-contiguous amino acids have been deleted relative to mature IL-1ra are also envisioned.

A functional variant of human IL-1ra can have at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with the mature 152 amino acid form of human IL-1ra and antagonize human Interleukin-1 type 1 receptor. (See, Eisenberg *et al.*, *Nature* 343:341-346 (1990).) The variant can comprise one or more additional amino acids (e.g., comprise 153 or 154 or more amino acids). For example, the variant IL-1ra can have an amino acid sequence that consists of an amino-terminal methionine residue followed by residues 26 to 177 of SEQ ID NO:33. (KINERET® (anakinra), Amgen Inc.).

As used herein "saporin" refers to a family of single-chain ribosome-inactivating polypeptides produced by the plant *Saponaria officinalis*. (Stirpe, F., *et al.*, *Biochem. J.* 216:617-625 (1983), Bagga, S. *et al.*, *J. Biol. Chem.* 278:4813-4820 (2003).) Saporin polypeptides exist in several forms that differ in length and/or amino acid sequence. (See, e.g., Id. and Barthelemy, I. *et al.*, *J. Biol. Chem.* 268:6541-6548 (1993).) Saporin-6 is the most active form of saporin. (Bagga, S. *et al.*, *J. Biol. Chem.* 278:4813-4820 (2003).) At least four naturally occurring isoforms of saporin-6 in which the amino acid at position 48 of the mature polypeptide (SEQ ID NO:65) is Asp or Glu, and the amino acid at position 91 of the mature polypeptide (SEQ ID NO:65) is Arg or Lys have been described. (Barthelemy, I. *et al.*, *J. Biol. Chem.* 268:6541-6548 (1993).) Additional forms of

- 13 -

saporin-6 include polypeptides in which the amino acid at position 99 of the mature polypeptide (SEQ ID NO:65) is Ser or Leu; the amino acid at position 134 of the mature polypeptide (SEQ ID NO:65) is Gln or Lys; the amino acid at position 147 of the mature polypeptide (SEQ ID NO:65) is Ser or Leu; the amino acid at position 149 of the mature polypeptide (SEQ ID NO:65) is Ser or Phe; the amino acid at position 162 of the mature polypeptide (SEQ ID NO:65) is Asp or Asn; the amino acid at position 177 of the mature polypeptide (SEQ ID NO:65) is Ala or Val; the amino acid at position 188 of the mature polypeptide (SEQ ID NO:65) is Ile or Thr; the amino acid at position 196 of the mature polypeptide (SEQ ID NO:65) is Asn or Asp; the amino acid at position 198 of the mature polypeptide (SEQ ID NO:65) is Glu or Asp; the amino acid at position 231 of the mature polypeptide (SEQ ID NO:65) is Asn or Ser; and polypeptides in which the amino acid at position 233 of the mature polypeptide (SEQ ID NO:65) is Lys or Arg. (Id.) A consensus sequence encompassing these isoforms and variants is presented in FIG. 14G (SEQ ID NO:67).

Accordingly, the term "saporin" includes precursor protein, mature polypeptide, native protein, polymorphic or allelic variants, and other isoforms (*e.g.*, produced by alternative splicing or other cellular processes), and modified or unmodified forms of the foregoing (*e.g.*, lipidated, glycosylated, PEGylated) including naturally occurring, synthetic or recombinantly produced polypeptides. Naturally occurring or endogenous saporin include wild type proteins such as mature saporin (*e.g.*, mature saporin-6), polymorphic or allelic variants and other isoforms which occur naturally in *Saponaria officinalis*. Such proteins can be recovered or isolated from *Saponaria officinalis* using any suitable methods. "Functional variants" of saporin include functional fragments, functional mutant proteins, and/or functional fusion proteins which can be produced using suitable methods (*e.g.*, mutagenesis (*e.g.*, chemical mutagenesis, radiation mutagenesis), recombinant DNA techniques). Generally, fragments or portions of saporin (*e.g.*, saporin-6) include those having a deletion and/or addition (*i.e.*, one or more amino acid deletions and/or additions) of an amino acid (*i.e.*, one or more amino acids) relative to mature saporin (such as N-terminal, C-terminal or internal deletions). ~~Fragments or~~ portions in which only contiguous amino acids have been deleted or in which non-

- 14 -

contiguous amino acids have been deleted relative to mature saporin are also envisioned. A variety of functional variants of saporin can be prepared. For example, fusion proteins of saporin-6 that contain amino-terminal extensions have been prepared and shown to retain full ribosome-inhibiting activity in rabbit
5 reticulocyte lysate assays. (Barthelemy, I. *et al.*, *J. Biol. Chem.* 268:6541-6548 (1993).) Variants of saporin-6 in which an active site residue, Tyr72, Tyr120, Glu176, Arg 179 or Trp208 (amino acids 72, 120, 176, 179 or 208 of SEQ ID NO:65), was replaced with alanine had reduced cytotoxic activity in *in vitro* assays. (Bagga, S. *et al.*, *J. Biol. Chem.* 278:4813-4820 (2003).) Accordingly, if preparing
10 additional functional variants of saporin is desired, mutation, substitution, replacement, deletion or modification of the active site residues should be avoided. Preferably, a functional variant of saporin that contains fewer amino acids than naturally occurring mature polypeptide includes at least the active site. For example, a variant of saporin-6 that contains fewer amino acids than naturally
15 occurring mature saporin-6 can include the active site residues of mature saporin-6 (Tyr72, Tyr120, Glu176, Arg 179 and Trp208 (amino acids 72, 120, 176, 179 and 208 of SEQ ID NO:65)), and be at least about 137 amino acids in length, at least about 150 amino acids in length, at least about 175 amino acids in length, at least about 200 amino acids in length, at least about 225 amino acids in length or at least
20 about 250 amino acids in length.

A "functional variant" of saporin has ribosome-inactivating activity (*e.g.*, rRNA N-Glycosidase activity) and/or cytotoxic activity. Such activity can readily be assessed using any suitable method, such as inhibition of protein synthesis using the well-known rabbit reticulocyte lysate assay or any of the well-known
25 cytotoxicity assays that employ tumor cell lines. (See, *e.g.*, Bagga, S. *et al.*, *J. Biol. Chem.* 278:4813-4820 (2003) and Barthelemy, I. *et al.*, *J. Biol. Chem.* 268:6541-6548 (1993).)

In some embodiments, a functional variant of saporin has at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least about
30 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with mature saporin-6 (SEQ ID NO:65).

- 15 -

The invention relates to drug compositions that comprise a drug and a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. As described herein in detail with respect to drug compositions that comprise an antigen-binding fragment of an antibody that has binding specificity for serum albumin, the drug and the polypeptide binding moiety can be bonded to each other covalently or noncovalently. In some embodiments, the drug composition is a fusion protein that comprises a polypeptide drug and a polypeptide binding moiety that contains an antigen-binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. In other embodiments, the drug composition comprises a drug that is covalently or noncovalently bonded to a polypeptide binding moiety that contains an antigen-binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*.

Typically, a polypeptide that enhances serum half-life *in vivo* is a polypeptide which occurs naturally *in vivo* and which resists degradation or removal by endogenous mechanisms which remove unwanted material from the organism (*e.g.*, human). For example, a polypeptide that enhances serum half-life *in vivo* can be selected from proteins from the extracellular matrix, proteins found in blood, proteins found at the blood brain barrier or in neural tissue, proteins localized to the kidney, liver, lung, heart, skin or bone, stress proteins, disease-specific proteins, or proteins involved in Fc transport.

Suitable polypeptides that enhance serum half-life *in vivo* include, for example, transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins (see U.S. Patent No. 5,977,307, the teachings of which are incorporated herein by reference), brain capillary endothelial cell receptor, transferrin, transferrin receptor (*e.g.*, soluble transferrin receptor), insulin, insulin-like growth factor 1 (IGF 1) receptor, insulin-like growth factor 2 (IGF 2) receptor, insulin receptor, blood coagulation factor X, α 1-antitrypsin and HNF 1 α . Suitable polypeptides that enhance serum half-life also include alpha-1 glycoprotein (orosomucoid; AAG), alpha-1 antichymotrypsin (ACT), alpha-1 microglobulin (protein HC; AIM), antithrombin III (AT III), apolipoprotein A-1 (Apo A-1), apolipoprotein B (Apo B), ceruloplasmin (Cp), complement component C3 (C3), complement component C4

(C4), C1 esterase inhibitor (C1 INH), C-reactive protein (CRP), ferritin (FER), hemopexin (HPX), lipoprotein(a) (Lp(a)), mannose-binding protein (MBP), myoglobin (Myo), prealbumin (transthyretin; PAL), retinol-binding protein (RBP), and rheumatoid factor (RF).

5 Suitable proteins from the extracellular matrix include, for example, collagens, laminins, integrins and fibronectin. Collagens are the major proteins of the extracellular matrix. About 15 types of collagen molecules are currently known, found in different parts of the body, e.g. type I collagen (accounting for 90% of body collagen) found in bone, skin, tendon, ligaments, cornea, internal organs or type II
10 collagen found in cartilage, vertebral disc, notochord, and vitreous humor of the eye.

 Suitable proteins from the blood include, for example, plasma proteins (*e.g.*, fibrin, α -2 macroglobulin, serum albumin, fibrinogen (*e.g.*, fibrinogen A, fibrinogen B), serum amyloid protein A, haptoglobin, profilin, ubiquitin, uteroglobulin and β -2-microglobulin), enzymes and enzyme inhibitors (*e.g.*, plasminogen, lysozyme,
15 cystatin C, alpha-1-antitrypsin and pancreatic trypsin inhibitor), proteins of the immune system, such as immunoglobulin proteins (*e.g.*, IgA, IgD, IgE, IgG, IgM, immunoglobulin light chains (kappa/lambda)), transport proteins (*e.g.*, retinol binding protein, α -1 microglobulin), defensins (*e.g.*, beta-defensin 1, neutrophil defensin 1, neutrophil defensin 2 and neutrophil defensin 3) and the like.

20 Suitable proteins found at the blood brain barrier or in neural tissue include, for example, melanocortin receptor, myelin, ascorbate transporter and the like.

 Suitable polypeptides that enhances serum half-life *in vivo* also include proteins localized to the kidney (*e.g.*, polycystin, type IV collagen, organic anion transporter Kl, Heymann's antigen), proteins localized to the liver (*e.g.*, alcohol
25 dehydrogenase, G250), proteins localized to the lung (*e.g.*, secretory component, which binds IgA), proteins localized to the heart (*e.g.*, HSP 27, which is associated with dilated cardiomyopathy), proteins localized to the skin (*e.g.*, keratin), bone specific proteins such as morphogenic proteins (BMPs), which are a subset of the transforming growth factor β superfamily of proteins that demonstrate osteogenic
30 activity (*e.g.*, BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8), tumor specific proteins (~~*e.g.*, trophoblast antigen, herceptin receptor, oestrogen receptor, cathepsins~~
(*e.g.*, cathepsin B, which can be found in liver and spleen)).

Suitable disease-specific proteins include, for example, antigens expressed only on activated T-cells, including LAG-3 (lymphocyte activation gene), osteoprotegerin ligand (OPGL; see *Nature* 402, 304-309 (1999)), OX40 (a member of the TNF receptor family, expressed on activated T cells and specifically up-regulated in human T cell leukemia virus type-I (HTLV-I)-producing cells; see *Immunol.* 165 (1):263-70 (2000)). Suitable disease-specific proteins also include, for example, metalloproteases (associated with arthritis/cancers) including CG6512 *Drosophila*, human paraplegin, human FtsH, human AFG3L2, murine ftsH; and angiogenic growth factors, including acidic fibroblast growth factor (FGF-1), basic fibroblast growth factor (FGF-2), vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), transforming growth factor- α (TGF α), tumor necrosis factor- α (TNF- α), angiogenin, interleukin-3 (IL-3), interleukin-8 (IL-8), platelet-derived endothelial growth factor (PD-ECGF), placental growth factor (PlGF), midkine platelet-derived growth factor-BB (PDGF), and fractalkine.

Suitable polypeptides that enhance serum half-life *in vivo* also include stress proteins such as heat shock proteins (HSPs). HSPs are normally found intracellularly. When they are found extracellularly, it is an indicator that a cell has died and spilled out its contents. This unprogrammed cell death (necrosis) occurs when as a result of trauma, disease or injury, extracellular HSPs trigger a response from the immune system. Binding to extracellular HSP can result in localizing the compositions of the invention to a disease site.

Suitable proteins involved in Fc transport include, for example, Brambell receptor (also known as FcRB). This Fc receptor has two functions, both of which are potentially useful for delivery. The functions are (1) transport of IgG from mother to child across the placenta (2) protection of IgG from degradation thereby prolonging its serum half-life. It is thought that the receptor recycles IgG from endosomes. (See, Holliger *et al*, *Nat Biotechnol* 15(7):632-6 (1997).)

The drug compositions of the invention can comprise any polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. Preferably, the polypeptide binding moiety comprises at least 31, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80 amino acids, at

least about 90 amino acids, at least about 100 amino acids or at least about 110 amino acids as a separate molecular entity. Preferably, the polypeptide binding moiety binds a polypeptide that enhances serum half-life *in vivo* with a KD of at least about 5 mM KD ($KD = K_{off}(kd)/K_{on}(ka)$). In some embodiments, the

5 polypeptide binding moiety binds a polypeptide that enhances serum half-life *in vivo* with a KD of about 10 to about 100 nM, or about 100 nM to about 500 nM, or about 500 nM to about 5 mM, as determined by surface plasmon resonance (e.g., using a BIACORE instrument). In particular embodiments, the polypeptide binding moiety binds a polypeptide that enhances serum half-life *in vivo* with a KD of about 50 nM,

10 or about 70 nM, or about 100 nM, or about 150 nM or about 200 nM.

Preferably, the polypeptide binding moiety that contains a binding site (e.g., an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo* is not a prokaryotic or bacterial polypeptide or peptide. Preferably, the polypeptide binding moiety is a eukaryotic, mammalian or human

15 polypeptide or peptide.

In certain embodiments, the polypeptide binding moiety that contains a binding site (e.g., an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo* is a folded protein domain. In other embodiments, the polypeptide binding moiety has a molecular weight of at

20 least about 4 KDa, at least about 4.5 KDa, at least about 5 KDa, at least about 5.5 KDa, at least about 6 KDa, at least about 6.5 KDa, at least about 7 KDa, at least about 7.5 KDa or at least about 8 KDa as a separate molecular entity.

Suitable polypeptide binding moieties that contain a binding site (e.g., an antigen-binding site) that has binding specificity for a polypeptide that enhances

25 serum half-life *in vivo* can be identified using any suitable method, such as by screening naturally occurring or non-naturally occurring polypeptides in a suitable adhesion assay. As described herein, preferred polypeptide binding moieties that have an antigen-binding site for a polypeptide that enhances serum half-life *in vivo* are antigen-binding fragments of antibodies that have binding specificity for serum

30 albumin. However, antigen-binding fragments of antibodies that have binding specificity for other polypeptides that enhance serum half-life *in vivo* can be used in the invention.

If desired, one or more of the complementarity determining regions (CDRs) of an antibody or antigen-binding fragment thereof that binds a polypeptide that enhances serum half-life *in vivo* can be formatted into a non-immunoglobulin structure that retains the antigen-binding specificity of the antibody or antigen-binding fragment. The drug compositions of the invention can comprise such a non-immunoglobulin binding moiety. Such non-immunoglobulin binding moieties can be prepared using any suitable method, for example natural bacterial receptors such as SpA have been used as scaffolds for the grafting of CDRs to generate polypeptide binding moieties which specifically bind an epitope. Details of this procedure are described in U.S. Patent Application No. 5,831,012, the teachings of which are incorporated herein by reference. Other suitable scaffolds include those based on fibronectin and affibodies. Details of suitable procedures are described in WO 98/58965. Other suitable scaffolds include lipocalin and CTLA4, as described in van den Beuken *et al.*, *J. Mol. Biol.* 310:591-601 (2001), and scaffolds such as those described in WO 00/69907 (Medical Research Council), which are based for example on the ring structure of bacterial GroEL or other chaperone polypeptides.

In some embodiments, the drug composition of the invention comprises a non-immunoglobulin binding moiety that has binding specificity for serum albumin, wherein the non-immunoglobulin binding moiety comprises one, two or three of the CDRs of a V_H , V_K or V_{HH} described herein and a suitable scaffold. In certain embodiments, the non-immunoglobulin binding moiety comprises CDR3 but not CDR1 or CDR2 of a V_H , V_K or V_{HH} described herein and a suitable scaffold. In other embodiments, the non-immunoglobulin binding moiety comprises CDR1 and CDR2, but not CDR3 of a V_H , V_K or V_{HH} described herein and a suitable scaffold. In other embodiments, the non-immunoglobulin binding moiety comprises CDR1, CDR2 and CDR3 of a V_H , V_K or V_{HH} described herein and a suitable scaffold. In other embodiments, the drug composition comprises only CDR3 of a V_H , V_K or V_{HH} described herein and a drug.

The drug compositions of the invention can be prepared using suitable methods, such as the methods described herein for preparation of drug fusions, drug conjugates and noncovalent drug conjugates. Additionally, the drug compositions of

- 20 -

the invention have the advantages and the utilities that are described in detail herein with respect to drug fusions, drug conjugates and noncovalent drug conjugates.

The invention provides drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) that have improved pharmacokinetic properties (*e.g.*, increase serum half-life) and other advantages in comparison to the drug alone (unconjugated drug, unfused drug). The drug conjugates, noncovalent drug conjugates and drug fusions comprise an antigen-binding fragment of an antibody that has binding specificity for serum albumin and one or more desired drugs.

As described herein, drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) of the invention can have dramatically prolonged *in vivo* serum half-life and/or increased AUC, as compared to drug alone. In addition, the activity of the drug is generally not substantially altered in the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion). However, some change in the activity of a drug composition compared to drug alone is acceptable and is generally compensated for by the improved pharmacokinetic properties of the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion). For example, drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) may bind the drug target with lower affinity than drug alone, but have about equivalent or superior efficacy in comparison to drug alone due to the improved pharmacokinetic properties (*e.g.*, prolonged *in vivo* serum half-life, larger AUC) of the drug composition. In addition, lower amounts of drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates and drug fusions) can be administered to achieve the desired therapeutic or diagnostic effect. Preferably the activity of the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) differs from that of the drug alone by a factor of no more than about 100, or no more than about 50, or no more than about 10, or no more than about 5, or no more than about 4, or no more than about 3, or no more than about 2. For example, a drug can have a K_D , K_i or neutralizing dose 50 (ND50) of 1 nM, and a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) ~~can have a K_D , K_i or ND50 of about 2 nM, or about 3 nM, or about 4 nM, or about 5 nM, or about 10 nM.~~

Preferably, the activity of the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) is not substantially reduced as compared to the activity of the drug. In certain embodiments, the activity of the drug composition is reduced, relative to the activity of drug, by no more than about 10%,
5 no more than about 9%, no more than about 8%, no more than about 7%, no more than about 6%, no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1% or is substantially unchanged. Alternatively stated, the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) retains at least about 90%, at least about 91%, at least about
10 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% of the activity of the drug, or substantially the same activity as the drug. Preferably, the activity of drug compositions (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) and drugs are determined and/or compared on a "drug basis."

15 As described and shown herein, the drug compositions (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) of the invention can have greater activity (*e.g.*, *in vivo* activity) than drug alone. For example, as shown in Example 6, DOM7m-16/IL-1ra was more effective in treating arthritis in a mouse model than IL-1ra when these agents were administered at the same dose by weight (10 mg/Kg
20 or 1 mg/Kg). DOM7m-16/IL-1ra was more effective even though its molecular weight is approximately twice the molecular weight of IL-1ra. Thus, mice that received DOM7m-16/IL-1ra received only about half of the IL-1ra (as a moiety in DOM7m-16/IL1-ra) as mice that received IL-1ra.

In certain embodiments, the drug composition (*e.g.*, drug conjugate,
25 noncovalent drug conjugate, drug fusion) has greater activity (*e.g.*, *in vivo* activity) than drug, for example, the drug composition can have at least about 100%, at least about 150%, at least about 200%, at least about 250%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, or at least about 500% of the activity of drug. Preferably, the activity of drug compositions (*e.g.*, drug conjugate,
30 noncovalent drug conjugate, drug fusion) and drugs are determined and/or compared on a "drug basis." The activity of drug compositions (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) and drugs can be determined using a

- 22 -

suitable *in vitro* or *in vivo* system. In certain embodiments, a drug composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) has greater activity than the drug it comprises, as determined *in vivo*. In other embodiments, a drug composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) has
5 greater activity than the drug it comprises, as determined *in vitro*.

Drug compositions (e.g., drug conjugates, noncovalent drug conjugates, drug fusions) that comprise a domain antibody (dAb) that has binding specificity for serum albumin provide further advantages. Domain antibodies are very stable, are small relative to antibodies and other antigen-binding fragments of antibodies, can
10 be produced in high yields by expression in *E. coli* or yeast (e.g., *Pichia pastoris*), and as described herein antigen-binding fragments of antibodies that bind serum albumin can be easily selected from libraries of human origin or from any desired species. Accordingly, drug compositions (e.g., drug conjugates, noncovalent drug conjugates, drug fusions) that comprise a dAb that binds serum albumin can be
15 produced more easily than therapeutics that are generally produced in mammalian cells (e.g., human, humanized or chimeric antibodies) and dAbs that are not immunogenic can be used (e.g., a human dAb can be used for a drug fusion or drug conjugate for treating or diagnosing disease in humans).

The immunogenicity of a drug can be reduced when the drug is part of a drug
20 composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) that contains a polypeptide binding moiety that binds serum albumin (e.g., an antigen-binding fragment of an antibody that binds serum albumin). Accordingly, a drug can be less immunogenic (than drug alone) or be substantially non-immunogenic in the context of a drug composition that contains a polypeptide binding moiety that
25 binds serum albumin (e.g., drug conjugate, noncovalent drug conjugate, drug fusion). Thus, such drug compositions (e.g., drug conjugates, noncovalent drug conjugates, drug fusions) can be administered to a subject repeatedly over time with minimal loss of efficacy due to the elaboration of anti-drug antibodies by the subject's immune system.

30 Additionally, the drug compositions (e.g., drug conjugates, noncovalent drug conjugates, drug fusions) described herein can have an enhanced safety profile and fewer side effects than drug alone. For example, as a result of the serum albumin-

- 23 -

binding activity of the antigen-binding fragment of an antibody that has binding specificity for serum albumin, the drug fusions and conjugates (drug conjugate, noncovalent drug conjugate) have enhanced residence time in the vascular circulation. Additionally, the conjugates and drug fusions are substantially unable to cross the blood brain barrier and to accumulate in the central nervous system following systemic administration (*e.g.*, intravascular administration). Accordingly, conjugates (drug conjugate, noncovalent drug conjugate) and drug fusions that contain a drug that has neurological toxicity or undesirable psychotropic effects can be administered with greater safety and reduced side effects in comparison to the drug alone. Similarly, the conjugates (drug conjugate, noncovalent drug conjugate) and drug fusions can have reduced toxicity toward particular organs (*e.g.*, kidney or liver) than drug alone. The conjugates and drug fusions described herein can also be used to sequester a drug or a target that binds a drug (*e.g.*, a toxin) in the vascular circulation, thereby decreasing the effects of the drug or target on tissues (*e.g.*, inhibiting the effects of a toxin).

Suitable methods for pharmacokinetic analysis and determination of *in vivo* half-life are well known in the art. Such methods are described, for example, in *Kenneth, A et al*: Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists, and in *Peters et al*, Pharmacokinetic analysis: A Practical Approach (1996). Reference is also made to "Pharmacokinetics", M Gibaldi & D Perron, published by Marcel Dekker, 2nd Rev. edition (1982), which describes pharmacokinetic parameters such as t_{α} and t_{β} half-lives ($t_{1/2\alpha}$, $t_{1/2\beta}$) and area under curve (AUC).

Half-lives ($t_{1/2\alpha}$ and $t_{1/2\beta}$) and AUC can be determined from a curve of serum concentration of conjugate or fusion against time. The WinNonlin analysis package (available from Pharsight Corp., Mountain View, CA 94040, USA) can be used, for example, to model the curve. In a first phase (the alpha phase) the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) is undergoing mainly distribution in the patient, with some elimination. A second phase (beta phase) is the terminal phase when the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) has been distributed and the serum concentration is decreasing as the drug composition is cleared from the

- 24 -

patient. The t_{α} half-life is the half-life of the first phase and the t_{β} half-life is the half-life of the second phase. Thus, the present invention provides a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) or a composition comprising a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) according to the invention having a t_{α} half-life in the range of 15 minutes or more. In one embodiment, the lower end of the range is 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12 hours. In addition, or alternatively, a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) or composition according to the invention will have a t_{α} half-life in the range of up to and including 12 hours. In one embodiment, the upper end of the range is 11, 10, 9, 8, 7, 6 or 5 hours. An example of a suitable range is 1 to 6 hours, 2 to 5 hours or 3 to 4 hours.

Advantageously, the present invention provides drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) having a t_{β} half-life in the range of 2.5 hours or more. In one embodiment, the lower end of the range is 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours. In some embodiments, the drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) have a t_{β} half-life in the range of up to and including 21 days. In one embodiment, the upper end of the range is 12 hours, 24 hours, 2 days, 3 days, 5 days, 10 days, 15 days or 20 days. In particular embodiments, a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) according to the invention will have a t_{β} half-life in the range 12 to 60 hours. In a further embodiment, it will be in the range 12 to 48 hours. In a further embodiment still, it will be in the range 12 to 26 hours.

In addition, or alternatively to the above criteria, the present invention provides drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) having an AUC value (area under the curve) in the range of 0.01 mg.min/mL or more, or 1 mg.min/mL or more. In one embodiment, the lower end of the range is 0.01, 0.1, 1, 5, 10, 15, 20, 30, 100, 200 or 300 mg.min/mL. In particular embodiments, the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) has an AUC in the range of up to 600 mg.min/mL. In

- 25 -

one embodiment, the upper end of the range is 500, 400, 300, 200, 150, 100, 75 or 50 mg.min/mL. In other embodiments, the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) has an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/mL, 15 to 100 mg.min/mL, 15 to 75 mg.min/mL, 15 to 50 mg.min/mL, 0.01 to 50 mg.min/mL, 0.1 to 50 mg.min/mL, 1 to 50 mg.min/mL, 5 to 50 mg.min/mL, and 10 to 50 mg.min/mL.

The invention relates to drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) that comprise a drug and a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. In preferred embodiments of drug compositions, the polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, has binding specificity for serum albumin.

In some embodiments, the drug composition comprises a drug that is covalently bonded to a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. In these embodiments, the drug can be covalently bonded to the polypeptide binding domain at any suitable position, such as the amino-terminus, the carboxyl-terminus or through suitable amino acid side chains (*e.g.*, the ϵ amino group of lysine).

In other embodiments, the drug composition comprises a drug that is noncovalently bonded to a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*. In such embodiments, the drug can be noncovalently bonded to the antigen-binding fragment directly (*e.g.*, through electrostatic interaction, hydrophobic interaction) or indirectly (*e.g.*, through noncovalent binding of complementary binding partners (*e.g.*, biotin and avidin), wherein one partner is covalently bonded to drug and the complementary binding partner is covalently bonded to the antigen-binding fragment). When complementary binding partners are employed, one of the binding partners can be covalently bonded to the drug directly or through a suitable linker moiety, and the

- 26 -

complementary binding partner can be covalently bonded to the polypeptide binding domain directly or through a suitable linker moiety.

In other embodiments, the drug composition is a fusion protein that comprises a polypeptide binding moiety that contains a binding site (e.g., an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo* and a polypeptide drug. The fusion proteins comprise a continuous polypeptide chain, said chain comprising a polypeptide binding moiety that contains a binding site (e.g., an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo* as a first moiety, and a polypeptide drug as a second moiety, which are present as discrete parts (moieties) of the polypeptide chain. The first and second moieties can be directly bonded to each other through a peptide bond, or linked through a suitable amino acid, or peptide or polypeptide linker. Additional moieties (e.g., third, fourth) and/or linker sequences can be present as appropriate. The first moiety can be in an N-terminal location, C-terminal location or internal relative to the second moiety (i.e., the polypeptide drug). In certain embodiments, the fusion protein comprises one or more one or more polypeptide binding moieties that contain a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo* and one or more polypeptide drug moieties. In these embodiments, the fusion protein can comprise one to about ten (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) polypeptide drug moieties that can be the same or different, and one to about twenty (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 19 or 20) polypeptide binding moieties that contain a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo* that can be the same or different.

The polypeptide binding moieties that contain a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo* and polypeptide drug moieties can be present in any desired location. For example, proceeding from the amino terminus to the carboxyl terminus, the moieties can be present in the following order: one or more polypeptide binding moieties, one or more polypeptide drug moieties, one or more polypeptide binding moieties. In another example, proceeding from the amino terminus to the carboxyl terminus, the moieties can be present in the following order: one or more polypeptide binding moieties,

- 27 -

one or more polypeptide drug moieties, one or more polypeptide binding moieties,
one or more polypeptide drug moieties, one or more polypeptide binding moieties.
As described herein, the polypeptide binding moieties and polypeptide drug moieties
can be directly bonded to each other through a peptide bond, or linked through a
5 suitable amino acid, or peptide or polypeptide linker.

In certain embodiments, the fusion protein is a continuous polypeptide chain
that has the formula (amino-terminal to carboxy-terminal):

10 a-(P)_{n2}-b-(X)_{n1}-c-(Q)_{n3}-d or a-(Q)_{n3}-b-(X)_{n1}-c-(P)_{n2}-d

wherein X is a polypeptide drug;

P and Q are each independently a polypeptide binding moiety that contains a
binding site that has binding specificity for a polypeptide that enhances serum half-
life *in vivo*;

15 a, b, c and d are each independently absent or one to about 100 amino acid
residues;

n₁, n₂ and n₃ represent the number of X, P or Q moieties present,
respectively;

n₁ is one to about 10;

20 n₂ is zero to about 10; and

n₃ is zero to about 10,

with the proviso that both n₂ and n₃ are not zero; and

with the proviso that when n₁ and n₂ are both one and n₃ is zero, X does not
comprise an antibody chain or a fragment of an antibody chain.

25 In some embodiments, n₂ is one, two, three, four, five or six, and n₃ is zero.
In other embodiments, n₃ is one, two, three, four, five or six, and n₂ is zero. In
other embodiments, n₁, n₂ and n₃ are each one.

In certain embodiments, X does not comprises an antibody chain or a
fragment of an antibody chain.

30 In preferred embodiments, P and Q are each independently a polypeptide
binding moiety that has binding specificity for serum albumin.

- 28 -

In particularly preferred embodiments, the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) comprises a polypeptide binding moiety that contains a binding site (*e.g.*, an antigen-binding site) that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, wherein
5 the polypeptide binding domain is an antigen-binding fragment of an antibody that has binding specificity for serum albumin.

The invention also relates to a method is for increasing the *in vivo* serum half-life of a drug, comprising bonding a drug to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances
10 serum half-life *in vivo*, whereby a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) that has a longer *in vivo* serum half-life, relative to drug, is produced.

In some embodiments, the method is for increasing the *in vivo* serum half-life of a drug without substantially reducing the activity of the drug, comprising
15 bonding a drug to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, whereby a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) that has a longer *in vivo* serum half-life relative to said drug, and has at least about 90% of the activity of said drug, is produced.

In other embodiments, the method is for increasing the *in vivo* serum half-life of a drug and reducing the immunogenicity of the drug, comprising bonding a drug to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, whereby a drug composition
20 (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) that has a longer *in vivo* serum half-life relative to drug, and is less immunogenic than said drug, is produced.

In other embodiments, the method is for decreasing the immunogenicity of a drug without substantially reducing the activity of the drug, comprising bonding a drug to a polypeptide binding moiety having a binding site that has binding
30 specificity for a polypeptide that enhances serum half-life *in vivo*, whereby a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) that is

- 29 -

less immunogenic than said drug, and has at least about 90% of the activity of said drug is produced.

In other embodiments, the method is for increasing the *in vivo* serum half-life of a drug, and reducing the immunogenicity of the drug without substantially
5 reducing the activity of the drug, comprising bonding a drug to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, whereby a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) that has a longer *in vivo* serum half-life relative to said drug, is less immunogenic than said drug, and has at least
10 about 90% of the activity of said drug is produced.

The drug and the polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo* can be bonded via a covalent bond (*e.g.*, peptide bond) or noncovalent bond, with or without the use of linkers, as described herein. In some embodiments, the drug and
15 the polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo* are bonded via a covalent bond. For example, the drug composition produced is a drug conjugate or drug fusion. In other embodiments, the drug and the polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in*
20 *vivo* are bonded via a noncovalent bond, and the drug composition is a noncovalent drug conjugate.

The drug composition produced using the method can have greater activity (*e.g.*, *in vivo* activity) than the drug. In some embodiments, the method is for producing a drug composition that has greater activity (*e.g.*, *in vivo* activity) than
25 drug alone, comprising bonding a drug to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, whereby a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) that has greater activity, relative to drug, is produced. In such embodiments, preferably, the activity of the drug composition is greater than
30 the activity of the drug as described herein.

~~In preferred embodiments, the polypeptide binding moiety has binding~~
specificity for serum albumin. In particularly preferred embodiments, the

- 30 -

polypeptide binding moiety is an antigen-binding fragment of an antibody that has binding specificity for serum albumin.

In certain embodiments, the method comprises selecting said polypeptide binding moiety from one or more polypeptides (*e.g.*, antigen-binding fragments of an antibody that has binding specificity for serum albumin), wherein the selected
5 polypeptide binding moiety binds a polypeptide that enhances serum half-life *in vivo* with a KD of at least about 5 mM.

The invention also relates to use of a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-
10 life *in vivo* for the manufacture of medicament, the medicament comprising a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) in which a drug is bonded to said polypeptide binding moiety, for increasing *in vivo* serum half-life of the drug.

In some embodiments, the use is for the manufacture of a medicament, the
15 medicament comprising a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) in which a drug is bonded to said polypeptide binding moiety, for increasing *in vivo* serum half-life of the drug without reducing the activity of the drug by more than about 10%.

In other embodiments, the use is for the manufacture of a medicament, the
20 medicament comprising a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) in which a drug is bonded to said polypeptide binding moiety, for increasing *in vivo* serum half-life of the drug and reducing the immunogenicity of the drug.

In other embodiments, the use is for the manufacture of a medicament, the
25 medicament comprising a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) in which a drug is bonded to said polypeptide binding moiety, for decreasing the immunogenicity of a drug without reducing the activity of the drug by more than about 10%.

In other embodiments, the use is for the manufacture of a medicament, the
30 medicament comprising a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) in which a drug is bonded to said polypeptide binding moiety, for increasing *in vivo* serum half-life of the drug, and reducing the

immunogenicity of the drug without reducing the activity of the drug by more than about 10%.

The drug composition can comprise a drug and polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo* that are bonded via a covalent bond (e.g., peptide bond) or noncovalent bond, with or without the use of linkers, as described herein. In some embodiments, the drug and the polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo* are bonded via a covalent bond. For example, the drug composition can be a drug conjugate or drug fusion. In other embodiments, the drug and the polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo* are bonded via a noncovalent bond, and the drug composition is a noncovalent drug conjugate.

In certain embodiments, the use is for the manufacture of a medicament, the medicament comprising a drug composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) in which a drug is bonded to said polypeptide binding moiety, for increasing the activity (e.g., *in vivo* activity) than said drug. In such embodiments, preferably, the activity of the drug composition is greater than the activity of the drug as described herein.

In preferred embodiments, the polypeptide binding moiety has binding specificity for serum albumin. In particularly preferred embodiments, the polypeptide binding moiety is an antigen-binding fragment of an antibody that has binding specificity for serum albumin.

Antigen-binding Fragment of an Antibody that Binds Serum Albumin

The drug conjugates, noncovalent drug conjugates and drug fusions of the invention comprise an (*i.e.*, one or more) antigen-binding fragment of an antibody that binds serum albumin. The antigen-binding fragment can have binding specificity for serum albumin of an animal to which the drug conjugate or drug fusion will be administered. Preferably, the antigen-binding fragment has binding specificity for human serum albumin. However, veterinary applications are contemplated and the antigen-binding fragment can have binding specificity for

- 32 -

serum albumin from a desired animal, for example serum albumin from dog, cat, horse, cow, chicken, sheep, pig, goat, deer, mink, and the like. In some embodiments the antigen-binding fragment has binding specificity for serum albumin from more than one species. For example, as described herein, human dAbs that have binding specificity for rat serum albumin and mouse serum albumin, and a dAb that has binding specificity for rat, mouse and human serum albumin have been produced. (Table 1 and FIG. 7) Such dAbs provide the advantage of allowing preclinical and clinical studies using the same drug conjugate or drug fusion and obviate the need to conduct preclinical studies with a suitable surrogate drug fusion or drug conjugate.

Antigen-binding fragments suitable for use in the invention include, for example, Fab fragments, Fab' fragments, F(ab')₂ fragments, Fv fragments (including single chain Fv (scFv) and disulfide bonded Fv), a single variable domain, and dAbs (V_H, V_L). Such antigen-binding fragments can be produced using any suitable method, such as by proteolysis of an antibody using pepsin, papain or other protease having the requisite cleavage specificity, or using recombinant techniques. For example, Fv fragments can be prepared by digesting an antibody with a suitable protease or using recombinant DNA technology. For example, a nucleic acid can be prepared that encodes a light chain variable region and heavy chain variable region that are connected by a suitable peptide linker, such as a chain of two to about twenty Glycyl residues. The nucleic acid can be introduced into a suitable host (*e.g.*, *E. coli*) using any suitable technique (*e.g.*, transfection, transformation, infection), and the host can be maintained under conditions suitable for expression of a single chain Fv fragment. A variety of antigen-binding fragments of antibodies can be prepared using antibody genes in which one or more stop codons have been introduced upstream of the natural stop site. For example, an expression construct encoding a F(ab')₂ portion of an immunoglobulin heavy chain can be designed by introducing a translation stop codon at the 3' end of the sequence encoding the hinge region of the heavy chain. The drug conjugates, noncovalent drug conjugates and drug fusions of the invention can comprise the individual heavy and light chains of ~~antibodies that bind serum albumin or portions of the individual chains that bind~~ serum albumin (*e.g.*, a single V_H, V_K or V_L).

- 33 -

Antibodies and antigen-binding fragments thereof which bind a desired serum albumin (*e.g.*, human serum albumin) can be selected from a suitable collection of natural or artificial antibodies or raised against an appropriate immunogen in a suitable host. For example, antibodies can be raised by immunizing
5 a suitable host (*e.g.*, mouse, human antibody-transgenic mouse, rat, rabbit, chicken, goat, non-human primate (*e.g.*, monkey)) with serum albumin (*e.g.*, isolated or purified human serum albumin) or a peptide of serum albumin (*e.g.*, a peptide comprising at least about 8, 9, 10, 11, 12, 15, 20, 25, 30, 33, 35, 37, or 40 amino acid residues). Antibodies and antigen-binding fragments that bind serum albumin
10 can also be selected from a library of recombinant antibodies or antigen-binding fragments, such as a phage display library. Such libraries can contain antibodies or antigen-binding fragments of antibodies that contain natural or artificial amino acid sequences. For example, the library can contain Fab fragments which contain artificial CDRs (*e.g.*, random amino acid sequences) and human framework regions.
15 (See, for example, U.S. Patent No. 6,300,064 (Knappik, *et al.*)). In other examples, the library contains scFv fragments or dAbs (single V_H, single V_κ or single V_λ) with sequence diversity in one or more CDRs. (See, *e.g.*, WO 99/20749 (Tomlinson and Winter), WO 03/002609 A2 (Winter *et al.*), WO 2004/003019A2 (Winter *et al.*)).

Suitable antibodies and antigen-binding fragments thereof that bind serum
20 albumin include, for example, human antibodies and antigen-binding fragments thereof, humanized antibodies and antigen-binding fragments thereof, chimeric antibodies and antigen-binding fragments thereof, rodent (*e.g.*, mouse, rat) antibodies and antigen-binding fragments thereof, and *Camelid* antibodies and antigen-binding fragments thereof. In certain embodiments, the drug conjugates,
25 noncovalent drug conjugates and drug fusions comprises a *Camelid* V_{HH} that binds serum albumin. *Camelid* V_{HH}s are immunoglobulin single variable domain polypeptides which are derived from heavy chain antibodies that are naturally devoid of light chains. Such antibodies occur in *Camelid* species including camel, llama, alpaca, dromedary, and guanaco. V_{HH} molecules are about ten times smaller
30 than IgG molecules, and as single polypeptides, are very stable and resistant to
~~extreme pH and temperature conditions. Suitable *Camelid* V_{HH} that bind serum~~
albumin include those disclosed in WO 2004/041862 (Ablynx N.V.) and herein

(FIG. 15 and SEQ ID NOS:77-88). In certain embodiments, the *Camelid* V_{HH} binds human serum albumin and comprises an amino acid sequence that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with SEQ ID NO: 72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, or SEQ ID NO:88. Amino acid sequence identity is preferably determined using a suitable sequence alignment algorithm and default parameters, such as BLAST P (Karlin and Altschul, *Proc. Natl. Acad. Sci. USA* 87(6):2264-2268 (1990)).

Preparation of the immunizing antigen, and polyclonal and monoclonal antibody production can be performed using any suitable technique. A variety of methods have been described. (See, *e.g.*, Kohler *et al.*, *Nature*, 256: 495-497 (1975) and *Eur. J. Immunol.* 6: 511-519 (1976); Milstein *et al.*, *Nature* 266: 550-552 (1977); Koprowski *et al.*, U.S. Patent No. 4,172,124; Harlow, E. and D. Lane, 1988, *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory: Cold Spring Harbor, NY); *Current Protocols In Molecular Biology*, Vol. 2 (Supplement 27, Summer '94), Ausubel, F.M. *et al.*, Eds., (John Wiley & Sons: New York, NY), Chapter 11, (1991).) Generally, where a monoclonal antibody is desired, a hybridoma is produced by fusing suitable cells from an immortal cell line (*e.g.*, a myeloma cell line such as SP2/0, P3X63Ag8.653 or a heteromyeloma) with antibody-producing cells. Antibody-producing cells can be obtained from the peripheral blood or, preferably the spleen or lymph nodes, of humans, human-antibody transgenic animals or other suitable animals immunized with the antigen of interest. Cells that produce antibodies of human origin (*e.g.*, a human antibody) can be produced using suitable methods, for example, fusion of a human antibody-producing cell and a heteromyeloma or trioma, or immortalization of an activated human B cell via infection with Epstein Barr virus. (See, *e.g.*, U.S. Patent No. 6,197,582 (Trakht); Niedbala *et al.*, *Hybridoma*, 17:299-304 (1998); Zanella *et al.*, *J Immunol Methods*, 156:205-215 (1992); Gustafsson *et al.*, *Hum Antibodies Hybridomas*, 2:26-32 (1991).) The fused or immortalized antibody-producing cells

(hybridomas) can be isolated using selective culture conditions, and cloned by limiting dilution. Cells which produce antibodies with the desired specificity can be identified using a suitable assay (*e.g.*, ELISA).

Antibodies also can be prepared directly (*e.g.*, synthesized or cloned) from
5 an isolated antigen-specific antibody producing cell (*e.g.*, a cell from the peripheral blood or, preferably the spleen or lymph nodes determined to produce an antibody with desired specificity), of humans, human-antibody transgenic animals or other suitable animals immunized with the antigen of interest (see, *e.g.*, U.S. Patent No. 5,627,052 (Schrader)).

10 When the drug conjugate, noncovalent drug conjugate or drug fusion is for administration to a human, the antibody or antigen-binding fragment thereof that binds serum albumin (*e.g.*, human serum albumin) can be a human, humanized or chimeric antibody or an antigen-binding fragment of such an antibody. These types of antibodies and antigen-binding fragments are less immunogenic or non-
15 immunogenic in humans and provide well-known advantages. For example, drug conjugates, noncovalent drug conjugates or drug fusions that contain an antigen-binding fragment of a human, humanized or chimeric antibody can be administered repeatedly to a human with less or no loss of efficacy (compared with other fully immunogenic antibodies) due to elaboration of human antibodies that bind to the
20 drug conjugate or drug fusion. When the drug conjugate, noncovalent drug conjugate or drug fusion is intended for veterinary administration, analogous antibodies or antigen-binding fragments can be used. For example, CDRs from a murine or human antibody can be grafted onto framework regions from a desired animal, such as a horse or cow.

25 Human antibodies and nucleic acids encoding same can be obtained, for example, from a human or from human-antibody transgenic animals. Human-antibody transgenic animals (*e.g.*, mice) are animals that are capable of producing a repertoire of human antibodies, such as XENOMOUSE (Abgenix, Fremont, CA), HUMAB-MOUSE, KIRIN TC MOUSE or KM-MOUSE (MEDAREX, Princeton,
30 NJ). Generally, the genome of human-antibody transgenic animals has been altered to include a transgene comprising DNA from a human immunoglobulin locus that

can undergo functional rearrangement. An endogenous immunoglobulin locus in a

- 36 -

human-antibody transgenic animal can be disrupted or deleted to eliminate the capacity of the animal to produce antibodies encoded by an endogenous gene. Suitable methods for producing human-antibody transgenic animals are well known in the art. (See, for example, U.S. Pat. Nos. 5,939,598 and 6,075,181 (Kucherlapati *et al.*), U.S. Pat. Nos. 5,569,825, 5,545,806, 5,625,126, 5,633,425, 5,661,016, and 5,789,650 (Lonberg *et al.*), Jakobovits *et al.*, *Proc. Natl. Acad. Sci. USA*, 90: 2551-2555 (1993), Jakobovits *et al.*, *Nature*, 362: 255-258 (1993), Jakobovits *et al.* WO 98/50433, Jakobovits *et al.* WO 98/24893, Lonberg *et al.* WO 98/24884, Lonberg *et al.* WO 97/13852, Lonberg *et al.* WO 94/25585, Lonberg *et al.* EP 0 814 259 A2, Lonberg *et al.* GB 2 272 440 A, Lonberg *et al.*, *Nature* 368:856-859 (1994), Lonberg *et al.*, *Int Rev Immunol* 13(1):65-93 (1995), Kucherlapati *et al.* WO 96/34096, Kucherlapati *et al.* EP 0 463 151 B1, Kucherlapati *et al.* EP 0 710 719 A1, Surani *et al.* US. Pat. No. 5,545,807, Bruggemann *et al.* WO 90/04036, Bruggemann *et al.* EP 0 438 474 B1, Taylor *et al.*, *Int. Immunol.* 6(4):579-591 (1994), Taylor *et al.*, *Nucleic Acids Research* 20(23):6287-6295 (1992), Green *et al.*, *Nature Genetics* 7:13-21 (1994), Mendez *et al.*, *Nature Genetics* 15:146-156 (1997), Tuailon *et al.*, *Proc Natl Acad Sci USA* 90(8):3720-3724 (1993) and Fishwild *et al.*, *Nat Biotechnol* 14(7):845-851 (1996), the teachings of each of the foregoing are incorporated herein by reference in their entirety.)

Human-antibody transgenic animals can be immunized with a suitable antigen (*e.g.*, human serum albumin), and antibody producing cells can be isolated and fused to form hybridomas using conventional methods. Hybridomas that produce human antibodies having the desired characteristics (*e.g.*, specificity, affinity) can be identified using any suitable assay (*e.g.*, ELISA) and, if desired, selected and subcloned using suitable culture techniques.

Humanized antibodies and other CDR-grafted antibodies can be prepared using any suitable method. The CDRs of a CDR-grafted antibody can be derived from a suitable antibody which binds a serum albumin (referred to as a donor antibody). Other sources of suitable CDRs include natural and artificial serum albumin-specific antibodies obtained from human or nonhuman sources, such as rodent (*e.g.*, mouse, rat, rabbit), chicken, pig, goat, non-human primate (*e.g.*, monkey) or a library.

The framework regions of a humanized antibody are preferably of human origin, and can be derived from any human antibody variable region having sequence similarity to the analogous or equivalent region (*e.g.*, heavy chain variable region or light chain variable region) of the antigen-binding region of the donor antibody. Other sources of framework regions of human origin include human variable region consensus sequences. (See, *e.g.*, Kettleborough, C.A. *et al.*, *Protein Engineering* 4:773-783 (1991); Carter *et al.*, WO 94/04679; Kabat, E.A., *et al.*, *Sequences of Proteins of Immunological Interest*, Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991)). Other types of CDR grafted antibodies can contain framework regions of suitable origin, such as framework regions encoded by germline antibody gene segments from horse, cow, dog, cat and the like.

Framework regions of human origin can include amino acid substitutions or replacements, such as "back mutations" which replace an amino acid residue in the framework region of human or animal origin with a residue from the corresponding position of the donor antibody. One or more mutations in the framework region can be made, including deletions, insertions and substitutions of one or more amino acids. Variants can be produced by a variety of suitable methods, including mutagenesis of nonhuman donor or acceptor human chains. (See, *e.g.*, U.S. Patent Nos. 5,693,762 (Queen *et al.*) and 5,859,205 (Adair *et al.*), the entire teachings of which are incorporated herein by reference.)

Constant regions of antibodies, antibody chains (*e.g.*, heavy chain, light chain) or fragments or portions thereof, if present, can be derived from any suitable source. For example, constant regions of human, humanized and certain chimeric antibodies, antibody chains (*e.g.*, heavy chain, light chain) or fragments or portions thereof, if present can be of human origin and can be derived from any suitable human antibody or antibody chain. For example, a constant region of human origin or portion thereof can be derived from a human κ or λ light chain, and/or a human γ (*e.g.*, $\gamma 1$, $\gamma 2$, $\gamma 3$, $\gamma 4$), μ , α (*e.g.*, $\alpha 1$, $\alpha 2$), δ or ϵ heavy chain, including allelic variants. In certain embodiments, the antibody or antigen-binding fragment (*e.g.*, antibody of human origin, human antibody) can include amino acid substitutions or replacements that alter or tailor function (*e.g.*, effector function). For example, a

- 38 -

constant region of human origin (*e.g.*, $\gamma 1$ constant region, $\gamma 2$ constant region) can be designed to reduce complement activation and/or Fc receptor binding. (See, for example, U.S. Patent Nos. 5,648,260 (Winter *et al.*), 5,624,821 (Winter *et al.*) and 5,834,597 (Tso *et al.*), the entire teachings of which are incorporated herein by reference.) Preferably, the amino acid sequence of a constant region of human origin that contains such amino acid substitutions or replacements is at least about 95% identical over the full length to the amino acid sequence of the unaltered constant region of human origin, more preferably at least about 99% identical over the full length to the amino acid sequence of the unaltered constant region of human origin.

Humanized antibodies, CDR grafted antibodies or antigen-binding fragments of a humanized or CDR grafted antibody can be prepared using any suitable method. Several such methods are well-known in the art. (See, *e.g.*, U.S. Patent No. 5,225,539 (Winter), U.S. Patent No. 5,530,101 (Queen *et al.*)). The portions of a humanized or CDR grafted antibody (*e.g.*, CDRs, framework, constant region) can be obtained or derived directly from suitable antibodies (*e.g.*, by *de novo* synthesis of a portion), or nucleic acids encoding an antibody or chain thereof having the desired property (*e.g.*, binds serum albumin) can be produced and expressed. To prepare a portion of a chain, one or more stop codons can be introduced at the desired position. For example, nucleic acid (*e.g.*, DNA) sequences coding for humanized or CDR grafted variable regions can be constructed using PCR mutagenesis methods to alter existing DNA sequences. (See, *e.g.*, Kamman, M., *et al.*, *Nucl. Acids Res.* 17:5404 (1989).) PCR primers coding for the new CDRs can be hybridized to a DNA template of a previously humanized variable region which is based on the same, or a very similar, human variable region (Sato, K., *et al.*, *Cancer Research* 53:851-856 (1993)). If a similar DNA sequence is not available for use as a template, a nucleic acid comprising a sequence encoding a variable region sequence can be constructed from synthetic oligonucleotides (see *e.g.*, Kolbinger, F., *Protein Engineering* 8:971-980 (1993)). A sequence encoding a signal peptide can also be incorporated into the nucleic acid (*e.g.*, on synthesis, upon insertion into a vector). ~~The natural signal peptide sequence from the acceptor antibody, a signal peptide sequence from another antibody or other suitable~~

sequence can be used (see, *e.g.*, Kettleborough, C.A., *Protein Engineering* 4:773-783 (1991)). Using these methods or other suitable methods, variants can be readily produced. In one embodiment, cloned variable regions can be mutated, and sequences encoding variants with the desired specificity can be selected (*e.g.*, from a phage library; see, *e.g.*, U.S. Patent No. 5,514,548 (Krebber *et al.*) and WO 93/06213 (Hoogenboom *et al.*)).

The antibody or antigen-binding fragment that binds serum albumin can be a chimeric antibody or an antigen-binding fragment of a chimeric antibody. The chimeric antibody or antigen-binding fragment thereof comprises a variable region from one species (*e.g.*, mouse) and at least a portion of a constant region from another species (*e.g.*, human). Chimeric antibodies and antigen-binding fragments of chimeric antibodies can be prepared using any suitable method. Several suitable methods are well-known in the art. (See, *e.g.*, U.S. Patent No. 4,816,567 (Cabilly *et al.*), U.S. Patent No. 5,116,946 (Capon *et al.*)).

A preferred method for obtaining antigen-binding fragments of antibodies that bind serum albumin comprises selecting an antigen-binding fragment (*e.g.*, scFvs, dAbs) that has binding specificity for a desired serum albumin from a repertoire of antigen-binding fragments. For example, as described herein dAbs that bind serum albumin can be selected from a suitable phage display library. A number of suitable bacteriophage display libraries and selection methods (*e.g.*, monovalent display and multivalent display systems) have been described. (See, *e.g.*, Griffiths *et al.*, U.S. Patent No. 6,555,313 B1 (incorporated herein by reference); Johnson *et al.*, U.S. Patent No. 5,733,743 (incorporated herein by reference); McCafferty *et al.*, U.S. Patent No. 5,969,108 (incorporated herein by reference); Mulligan-Kehoe, U.S. Patent No. 5,702,892 (incorporated herein by reference); Winter, G. *et al.*, *Annu. Rev. Immunol.* 12:433-455 (1994); Soumillon, P. *et al.*, *Appl. Biochem. Biotechnol.* 47(2-3):175-189 (1994); Castagnoli, L. *et al.*, *Comb. Chem. High Throughput Screen*, 4(2):121-133 (2001); WO 99/20749 (Tomlinson and Winter); WO 03/002609 A2 (Winter *et al.*); WO 2004/003019A2 (Winter *et al.*)). The polypeptides displayed in a bacteriophage library can be displayed on any suitable bacteriophage, such as a filamentous phage (*e.g.*, fd, M13, F1), a lytic phage (*e.g.*,

- 40 -

T4, T7, lambda), or an RNA phage (*e.g.*, MS2), for example, and selected for binding to serum albumin (*e.g.*, human serum albumin).

Generally, a library of phage that displays a repertoire of polypeptides as fusion proteins with a suitable phage coat protein is used. Such a library can be produced using any suitable methods, such as introducing a library of phage vectors or phagemid vectors encoding the displayed antibodies or antigen-binding fragments thereof into suitable host bacteria, and culturing the resulting bacteria to produce phage (*e.g.*, using a suitable helper phage or complementing plasmid if desired). The library of phage can be recovered from such a culture using any suitable method, such as precipitation and centrifugation.

The library can comprise a repertoire of antibodies or antigen-binding fragments thereof that contains any desired amount of amino acid sequence diversity. For example, the repertoire can contain antibodies or antigen-binding fragments thereof that have amino acid sequences that correspond to naturally occurring antibodies from a desired organism, and/or can contain one or more regions of random or randomized amino acid sequences (*e.g.*, CDR sequences). The antibodies or antigen-binding fragments thereof in such a repertoire or library can comprise defined regions of random or randomized amino acid sequence and regions of common amino acid sequence. In certain embodiments, all or substantially all polypeptides in a repertoire are a desired type of antigen-binding fragment of an antibody (*e.g.*, human V_H or human V_L). For example, each polypeptide in the repertoire can contain a V_H, a V_L or an Fv (*e.g.*, a single chain Fv).

Amino acid sequence diversity can be introduced into any desired region of antibodies or antigen-binding fragments thereof using any suitable method. For example, amino acid sequence diversity can be introduced into a target region, such as a complementarity determining region of an antibody variable domain, by preparing a library of nucleic acids that encode the diversified antibodies or antigen-binding fragments thereof using any suitable mutagenesis methods (*e.g.*, low fidelity PCR, oligonucleotide-mediated or site directed mutagenesis, diversification using NNK codons) or any other suitable method. If desired, a region of the antibodies or antigen-binding fragments thereof to be diversified can be randomized.

A suitable phage display library can be used to select antibodies or antigen-binding fragments of antibodies that bind serum albumin and have other beneficial properties. For example, antibodies or antigen-binding fragments that resist aggregation when unfolded can be selected. Aggregation is influenced by polypeptide concentration and is thought to arise in many cases from partially folded or unfolded intermediates. Factors and conditions that favor partially folded intermediates, such as elevated temperature and high polypeptide concentration, promote irreversible aggregation. (Fink, A.L., *Folding & Design* 3:R1-R23 (1998).) For example, storing purified polypeptides in concentrated form, such as a lyophilized preparation, frequently results in irreversible aggregation of at least a portion of the polypeptides. Also, production of a polypeptide by expression in biological systems, such as *E. coli*, often results in the formation of inclusion bodies which contain aggregated polypeptides. Recovering active polypeptides from inclusion bodies can be very difficult and require adding additional steps, such as a refolding step, to a biological production system.

Antibodies and antigen-binding fragments that resist aggregation and unfold reversibly when heated can be selected from a suitable phage display library. Generally, a phage display library comprising a repertoire of displayed antibodies or antigen-binding fragments thereof is heated to a temperature (T_s) at which at least a portion of the displayed antibodies or antigen-binding fragments thereof are unfolded, then cooled to a temperature (T_c) wherein $T_s > T_c$, whereby at least a portion of the antibodies or antigen-binding fragments thereof have refolded and a portion of the polypeptides have aggregated. Then, antibodies or antigen-binding fragments thereof that unfold reversibly and bind serum albumin are recovered at a temperature (T_r). The recovered antibody or antigen-binding fragment thereof that unfolds reversibly has a melting temperature (T_m), and preferably, the repertoire was heated to T_s , cooled to T_c and the antibody or antigen-binding fragment thereof that unfolds reversibly was isolated at T_r , such that $T_s > T_m > T_c$, and $T_s > T_m > T_r$. Generally, the phage display library is heated to about 80°C and cooled to about room temperature or about 4°C before selection. Antibodies or antigen-binding fragment thereof that unfold reversibly and resist aggregation can also be designed or engineered by replacing certain amino acid residue with residues that confer the

ability to unfold reversibly. (See, WO 2004/101790 (Jespers *et al.*), and U.S. Provisional Patent Application Nos: 60/470,340 (filed on May 14, 2003) and 60/554,021 (filed on March 17, 2004) for detailed discussion of methods for selecting and for designing or engineering antibodies or antigen-binding fragments thereof that unfold reversibly. The teachings of WO 2004/101790 and both of the foregoing U.S. Provisional Patent Applications are incorporated herein by reference.).

Antibodies or antigen-binding fragments thereof that unfold reversibly and resist aggregation provide several advantages. For example, due to their resistance to aggregation, antibodies or antigen-binding fragments thereof that unfold reversibly can readily be produced in high yield as soluble proteins by expression using a suitable biological production system, such as *E. coli*. In addition, antibodies or antigen-binding fragments thereof that unfold reversibly can be formulated and/or stored at higher concentrations than conventional polypeptides, and with less aggregation and loss of activity. DOM7h-26 (SEQ ID NO:20) is a human V_H that unfolds reversibly.

Preferably, the antibody or antigen-binding fragment thereof that binds serum albumin comprises a variable domain (V_H, V_κ, V_λ) in which one or more of the framework regions (FR) comprise (a) the amino acid sequence of a human framework region, (b) at least 8 contiguous amino acids of the amino acid sequence of a human framework region, or (c) an amino acid sequence encoded by a human germline antibody gene segment, wherein said framework regions are as defined by Kabat. In certain embodiments, the amino acid sequence of one or more of the framework regions is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequences of one or more of said framework regions collectively comprise up to 5 amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.

In other embodiments, the amino acid sequences of FR1, FR2, FR3 and FR4 ~~are the same as the amino acid sequences of corresponding framework regions~~ encoded by a human germline antibody gene segment, or the amino acid sequences

- 43 -

of FR1, FR2, FR3 and FR4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segments. In other embodiments, the amino acid sequence of said FR1, FR2 and FR3 are the same as the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.

In particular embodiments, the antigen binding fragment of an antibody that binds serum albumin comprises an immunoglobulin variable domain (*e.g.*, V_H , V_L) based on a human germline sequence, and if desired can have one or more diversified regions, such as the complementarity determining regions. Suitable human germline sequence for V_H include, for example, sequences encoded by the V_H gene segments DP4, DP7, DP8, DP9, DP10, DP31, DP33, DP45, DP46, DP47, DP49, DP50, DP51, DP53, DP54, DP65, DP66, DP67, DP68 and DP69, and the JH segments JH1, JH2, JH3, JH4, JH4b, JH5 and JH6. Suitable human germline sequence for V_L include, for example, sequences encoded by the V_K gene segments DPK1, DPK2, DPK3, DPK4, DPK5, DPK6, DPK7, DPK8, DPK9, DPK10, DPK12, DPK13, DPK15, DPK16, DPK18, DPK19, DPK20, DPK21, DPK22, DPK23, DPK24, DPK25, DPK26 and DPK 28, and the J_K segments J_K 1, J_K 2, J_K 3, J_K 4 and J_K 5.

In certain embodiments, the drug conjugate, noncovalent drug conjugate or drug fusion does not contain a mouse, rat and/or rabbit antibody that binds serum albumin or antigen-binding fragment of such an antibody.

The antigen-binding fragment can bind serum albumin with any desired affinity, on rate and off rate. The affinity (K_D), on rate (K_{on} or k_a) and off rate (K_{off} or k_d) can be selected to obtain a desired serum half-life for a particular drug. For example, it may be desirable to obtain a maximal serum half-life for a drug that neutralizes an inflammatory mediator of a chronic inflammatory disorder (*e.g.*, a dAb that binds and neutralizes an inflammatory cytokine), while a shorter half-life may be desirable for a drug that has some toxicity (*e.g.*, a chemotherapeutic agent).

Generally, a fast on rate and a fast or moderate off rate for binding to serum albumin is preferred. ~~Drug conjugates and drug fusions that comprise an antigen-binding fragment with these characteristics will quickly bind serum albumin after being~~

administered, and will dissociate and rebind serum albumin rapidly. These characteristics will reduce rapid clearance of the drug (*e.g.*, through the kidneys) but still provide efficient delivery and access to the drug target.

The antigen-binding fragment that binds serum albumin (*e.g.*, dAb) generally
5 binds with a K_D of about 1 nM to about 500 μ M. In some embodiments, the
antigen-binding fragment binds serum albumin with a K_D ($K_D = K_{off}(kd)/K_{on}(ka)$)
of about 10 to about 100 nM, or about 100 nM to about 500 nM, or about 500 nM to
about 5 μ M, as determined by surface plasmon resonance (*e.g.*, using a BIAcore
instrument). In particular embodiments, the drug conjugate, noncovalent drug
10 conjugate or drug fusion comprises an antigen-binding fragment of an antibody
(*e.g.*, a dAb) that binds serum albumin (*e.g.*, human serum albumin) with a K_D of
about 50 nM, or about 70 nM, or about 100 nM, or about 150 nM or about 200 nM.
The improved pharmacokinetic properties (*e.g.*, prolonged $t_{1/2\beta}$, increased AUC) of
drug conjugates, noncovalent drug conjugates and drug fusions described herein
15 may correlate with the affinity of the antigen-binding fragment that binds serum
albumin. Accordingly, drug conjugates, noncovalent drug conjugates and drug
fusions that have improved pharmacokinetic properties can generally be prepared
using an antigen-binding fragment that binds serum albumin (*e.g.*, human serum
albumin) with high affinity (*e.g.*, K_D of about 500 nM or less, about 250 nM or less,
20 about 100 nM or less, about 50 nM or less, about 10 nM or less, or about 1 nM or
less, or about 100 pM or less).

Preferably, the drug that is conjugated or fused to the antigen-binding
fragment that binds serum albumin, binds to its target (the drug target) with an
affinity (K_D) that is stronger than the affinity of the antigen-binding fragment for
25 serum albumin and/or a K_{off} (kd) that is faster than the K_{off} of the antigen binding
fragment for serum albumin, as measured by surface plasmon resonance (*e.g.*, using
a BIAcore instrument). For example, the drug can bind its target with an affinity
that is about 1 to about 100000, or about 100 to about 100000, or about 1000 to
about 100000, or about 10000 to about 100000 times stronger than the affinity of
30 antigen-binding fragment that binds SA for SA. For example, the antigen-binding
~~fragment of the antibody that binds SA can bind with an affinity of about 10 μ M,~~
while the drug binds its target with an affinity of about 100 pM.

- 45 -

In particular embodiments, the antigen-binding fragment of an antibody that binds serum albumin is a dAb that binds human serum albumin. For example, a V_K dAb having an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, or a V_H dAb having an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In other embodiments, the antigen-binding fragment of an antibody that binds serum albumin is a dAb that binds human serum albumin and comprises the CDRs of any of the foregoing amino acid sequences. In other embodiments, the antigen-binding fragment of an antibody that binds serum albumin is a dAb that binds human serum albumin and comprises an amino acid sequence that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 or SEQ ID NO:23. Amino acid sequence identity is preferably determined using a suitable sequence alignment algorithm and default parameters, such as BLAST P (Karlin and Altschul, *Proc. Natl. Acad. Sci. USA* 87(6):2264-2268 (1990)).

Drugs

Certain drug compositions of the invention (e.g., drug conjugates, noncovalent drug conjugates) can comprise any drug (e.g., small organic molecule, nucleic acid, polypeptide) that can be administered to an individual to produce a beneficial therapeutic or diagnostic effect, for example, through binding to and/or altering the function of a biological target molecule in the individual. Other drug compositions of the invention (e.g., drug fusions) can comprise a polypeptide or peptide drug. In preferred embodiments of drug fusions, the drug does not comprise an antibody chain or fragment of an antibody chain (e.g., V_H , V_K , V_L).

- 46 -

Suitable drugs for use in the invention include, for example, immunosuppressive agents (*e.g.*, cyclosporin A, rapamycin, FK506, prednisone), antiviral agents (acyclovir, ganciclovir, indinavir), antibiotics (penicillin, mynocylin, tetracycline), anti-inflammatory agents (aspirin, ibuprofen, prednisone),

5 cytotoxins or cytotoxic agents (*e.g.*, paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin C, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracindione, mitoxantrone, mithramycin, actinomycin D, 1-dihydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs of

10 any of the foregoing agents. Suitable drugs also include antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (*e.g.*, mechlorethamine, thioepachlorambucil, CC-1065, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine

15 platinum (II) (DDP) cisplatin), anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), radionuclides (*e.g.*, iodine-125, -126) yttrium (*e.g.*, yttrium-90, -91) and praseodymium (*e.g.*, praseodymium-144, -145), and protease inhibitors (*e.g.*, inhibitors of matrix

20 metalloproteinases). Other suitable drugs are nucleic acids such as antisense nucleic acids and RNAi. Calicheamicin is also suitable for use in the invention.

Suitable drugs also include analgesic agents, including narcotics (*e.g.*, codeine, nalmeferne, naloxone, fentanyl, meperidine, morphine, tramadol, propoxyphene, oxycodone, methadone, nalbuphine), nonsteroidal anti-inflammatory

25 agents (*e.g.*, indomethacin, ketorolac, arthrotec, ibuprofen, naproxen, salicylate, celecoxib, rofecoxib), acetaminophen, capsaicin, ziconotide and the like.

In certain embodiments, the drug is a polypeptide toxin, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin. Other suitable polypeptide drugs include antibodies or antigen-binding fragments (*e.g.*, dAbs) of

30 antibodies, polypeptide agonists, activators, secretagogues, antagonists or inhibitors. For example, the polypeptide or peptide drug can bind and agonise or antagonize a cell surface protein, such as a CD antigen, cytokine receptor (*e.g.*, interleukin

receptor, chemokine receptor), adhesion molecule or costimulatory molecule. For example, the polypeptide drug can bind a cytokine, growth factors, cytokine receptor, growth factor receptor and other target ligand, which include but are not limited to: ApoE, Apo-SAA, BDNF, Cardiotrophin-1, CEA, CD40, CD40 Ligand, CD56, CD38, CD138, EGF, EGF receptor, ENA-78, Eotaxin, Eotaxin-2, Exodus-2, FAP α , FGF-acidic, FGF-basic, fibroblast growth factor-10, FLT3 ligand, Fractalkine (CX3C), GDNF, G-CSF, GM-CSF, GF- β 1, human serum albumin, insulin, IFN- γ , IGF-I, IGF-II, IL-1 α , IL-1 β , IL-1 receptor, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (72 a.a.), IL-8 (77 a.a.), IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18 (IGIF), Inhibin α , Inhibin β , IP-10, keratinocyte growth factor-2 (KGF-2), KGF, Leptin, LIF, Lymphotactin, Mullerian inhibitory substance, monocyte colony inhibitory factor, monocyte attractant protein, M-CSF, MDC (67 a.a.), MDC (69 a.a.), MCP-1 (MCAF), MCP-2, MCP-3, MCP-4, MDC (67 a.a.), MDC (69 a.a.), MIG, MIP-1 α , MIP-1 β , MIP-3 α , MIP-3 β , MIP-4, myeloid progenitor inhibitor factor-1 (MPLF-1), NAP-2, Neurturin, Nerve growth factor, β -NGF, NT-3, NT-4, Oncostatin M, PDGF-AA, PDGF-AB, PDGF-BB, PF-4, RANTES, SDF1 α , SDF1 β , SCF, SCGF, stem cell factor (SCF), TARC, TGF- α , TGF- β , TGF- β 2, TGF- β 3, tumour necrosis factor (TNF), TNF- α , TNF- β , TNF receptor I, TNF receptor II, TNIL-1, TPO, VEGF, VEGF A, VEGF B, VEGF C, VEGF D, VEGF receptor 1, VEGF receptor 2, VEGF receptor 3, GCP-2, GRO/MGSA, GRO- β , GRO- γ , HCC1, 1-309, HER 1, HER 2, HER 3 and HER 4. It will be appreciated that this list is by no means exhaustive.

Suitable drugs also include hormones, including pituitary hormone (PTH), adrenocorticotrophic hormone (ACTH), renin, luteinizing hormone-releasing hormone (LHRH), gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), aldosterone, and the like. Suitable drugs also include keratinocyte growth factor, interferons (*e.g.*, IFN- α , IFN- β , IFN- γ), erythropoietin (EPO), proteases, elastases, LHRH analogs, agonists and antagonists, opioid receptor agonists, such as kappa opioid receptor agonists (*e.g.*, dynorphin A), calcitonin and calcitonin analogs, antidiuretic hormone (vasopressin), oxytocin antagonists, vasoactive intestinal peptide, thrombin inhibitors, von Willebrand factor, surfactants and snail venom (*e.g.*, ziconotide).

Suitable drugs also include peptides and polypeptides that have anti-cancer activities (e.g., proliferation inhibiting, growth inhibiting, apoptosis inducing, metastasis inhibiting, adhesion inhibiting, neovascularization inhibiting). Several such peptides and polypeptides are known in the art. (See. e.g., Janin Y.L., *Amino*
5 *Acids*, 25:1-40 (2003). The entire teaching of this reference, particularly the peptides and polypeptides disclosed therein, are incorporated herein by reference.) The amino acid sequences of several such peptides are presented in Table 8.

Other suitable drugs include peptides and polypeptides that have anti-viral activity. Several such peptides and polypeptides are known in the art, for example
10 the peptides and polypeptides disclosed in Giannecchini, *et al.*, *J Viro.*, 77(6):3724-33 (2003); Wang, J., *et al.*, *Clin Chem* (2003); Hilleman, M.R., *Vaccine*, 21(32):4626-49 (2003); Tziveleka, L.A., *et al.*, *Curr Top Med Chem*, 3(13):1512-35 (2003); Poritz, M.A., *et al.*, *Virology*, 313(1):170-83 (2003); Oevermann, A., *et al.*, *Antiviral Res*, 59(1):23-33 (2003); Cole, A.M. *et al.*, *Curr Pharm Des*, 9(18):1463-
15 73 (2003); Pinon, J.D., *et al.*, *Virol*, 77(5):3281-90 (2003); Sia, S.K., *et al.*, *Proc Natl Acad Sci USA*, 99(23):14664-9 (2002); Bahbouhi, B., *et al.*, *Biochem J*, 66(Pt 3):863-72 (2002); de Soultrait, V.R., *et al.*, *J Mol Biol*, 18(1):45-58 (2002); Witherell, G., *Curr Opin Investig Drugs*, 2(3):340-7 (2001); Ruff, M.R., *et al.*, *Antiviral Res*, 52(1):63-75 (2001); Bultmann, H., *et al.*, *J. Virol*, 75(6):2634-45
20 (2001); Egal, M., *et al.*, *Int J Antimicrob AGents*, 13(1):57-60 (1999); and Robinson, W.E., Jr., *J Leukoc Biol*, 63(1):94-100(1998). The entire teachings of these references, particularly the peptides and polypeptides disclosed therein, are incorporated herein by reference. These peptides and polypeptides are examples of drugs that can be used in the compositions, drug fusions, drug conjugates,
25 noncovalent drug conjugates of the present invention.

The polypeptide drug can also be a cytokine or growth factor or soluble portion of a receptor (e.g., a cytokine receptor, growth factor receptor, hormone receptor) or other polypeptide such as the polypeptides listed above. For example, suitable polypeptide drugs also include receptor (e.g., growth factor receptor,
30 cytokine receptor, hormone receptor) agonists and antagonists, such as interleukin 1 receptor antagonist (Eisenberg *et al.*, *Nature* 343:341-346 (1990)), thrombopoietin receptor agonists (e.g., GW395058 (de Serres *et al.*, *Stem Cells* 17:316-326 (1999)),

- melanocortin receptor antagonists (e.g., MCR-4 antagonists (Cepoi et al., *Brain Res.* 1000:64-71 (2004)), anginex, 6DBF7 (Mayo et al., *J. Biol. Chem.* 278:45746-45752 (2003)), chemokine mimetics (e.g., RANTES mimetics (Nardese et al., *Nat. Struct. Biol.* 8:611-615 (2001)), growth hormone (e.g., human growth hormone), growth
- 5 hormone analogs and growth hormone secretagogues (e.g., CP-424,391 (MacAndrew et al., *Eur. J. Pharmacol.* 432:195-202 (2001)), growth hormone releasing hormone mimetics (e.g., MK-677 (Chapman et al., *J. Clin. Endocrinol. Metab.* 82:3455-3463 (1997)), inhibitors of cellular adhesion molecule interactions (e.g., LFA-1/ICAM-1, VLA-1/VCAM-1 (Yusuf-Makagiansar et al., *Med. Res. Rev.* 10 22:146-167 (2002)), mimetics of interferon (e.g., SYR6 (Sato et al., *Biochem. J.* 371(Pt.2):603-608 (2003)), mimetics of herceptin (*Nature Biotechnol.* 18:137 (2000)), inhibitors of antigen presentation (Bolin et al., *J. Med. Chem.* 43:2135-2148 (2000)), GPIIb/IIIa antagonists (e.g., FK633 (Aoki et al., *Thromb. Res.* 81:439-450 (1996)), alphavbeta3 antagonists (e.g., SC56631 (Engleman et al., *J. Clin. Invest.* 15 99:2284-2292 (1997)), erythropoietin mimetics (e.g., EMP1 (Johnson et al., *Biochemistry* 37:3699-3710 (1998)), opioid receptor antagonists (e.g., [(2S, 3R)-TMT1]DPDPE (Liao et al., *J. Med. Chem.* 41:4767-4776 (1998)), hematopoietic factors (e.g., erythropoietin (EPO), granulocyte colony stimulating factor (GM-CSF)).
- 20 Additional suitable peptide and polypeptide drugs include peptide antagonists that bind human type 1 IL-1 receptor (e.g., AF 11377 (FEWTPGYWQPYALPL, SEQ ID NO:56), AF11869 (FEWTPGYWQJYALPL, SEQ ID NO:57 (J = 1-azetidine-2-carboxylic acid), FEWTPGYWQJY (SEQ ID NO:58), FEWTPGWYQJY (SEQ ID NO:59), FEWTPGWYQJYALPL (SEQ ID
- 25 NO:60), or any of the foregoing sequences optionally containing an acylated amino terminus and/or an aminated carboxyl terminus (Akeson et al., *J. Biol. Chem.* 271:30517-305123 (1996)), peptide antagonists of TNF-alpha-mediated cytotoxicity (e.g., those disclosed in Chirinos-Rojas et al., *J. Immunol.* 161:5621-5626 (1998)), peptide agonists of erythropoietin receptor (e.g., those disclosed in McConnel et al., 30 *Biol. Chem.* 379:1279-1286 (1998) or Wrighton et al., *Science* 273:458-464 (1996)), glucagon-like peptide-1 (GLP-1, e.g., GLP-1(7-37), GLP-1(7-36)amide and analogs thereof (see, e.g., Ritzel U. et al., *J. Endocrinology* 159:93-102 (1998)), and

interferons (*e.g.*, INF α , INF β , INF γ). Additional suitable polypeptide and peptide drugs include integrin inhibitors (*e.g.*, RGD peptides, such as H-Glu[cyclo(Arg-Gly-Asp-D-Phe-Lys)]₂ (Janssen, M.L., *et al.*, *Cancer Research* 62:6146- 6151 (2002)), cyclo(Arg-Gly-Asp-D-Phe-Lys) (Kantlehner M., *et al.*, *Angew. Chem. Int. Ed.* 38:560 (1999)), cyclo(Arg-Gly-Asp-D-Tyr-Lys) (Haubner, R., *et al.*, *J. Nucl. Med.* 42:326-336 (2001)), ribosome-inactivating proteins (RIPs) such as Saporin (*e.g.*, SEQ ID NO:67), matrix metalloproteinase inhibitors (*e.g.*, U.S. Patent No. 5,616,605), and antiviral peptides and polypeptides, such as HIV fusion inhibitors (*e.g.*, T-1249 and T-20 (FUZEON® (enfuvirtide); Trimeris Inc.), and soluble receptor antagonists such as immunoadhesins (*e.g.*, LFA3-Ig, CTLA4-Ig).

Antimicrobial polypeptide and peptide drugs are also suitable for use in the invention. Examples of suitable antimicrobial polypeptide and peptide drugs include adenoregulin, dermcidin-1L, cathelicidins (*e.g.*, cathelicidin-like peptide, human LL-37/hCAP-18), defensins, including α -defensins (*e.g.*, human neutrophil peptide 1 (HNP-1), HNP-2, HNP-3, HNP-4, human defensin 5, human defensin 6), β -defensins (*e.g.*, human β -defensin-1, human β -defensin-2), and θ -defensins (*e.g.*, θ -defensin-1), histatins (*e.g.*, histatin 1, histatin 3, histatin 5), lactoferricin-derived peptide and related peptides (see, Tomita M., *et al.*, *Acta Paediatr. Jpn.* 36:585-591 (1994) and Strom, M.B., *et al. Biochem Cell Biol.* 80:65-74 (2002)).

Drug Fusions

The drug fusions of the invention are fusion proteins that comprise a continuous polypeptide chain, said chain comprising an antigen-binding fragment of an antibody that binds serum albumin as a first moiety, linked to a second moiety that is a polypeptide drug. The first and second moieties can be directly bonded to each other through a peptide bond, or linked through a suitable amino acid, or peptide or polypeptide linker. Additional moieties (*e.g.*, third, fourth) and/or linker sequences can be present as appropriate. The first moiety can be in an N-terminal location, C-terminal location or internal relative to the second moiety (*i.e.*, the polypeptide drug). In certain embodiments, each moiety can be present in more than one copy. For example, the drug fusion can comprise two or more first moieties each comprising an antigen-binding fragment of an antibody that binds serum

- 51 -

albumin (*e.g.*, a V_H that binds human serum albumin and a V_L that bind human serum albumin or two or more V_H s or V_L s that bind human serum albumin).

In some embodiments the drug fusion is a continuous polypeptide chain that has the formula:

5

$$a-(X)_{n1}-b-(Y)_{n2}-c-(Z)_{n3}-d \quad \text{or} \quad a-(Z)_{n3}-b-(Y)_{n2}-c-(X)_{n1}-d;$$

wherein X is a polypeptide drug that has binding specificity for a first target;

Y is a single chain antigen-binding fragment of an antibody that has binding specificity for serum albumin;

10

Z is a polypeptide drug that has binding specificity for a second target;

a, b, c and d are each independently absent or one to about 100 amino acid residues;

$n1$ is one to about 10;

15

$n2$ is one to about 10; and

$n3$ is zero to about 10,

with the proviso that when $n1$ and $n2$ are both one and $n3$ is zero, X does not comprise an antibody chain or a fragment of an antibody chain.

In one embodiment, neither X nor Z comprises an antibody chain or a fragment of an antibody chain. In one embodiment, $n1$ is one, $n3$ is one and $n2$ is two, three, four, five, six, seven, eight or nine. Preferably, Y is an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin. More preferably, Y is a dAb (*e.g.*, a V_H , V_K or V_λ) that binds human serum albumin. In a particular embodiment, X or Z is human IL-1ra or a functional variant of human IL-1ra.

25

In certain embodiments, Y comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26. In other embodiments, Y comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

30

In other embodiments, the drug fusion comprises moieties X' and Y', wherein X' is a polypeptide drug, with the proviso that X' does not comprise an antibody chain or a fragment of an antibody chain; and Y' is a single chain antigen-binding fragment of an antibody that has binding specificity for serum albumin.

- 5 Preferably, Y' is an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin. More preferably, Y' is a dAb (*e.g.*, a V_H, V_κ or V_λ) that binds human serum albumin. X' can be located amino terminally to Y', or Y' can be located amino terminally to X'. In some
- 10 embodiments, X' and Y' are separated by an amino acid, or by a peptide or polypeptide linker that comprises from two to about 100 amino acids. In a particular embodiment, X' is human IL-1ra or a functional variant of human IL-1ra.

- In certain embodiments, Y' comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID
- 15 NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26. In other embodiments, Y' comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

- In particular embodiments the drug fusion comprises a dAb that binds serum
- 20 albumin and human IL-1ra (*e.g.*, SEQ ID NO: 28). Preferably, the dAb binds human serum albumin and comprises human framework regions.

- In other embodiments, the drug fusion or drug conjugate comprises a functional variant of human IL-1ra that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least
- 25 about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with the mature 152 amino acid form of human IL-1ra and antagonizes human Interleukin-1 type 1 receptor. (See, Eisenberg *et al.*, *Nature* 343:341-346 (1990).) The variant can comprise one or more additional amino acids (*e.g.*, comprise 153 or 154 or more amino acids). The drug fusions of the invention can be
- 30 produced using any suitable method. For example, some embodiments can be ~~produced by the insertion of a nucleic acid encoding the drug fusion into a suitable~~ expression vector. The resulting construct is then introduced into a suitable host cell

for expression. Upon expression, fusion protein can be isolated or purified from a cell lysate or preferably from the culture media or periplasm using any suitable method. (See *e.g.*, *Current Protocols in Molecular Biology* (Ausubel, F.M. *et al.*, eds., Vol. 2, Suppl. 26, pp. 16.4.1-16.7.8 (1991)).

5 Suitable expression vectors can contain a number of components, for example, an origin of replication, a selectable marker gene, one or more expression control elements, such as a transcription control element (*e.g.*, promoter, enhancer, terminator) and/or one or more translation signals, a signal sequence or leader sequence, and the like. Expression control elements and a signal sequence, if
10 present, can be provided by the vector or other source. For example, the transcriptional and/or translational control sequences of a cloned nucleic acid encoding an antibody chain can be used to direct expression.

 A promoter can be provided for expression in a desired host cell. Promoters can be constitutive or inducible. For example, a promoter can be operably linked to
15 a nucleic acid encoding an antibody, antibody chain or portion thereof, such that it directs transcription of the nucleic acid. A variety of suitable promoters for procaryotic (*e.g.*, lac, tac, T3, T7 promoters for *E. coli*) and eucaryotic (*e.g.*, simian virus 40 early or late promoter, Rous sarcoma virus long terminal repeat promoter, cytomegalovirus promoter, adenovirus late promoter) hosts are available.

20 In addition, expression vectors typically comprise a selectable marker for selection of host cells carrying the vector, and, in the case of a replicable expression vector, an origin or replication. Genes encoding products which confer antibiotic or drug resistance are common selectable markers and may be used in procaryotic (*e.g.*, lactamase gene (ampicillin resistance), *Tet* gene for tetracycline resistance) and
25 eucaryotic cells (*e.g.*, neomycin (G418 or geneticin), gpt (mycophenolic acid), ampicillin, or hygromycin resistance genes). Dihydrofolate reductase marker genes permit selection with methotrexate in a variety of hosts. Genes encoding the gene product of auxotrophic markers of the host (*e.g.*, *LEU2*, *URA3*, *HIS3*) are often used as selectable markers in yeast. Use of viral (*e.g.*, baculovirus) or phage vectors, and
30 vectors which are capable of integrating into the genome of the host cell, such as retroviral vectors, are also contemplated. Suitable expression vectors for expression in mammalian cells and prokaryotic cells (*E. coli*), insect cells (*Drosophila*

Schnieder S2 cells, Sf9) and yeast (*P. methanolica*, *P. pastoris*, *S. cerevisiae*) are well-known in the art.

Recombinant host cells that express a drug fusion and a method of preparing a drug fusion as described herein are provided. The recombinant host cell comprises
5 a recombinant nucleic acid encoding a drug fusion. Drug fusions can be produced by the expression of a recombinant nucleic acid encoding the protein in a suitable host cell, or using other suitable methods. For example, the expression constructs described herein can be introduced into a suitable host cell, and the resulting cell can be maintained (*e.g.*, in culture, in an animal) under conditions suitable for expression
10 of the constructs. Suitable host cells can be prokaryotic, including bacterial cells such as *E. coli*, *B. subtilis* and or other suitable bacteria, eucaryotic, such as fungal or yeast cells (*e.g.*, *Pichia pastoris*, *Aspergillus species*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Neurospora crassa*), or other lower eucaryotic cells, and cells of higher eucaryotes such as those from insects (*e.g.*, Sf9 insect cells (WO
15 94/26087 (O'Connor)) or mammals (*e.g.*, COS cells, such as COS-1 (ATCC Accession No. CRL-1650) and COS-7 (ATCC Accession No. CRL-1651), CHO (*e.g.*, ATCC Accession No. CRL-9096), 293 (ATCC Accession No. CRL-1573), HeLa (ATCC Accession No. CCL-2), CV1 (ATCC Accession No. CCL-70), WOP (Dailey *et al.*, *J. Virol.* 54:739-749 (1985)), 3T3, 293T (Pear *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 90:8392-8396 (1993)), NSO cells, SP2/0, HuT 78 cells, and the like
20 (see, *e.g.*, Ausubel, F.M. *et al.*, eds. *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons Inc., (1993)).

The invention also includes a method of producing a drug fusion, comprising maintaining a recombinant host cell of the invention under conditions appropriate
25 for expression of a drug fusion. The method can further comprise the step of isolating or recovering the drug fusion, if desired. In another embodiment, the components of the drug fusion (*e.g.*, dAb that binds human serum albumin and IL-1ra) are chemically assembled to create a continuous polypeptide chain.

30 Conjugates

In another aspect, the invention provides conjugates comprising an antigen-binding fragment of an antibody that binds serum albumin that is bonded to a drug.

- 55 -

Such conjugates include "drug conjugates," which comprise an antigen-binding fragment of an antibody that binds serum albumin to which a drug is covalently bonded, and "noncovalent drug conjugates," which comprise an antigen-binding fragment of an antibody that binds serum albumin to which a drug is noncovalently bonded. Preferably, the conjugates are sufficiently stable so that the antigen-binding fragment of an antibody that binds serum albumin and drug remain substantially bonded (either covalently or noncovalently) to each other under *in vivo* conditions (e.g., when administered to a human). Preferably, no more than about 20%, no more than about 15%, no more than about 10%, no more than about 9%, no more than about 8%, no more than about 7%, no more than about 6%, no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1% or substantially none of the conjugates dissociate or break down to release drug and antigen-binding fragment under *in vivo* conditions. For example, stability under "*in vivo*" conditions can be conveniently assessed by incubating drug conjugate or noncovalent drug conjugate for 24 hours in serum (e.g., human serum) at 37°C. In one example of such a method, equal amounts of a drug conjugate and the unconjugated drug are diluted into two different vials of serum. Half of the contents of each vial is immediately frozen at -20°C, and the other half incubated for 24 hours at 37°C. All four samples can then be analyzed using any suitable method, such as SDS-PAGE and/or Western blotting. Western blots can be probed using an antibody that binds the drug. All drug in the drug conjugate lanes will run at the size of the drug conjugate if there was no dissociation. Many other suitable methods can be used to assess stability under "*in vivo*" conditions, for example, by analyzing samples prepared as described above using suitable analytic methods, such as chromatography (e.g., gel filtration, ion exchange, reversed phase), ELISA, mass spectroscopy and the like.

Drug Conjugates

In another aspect, the invention provides a drug conjugate comprising an antigen-binding fragment of an antibody that has binding specificity for serum albumin, and a drug that is covalently bonded to said antigen-binding fragment, with the proviso that the drug conjugate is not a single continuous polypeptide chain.

- 56 -

In some embodiments, the drug conjugate comprises an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin, and a drug that is covalently bonded to said V_H or V_L , with the proviso that the drug conjugate is not a single continuous polypeptide chain. Preferably the drug conjugate comprises a single V_H that binds serum albumin or a single V_L that binds serum albumin. In certain embodiments, the drug conjugate comprises a V_k dAb that binds human serum albumin and comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26. In other embodiments, the drug conjugate comprises a V_H dAb that binds human serum albumin and comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

The drug conjugates can comprise any desired drug and can be prepared using any suitable methods. For example, the drug can be bonded to the antigen-binding fragment of an antibody that binds serum albumin directly or indirectly through a suitable linker moiety at one or more positions, such as the amino-terminus, the carboxyl-terminus or through amino acid side chains. In one embodiment, the drug conjugate comprises a dAb that binds human serum albumin and a polypeptide drug (*e.g.*, human IL-1ra or a functional variant of human IL-1ra), and the amino-terminus of the polypeptide drug (*e.g.*, human IL-1ra or a functional variant of human IL-1ra) is bonded to the carboxyl-terminus of the dAb directly or through a suitable linker moiety. In other embodiments, the drug conjugate comprises a dAb that binds human serum albumin and two or more different drugs that are covalently bonded to the dAb. For example, a first drug can be covalently bonded (directly or indirectly) to the carboxyl terminus of the dAb and a second drug can be covalently bonded (directly or indirectly) to the amino-terminus or through a side chain amino group (*e.g.*, ϵ amino group of lysine). Such drug conjugates can be prepared using well-known methods of selective coupling. (See, —

e.g., Hermanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, CA (1996).)

A variety of methods for conjugating drugs to an antigen-binding fragment of an antibody that has binding specificity for serum albumin can be used. The particular method selected will depend on the drug to be conjugated. If desired, linkers that contain terminal functional groups can be used to link the antigen-binding fragment and the drug. Generally, conjugation is accomplished by reacting a drug that contains a reactive functional group (or is modified to contain a reactive functional group) with a linker or directly with an antigen-binding fragment of an antibody that binds serum albumin. Covalent bonds form by reacting a drug that contains (or is modified to contain) a chemical moiety or functional group that can, under appropriate conditions, react with a second chemical group thereby forming a covalent bond. If desired, a suitable reactive chemical group can be added to the antigen-binding fragment or to a linker using any suitable method. (See, *e.g.*, Hermanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, CA (1996).) Many suitable reactive chemical group combinations are known in the art, for example an amine group can react with an electrophilic group such as tosylate, mesylate, halo (chloro, bromo, fluoro, iodo), N-hydroxysuccinimidyl ester (NHS), and the like. Thiols can react with maleimide, iodoacetyl, acryloyl, pyridyl disulfides, 5-thiol-2-nitrobenzoic acid thiol (TNB-thiol), and the like. An aldehyde functional group can be coupled to amine- or hydrazide-containing molecules, and an azide group can react with a trivalent phosphorous group to form phosphoramidate or phosphorimide linkages. Suitable methods to introduce activating groups into molecules are known in the art (see for example, Hermanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, CA (1996)).

In some embodiments, the antigen-binding fragment of an antibody that has binding specificity for serum albumin is bonded to a drug by reaction of two thiols to form a disulfide bond. In other embodiments, the antigen-binding fragment of an antibody that has binding specificity for serum albumin is bonded to a drug by reaction of an isothiocyanate group and a primary amine to produce an isothiourea bond.

- 58 -

Suitable linker moieties can be linear or branched and include, for example, tetraethylene glycol, C₂-C₁₂ alkylene, -NH-(CH₂)_p-NH- or -(CH₂)_p-NH- (wherein p is one to twelve), -CH₂-O-CH₂-CH₂-O-CH₂-CH₂-O-CH₂-NH-, a polypeptide chain comprising one to about 100 (preferably one to about 12) amino acids and the like.

5

Noncovalent Drug Conjugates

Some noncovalent bonds (*e.g.*, hydrogen bonds, van der Waals interactions) can produce stable, highly specific intermolecular connections. For example, molecular recognition interactions achieved through multiple noncovalent bonds between complementary binding partners underlie many important biological interactions, such as the binding of enzymes to their substrates, the recognition of antigens by antibodies, the binding of ligands to their receptors, and stabilization of the three dimensional structure of proteins and peptide. Accordingly, such weak noncovalent interactions (*e.g.*, hydrogen bonding, van Der Waals interactions, electrostatic interactions, hydrophobic interactions and the like) can be utilized to bind a drug to the antigen-binding fragment of an antibody that has binding specificity for serum albumin.

Preferably, the noncovalent bond linking the antigen-binding fragment and drug be of sufficient strength that the antigen-binding fragment and drug remain substantially bonded to each under *in vivo* conditions (*e.g.*, when administered to a human). Generally, the noncovalent bond linking the antigen-binding fragment and drug has a strength of at least about 10¹⁰ M⁻¹. In preferred embodiments, the strength of the noncovalent bond is at least about 10¹¹ M⁻¹, at least about 10¹² M⁻¹, at least about 10¹³ M⁻¹, at least about 10¹⁴ M⁻¹ or at least about 10¹⁵ M⁻¹. The interactions between biotin and avidin and between biotin and streptavidin are known to be very efficient and stable under many conditions, and as described herein noncovalent bonds between biotin and avidin or between biotin and streptavidin can be used to prepare a noncovalent drug conjugate of the invention.

The noncovalent bond can be formed directly between the antigen-binding ~~fragment of an antibody that has a specificity for serum albumin and drug, or can be~~ formed between suitable complementary binding partners (*e.g.*, biotin and avidin or

30

- 59 -

streptavidin) wherein one partner is covalently bonded to drug and the complementary binding partner is covalently bonded to the antigen-binding fragment. When complementary binding partners are employed, one of the binding partners can be covalently bonded to the drug directly or through a suitable linker moiety, and the complementary binding partner can be covalently bonded to the antigen-binding fragment of an antibody that binds serum albumin directly or through a suitable linker moiety.

Complementary binding partners are pairs of molecules that selectively bind to each other. Many complementary binding partners are known in the art, for example, antibody (or an antigen-binding fragment thereof) and its cognate antigen or epitope, enzymes and their substrates, and receptors and their ligands. Preferred complementary binding partners are biotin and avidin, and biotin and streptavidin.

Direct or indirect covalent bonding of a member of a complementary binding pair to an antigen-binding fragment that has binding specificity for serum albumin or a drug can be accomplished as described above, for example, by reacting a complementary binding partner that contains a reactive functional group (or is modified to contain a reactive functional group) with an antigen-binding fragment of an antibody that binds serum albumin, with or without the use of a linker. The particular method selected will depend on the compounds (*e.g.*, drug, complementary binding partner, antigen-binding fragment of an antibody that binds serum albumin) to be conjugated. If desired, linkers (*e.g.*, homobifunctional linkers, heterobifunctional linkers) that contain terminal reactive functional groups can be used to link the antigen-binding fragment and/or the drug to a complementary binding partner. In one embodiment, a heterobifunctional linker that contains two distinct reactive moieties can be used. The heterobifunctional linker can be selected so that one of the reactive moieties will react with the antigen-binding fragment of an antibody that has binding specificity for serum albumin or the drug, and the other reactive moiety will react with the complementary binding partner. Any suitable linker (*e.g.*, heterobifunctional linker) can be used and many such linkers are known in the art and available for commercial sources (*e.g.*, Pierce Biotechnology, Inc., IL).

Compositions and Therapeutic and Diagnostic Methods

- 60 -

Compositions comprising drug compositions of the invention (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), including pharmaceutical or physiological compositions (*e.g.*, for human and/or veterinary administration) are provided. Pharmaceutical or physiological compositions comprise one or more drug compositions (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion), and a pharmaceutically or physiologically acceptable carrier. Typically, these carriers include aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and/or buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride and lactated Ringer's. Suitable physiologically-acceptable adjuvants, if necessary to keep a polypeptide complex in suspension, may be chosen from thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin and alginates. Intravenous vehicles include fluid and nutrient replenishers and electrolyte replenishers, such as those based on Ringer's dextrose. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents and inert gases, may also be present (Mack (1982) *Remington's Pharmaceutical Sciences*, 16th Edition).

The compositions can comprise a desired amount of drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion). For example the compositions can comprise about 5% to about 99% drug conjugate, noncovalent drug conjugate or drug fusion by weight. In particular embodiments, the composition can comprise about 10% to about 99%, or about 20% to about 99%, or about 30% to about 99% or about 40% to about 99%, or about 50% to about 99%, or about 60% to about 99%, or about 70% to about 99%, or about 80% to about 99%, or about 90% to about 99%, or about 95% to about 99% drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion), by weight. In one example, the composition is freeze dried (lyophilized).

The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), described herein will typically find use in preventing, suppressing or treating inflammatory states (*e.g.*, acute and/or chronic inflammatory diseases), such as chronic obstructive pulmonary disease (*e.g.*, chronic bronchitis, chronic obstructive bronchitis, emphysema), allergic hypersensitivity, cancer, bacterial or viral infection, pneumonia, such as bacterial pneumonia (*e.g.*, Staphylococcal

pneumonia)), autoimmune disorders (which include, but are not limited to, Type I diabetes, multiple sclerosis, arthritis (*e.g.*, osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, lupus arthritis, spondylarthropathy (*e.g.*, ankylosing spondylitis)), systemic lupus erythematosus, inflammatory bowel disease (*e.g.*, Crohn's disease, ulcerative colitis), Behcet's syndrome and myasthenia gravis), endometriosis, psoriasis, abdominal adhesions (*e.g.*, post abdominal surgery), asthma, and septic shock. The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), described herein can be used for preventing, suppressing or treating pain, such as chronic or acute traumatic pain, chronic or acute neuropathic pain, acute or chronic musculoskeletal pain, chronic or acute cancer pain and the like. The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), described herein can also be administered for diagnostic purposes.

Cancers that can be prevented, suppressed or treated using the drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions), described herein include lymphomas (*e.g.*, B cell lymphoma, acute myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma), myelomas (*e.g.*, multiple myeloma), lung cancer (*e.g.*, small cell lung carcinoma, non-small cell lung carcinoma), colorectal cancer, head and neck cancer, pancreatic cancer, liver cancer, stomach cancer, breast cancer, ovarian cancer, bladder cancer, leukemias (*e.g.*, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia), adenocarcinomas, renal cancer, haematopoietic cancers (*e.g.*, myelodysplastic syndrome, myeloproliferative disorder (*e.g.*, polycythemia vera, essential (or primary) thrombocythemia, idiopathic myelofibrosis), and the like.

The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) described herein are also suitable for use in preventing, suppressing or treating endometriosis, fibrosis, infertility, premature labour, erectile dysfunction, osteoporosis, diabetes (*e.g.*, type II diabetes), growth disorder, HIV infection, respiratory distress syndrome, tumors and bedwetting.

In the instant application, the term "prevention" involves administration of
the protective composition prior to the induction of the disease. "Suppression" refers

- 62 -

to administration of the composition after an inductive event, but prior to the clinical appearance of the disease. "Treatment" involves administration of the protective composition after disease symptoms become manifest.

Animal model systems which can be used to screen the effectiveness of drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) in protecting against or treating the disease are available. Methods for the testing of systemic lupus erythematosus (SLE) in susceptible mice are known in the art (Knight *et al.* (1978) *J. Exp. Med.*, 147: 1653; Reinersten *et al.* (1978) *New Eng. J. Med.*, 299: 515). Myasthenia Gravis (MG) is tested in SJL/J female mice by inducing the disease with soluble AchR protein from another species (Lindstrom *et al.* (1988) *Adv. Immunol.*, 42: 233). Arthritis is induced in a susceptible strain of mice by injection of Type II collagen (Stuart *et al.* (1984) *Ann. Rev. Immunol.*, 42: 233). A model by which adjuvant arthritis is induced in susceptible rats by injection of mycobacterial heat shock protein has been described (Van Eden *et al.* (1988) *Nature*, 331: 171). Effectiveness for treating osteoarthritis can be assessed in a murine model in which arthritis is induced by intra-articular injection of collagenase (Blom, A.B. *et al.*, *Osteoarthritis Cartilage* 12:627-635 (2004)). Thyroiditis is induced in mice by administration of thyroglobulin as described (Maron *et al.* (1980) *J. Exp. Med.*, 152: 1115). Insulin dependent diabetes mellitus (IDDM) occurs naturally or can be induced in certain strains of mice such as those described by Kanasawa *et al.* (1984) *Diabetologia*, 27: 113. EAE in mouse and rat serves as a model for MS in human. In this model, the demyelinating disease is induced by administration of myelin basic protein (see Paterson (1986) *Textbook of Immunopathology*, Mischer *et al.*, eds., Grune and Stratton, New York, pp. 179-213; McFarlin *et al.* (1973) *Science*, 179: 478; and Satoh *et al.* (1987) *J. Immunol.*, 138: 179).

The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) of the present invention may be used as separately administered compositions or in conjunction with other agents. These can include various immunotherapeutic drugs, such as cyclosporine, methotrexate, adriamycin or cisplatinum, immunotoxins and the like. Pharmaceutical compositions can include "cocktails" of various cytotoxic or other agents in conjunction with the drug

composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) of the present invention, or combinations of drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) according to the present invention comprising different drugs.

5 The drug compositions (*e.g.*, drug conjugates, noncovalent drug conjugates, drug fusions) can be administered to any individual or subject in accordance with any suitable techniques. A variety of routes of administration are possible including, for example, oral, dietary, topical, transdermal, rectal, parenteral (*e.g.*, intravenous, intraarterial, intramuscular, subcutaneous, intradermal, intraperitoneal, intrathecal, intraarticular injection), and inhalation (*e.g.*, intrabronchial, intranasal or oral
10 inhalation, intranasal drops) routes of administration, depending on the drug composition and disease or condition to be treated. Administration can be local or systemic as indicated. The preferred mode of administration can vary depending upon the drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug
15 fusion) chosen, and the condition (*e.g.*, disease) being treated. The dosage and frequency of administration will depend on the age, sex and condition of the patient, concurrent administration of other drugs, counterindications and other parameters to be taken into account by the clinician. A therapeutically effective amount of a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) is
20 administered. A therapeutically effective amount is an amount sufficient to achieve the desired therapeutic effect, under the conditions of administration.

 The term "subject" or "individual" is defined herein to include animals such as mammals, including, but not limited to, primates (*e.g.*, humans), cows, sheep, goats, horses, dogs, cats, rabbits, guinea pigs, rats, mice or other bovine, ovine,
25 equine, canine, feline, rodent or murine species.

 The drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) can be administered as a neutral compound or as a salt. Salts of compounds (*e.g.*, drug compositions, drug conjugates, noncovalent drug conjugates, drug fusions) containing an amine or other basic group can be obtained, for example,
30 by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, ~~hydrogen bromide, acetic acid, perchloric acid and the like.~~ ~~Compounds with a~~ quaternary ammonium group also contain a counteranion such as chloride, bromide,

iodide, acetate, perchlorate and the like. Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base. Salts of acidic functional groups contain a counteranion such as sodium, potassium and the like.

5 The invention also provides a kit for use in administering a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) to a subject (*e.g.*, patient), comprising a drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion), a drug delivery device and, optionally, instructions for use. The drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug
10 fusion) can be provided as a formulation, such as a freeze dried formulation. In certain embodiments, the drug delivery device is selected from the group consisting of a syringe, an inhaler, an intranasal or ocular administration device (*e.g.*, a mister, eye or nose dropper), and a needleless injection device.

 The drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) of this invention can be lyophilized for storage and reconstituted in a
15 suitable carrier prior to use. Any suitable lyophilization method (*e.g.*, spray drying, cake drying) and/or reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilisation and reconstitution can lead to varying degrees of antibody activity loss (*e.g.*, with conventional
20 immunoglobulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate. In a particular embodiment, the invention provides a composition comprising a lyophilized (freeze dried) drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) as described herein. Preferably, the lyophilized (freeze
25 dried) drug composition (*e.g.*, drug conjugate, noncovalent drug conjugate, drug fusion) loses no more than about 20%, or no more than about 25%, or no more than about 30%, or no more than about 35%, or no more than about 40%, or no more than about 45%, or no more than about 50% of its activity (*e.g.*, binding activity for serum albumin) when rehydrated. Activity is the amount of drug composition (*e.g.*,
30 drug conjugate, noncovalent drug conjugate, drug fusion) required to produce the effect of the drug composition before it was lyophilized. For example, the amount of drug conjugate or drug fusion needed to achieve and maintain a desired serum

concentration for a desired period of time. The activity of the drug composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) can be determined using any suitable method before lyophilization, and the activity can be determined using the same method after rehydration to determine amount of lost activity.

5 Compositions containing the drug composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, an amount sufficient to achieve the desired therapeutic or prophylactic effect, under the conditions of administration, such as at least partial inhibition, suppression,
10 modulation, killing, or some other measurable parameter, of a population of selected cells is defined as a "therapeutically-effective amount or dose." Amounts needed to achieve this dosage will depend upon the severity of the disease and the general state of the patient's own immune system and general health, but generally range from about 10 µg/kg to about 80 mg/kg, or about 0.005 to 5.0 mg of drug conjugate or
15 drug fusion per kilogram of body weight, with doses of 0.05 to 2.0 mg/kg/dose being more commonly used. For example, a drug composition (e.g., drug fusion, drug conjugate, noncovalent drug conjugate) of the invention can be administered daily (e.g., up to four administrations per day), every two days, every three days, twice weekly, once weekly, once every two weeks, once a month, or once every two
20 months, at a dose of, for example, about 10 µg/kg to about 80 mg/kg, about 100 µg/kg to about 80 mg/kg, about 1 mg/kg to about 80 mg/kg, about 1 mg/kg to about 70 mg/kg, about 1 mg/kg to about 60 mg/kg, about 1 mg/kg to about 50 mg/kg, about 1 mg/kg to about 40 mg/kg, about 1 mg/kg to about 30 mg/kg, about 1 mg/kg to about 20 mg/kg, about 1 mg/kg to about 10 mg/kg, about 10 µg/kg to about 10
25 mg/kg, about 10 µg/kg to about 5 mg/kg, about 10 µg/kg to about 2.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg or about 10 mg/kg.

For prophylactic applications, compositions containing the drug composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion) or cocktails thereof
30 may also be administered in similar or slightly lower dosages. A composition ~~containing a drug composition (e.g., drug conjugate, noncovalent drug conjugate, drug fusion)~~ according to the present invention may be utilised in prophylactic and

- 66 -

therapeutic settings to aid in the alteration, inactivation, killing or removal of a select target cell population in a mammal.

5 EXAMPLES

Interleukin 1 receptor antagonist (IL1-ra) is an antagonist that blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type 1 receptor (IL-1R1). IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. IL-1 has a range of activities including cartilage degradation and stimulation of bone resorption. In rheumatoid arthritis patients, the amount of locally produced IL-1 is elevated and the levels of naturally occurring IL1-ra are insufficient to compete with these abnormally increased amounts. There are several treatments available for RA including disease modifying antirheumatic drugs (DMARDS) such as methotrexate, and biologics such as KINERET® (anakinra, Amgen Inc).

KINERET® (anakinra, Amgen Inc) is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist which consists of 153 amino acids and has a molecular weight of 17.3 kilodaltons. (The amino acid sequence of KINERET® (anakinra, Amgen Inc) corresponds to the 152 amino acids in naturally occurring IL-1ra and an additional N-terminal methionine.) KINERET® (anakinra, Amgen Inc) is indicated for the reduction in signs and symptoms of moderate to severe rheumatoid arthritis in patients 18 years of age or older who have failed one or more DMARDS. Dosage is a single use daily subcutaneous injection of 100mgs of drug. The $T_{1/2}$ is 4-6 hours and 71% of patients develop injection site reactions in 14-28 days.

Here we demonstrate that linking a therapeutic polypeptide to a serum-albumin binding dAb results in a compound which (i) has activity similar to the therapeutic polypeptide alone and (ii) also binds serum albumin. Furthermore, the present invention provides a method to create a long serum half-life version of the therapeutic polypeptide. For example, we have linked a serum albumin binding dAb to IL1-ra which results in a compound of longer serum half-life than IL1-ra alone.

- 67 -

5 Example 1 Selection of domain antibodies that bind mouse, rat and human serum albumin

 This example explains a method for making a single domain antibody (dAb) directed against serum albumin. Selection of dAbs against mouse serum albumin (MSA), human serum albumin (HSA) and rat serum albumin (RSA) is described.

10 The dAbs against mouse serum albumin were selected as described in WO 2004/003019 A2. Three human phage display antibody libraries were used. Each library was based on a single human framework for V_H (V3-23/DP47 and J_H4b) or V_κ (o12/o2/DPK9 and J_κ1) with side chain diversity encoded by NNK codons incorporated in complementarity determining regions (CDR1, CDR2 and CDR3).

15 Library 1 (V_H):

 Diversity at positions: H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58, H95, H97, H98.

 Library size: 6.2 x 10⁹

 Library 2 (V_H):

20 Diversity at positions: H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58, H95, H97, H98, H99, H100, H100A, H100B.

 Library size: 4.3 x 10⁹

 Library 3 (V_κ):

 Diversity at positions: L30, L31, L32, L34, L50, L53, L91, L92, L93, L94, L96

25 Library size: 2 x 10⁹

 The V_H and V_κ libraries had been preselected for binding to generic ligands protein A and protein L respectively so that the majority of clones in the selected libraries were functional. The sizes of the libraries shown above correspond to the sizes after preselection.

Two rounds of selection were performed on serum albumin using each of the libraries separately. For each selection, antigen was coated on immunotube (nunc) in 4 mL of PBS at a concentration of 100 µg/ml. In the first round of selection, each of the three libraries was panned separately against HSA (Sigma) or MSA (Sigma).

5 In the second round of selection, phage from each of the six first round selections was panned against (i) the same antigen again (eg 1st round MSA, 2nd round MSA) and (ii) against the reciprocal antigen (eg 1st round MSA, 2nd round HSA) resulting in a total of twelve 2nd round selections. In each case, after the second round of selection 48 clones were tested for binding to HSA and MSA. Soluble dAb
10 fragments were produced as described for scFv fragments by Harrison *et al*, *Methods Enzymol.* 1996; 267: 83-109 and standard ELISA protocol was followed (Hoogenboom *et al.* (1991) *Nucleic Acids Res.* , 19: 4133) except that 2% tween PBS was used as a blocking buffer and bound dAbs were detected with either protein L-HRP (Sigma) (for the V_κS) and protein A-HRP (Amersham Pharmacia
15 Biotech) (for the V_HS).

dAbs that gave a signal above background indicating binding to MSA, HSA or both were tested in ELISA insoluble form for binding to plastic alone but all were specific for serum albumin. Clones were then sequenced (see Table 1) revealing that 21 unique dAb sequences had been identified. The minimum similarity (at the amino
20 acid level) between the V_κ dAb clones selected was 86.25% ((69/80) X100; the result when all the diversified residues are different, *e.g.*, clones 24 and 34). The minimum similarity between the V_H dAb clones selected was 94 % ((127/136) X100).

Next, the serum albumin binding dAbs were tested for their ability to capture
25 biotinylated antigen from solution. ELISA protocol (as above) was followed except that ELISA plate was coated with 1 µg/ml protein L (for the V_κ clones) and 1 µg/ml protein A (for the V_H clones). Soluble dAb was captured from solution as in the protocol and detection was with biotinylated MSA or HSA and streptavidin HRP. The biotinylated MSA and HSA had been prepared according to the manufacturer's
30 instructions, with the aim of achieving an average of 2 biotins per serum albumin molecule. ~~Twenty four clones were identified that captured biotinylated MSA from~~ solution in the ELISA. Two of these (clones 2 and 38 below) also captured

- 69 -

biotinylated HSA. Next, the dAbs were tested for their ability to bind MSA coated on a CM5 biacore chip. Eight clones were found that bound MSA on the biacore.

dAbs against human serum albumin and rat serum albumin were selected as previously described for the anti-MSA dAbs except for the following modifications to the protocol: The phage library of synthetic V_H domains was the library 4G,
5 which is based on a human V_H3 comprising the DP47 germline gene and the J_H4 segment. The diversity at the following specific positions was introduced by mutagenesis (using NNK codons; numbering according to Kabat) in CDR1: 30, 31, 33, 35; in CDR2: 50, 52, 52a, 53, 55, 56; and in CDR3: 4-12 diversified residues:
10 e.g. H95, H96, H97, and H98 in 4G H11 and H95, H96, H97, H98, H99, H100, H100a, H100b, H100c, H100d, H100e and H100f in 4G H19. The last three CDR3 residues are FDY so CDR3 lengths vary from 7-15 residues. The library comprises >1x10¹⁰ individual clones.

A subset of the V_H and V_K libraries had been preselected for binding to
15 generic ligands protein A and protein L respectively so that the majority of clones in the unselected libraries were functional. The sizes of the libraries shown above correspond to the sizes after preselection.

Two rounds of selection were performed on rat and human serum albumin using subsets of the V_H and V_K libraries separately. For each selection, antigen was
20 either (i) coated on immunotube (nunc) in 4ml of PBS at a concentration of 100µg/ml or (ii) bitotinylated and then used for soluble selection followed by capture on streptavidin beads (in the 1st round) and neutravidin beads (in the 2nd round). (See Table 1 for details of the selection strategy used to isolate each clone.) In each case, after the second round of selection 24 phage clones were tested for
25 binding to HSA or RSA.

If a significant proportion of the clones in one of the selections were positive in the phage ELISA, then DNA from this selection was cloned into an expression vector for production of soluble dAb, and individual colonies were picked. Soluble dAb fragments were produced as described for scFv fragments by Harrison *et al*
30 (Methods Enzymol. 1996;267:83-109) and standard ELISA protocol was followed (~~Hoogenboom *et al.* (1991) Nucleic Acids Res., 19: 4133) except that 2% TWEEN~~ PBS was used as a blocking buffer and bound dAbs were detected with anti-myc-

HRP . Clones that were positive in ELISA were then screened for binding to MSA, RSA or HSA using a BIACORE surface plasmon resonance instrument (Biacore AB). dAbs which bound to MSA, RSA or HSA were further analysed. Clones were then sequenced and unique dAb sequences identified.

5

Table 1. Selection protocols for dAbs that bind serum albumin

dAb	Library	R1 selection	R2 selection	Biacore binding
DOM7r-1	4G V κ	10 μ g/ml tube RSA	10 μ g/ml tube RSA	RSA
DOM7r-3	4G V κ	10 μ g/ml tube RSA	10 μ g/ml tube RSA	RSA
DOM7r-4	4G V κ	10 μ g/ml tube RSA	10 μ g/ml tube RSA	RSA, MSA
DOM7r-5	4G V κ	10 μ g/ml tube RSA	10 μ g/ml tube RSA	RSA
DOM7r-7	4G V κ	10 μ g/ml tube RSA	10 μ g/ml tube RSA	RSA, MSA
DOM7r-8	4G V κ	10 μ g/ml tube RSA	10 μ g/ml tube RSA	RSA, MSA
DOM7h-1	4G V κ	10 μ g/ml tube HSA	10 μ g/ml tube HSA	HSA
DOM7h-2	4G V κ	Soluble 100nM HSA	Soluble 50nM HSA	HSA
DOM7h-3	4G V κ	10 μ g/ml tube HSA	10 μ g/ml tube HSA	-
DOM7h-4	4G V κ	10 μ g/ml tube HSA	10 μ g/ml tube HSA	-
DOM7h-6	4G V κ			
DOM7h-7	4G V κ			
DOM7h-8	4G V κ	Soluble 200nM HAS	Soluble 50nM RSA	HSA, RSA, MSA

- 71 -

DOM7r-13	4G V _K	Soluble 200nM HAS	Soluble 50nM RSA	RSA, MSA
DOM7r-14	4G V _K	Soluble 200nM HAS	Soluble 50nM RSA	RSA, MSA
DOM7h-21	4G V _H	100µg/ml HSA tube	100 µg/ml HSA tube	HSA
DOM7h-22	4G V _H	100µg/ml HSA tube	100µg/ml HSA tube	HSA
DOM7h-23	4G V _H	100µg/ml HSA tube	100µg/ml HSA tube	HSA
DOM7h-24	4G V _H	100µg/ml HSA tube	100µg/ml HSA tube	HSA
DOM7h-25	4G V _H	100µg/ml HSA tube	100µg/ml HSA tube	HSA
DOM7h-26	4G V _H	100µg/ml HSA tube	100µg/ml HSA tube	HSA
DOM7h-27	4G V _H	100µg/ml HSA tube	100µg/ml HSA tube	HSA

dAbs that bound serum albumin on a BIACORE chip (Biacore AB) were then further analysed to obtain information on affinity. The analysis was performed using a CM5 chip (carboxymethylated dextran matix) that was coated with serum albumin. Flow cell 1 was an uncoated, blocked negative control, flow cell 2 was coated with HSA, flow cell 3 was coated with RSA and flow cell 4 was coated with MSA. The serum albumins were immobilised in acetate buffer pH 5.5 using the BIACORE coating wizard which was programmed to aim for 500 resonance units (RUs) of coated material. Each dAb of interest was expressed in the periplasm of *E. coli* on a 200 mL-500 mL scale and purified from the supernatant using batch absorbtion to protein A-streamline affinity resin (Amersham, UK) for the V_Hs and to protein L-agarose affinity resin (Affitech, Norway) for the V_Ks followed by elution with glycine at pH 2.2 and buffer exchange to PBS. A range of concentrations of

- 72 -

dAb were prepared (in the range 5nM to 5µM) by dilution into BIACORE HBS-EP buffer and flowed across the BIACORE chip.

Affinity (KD) was calculated from the BIACORE traces by fitting onrate and offrate curves to traces generated by concentrations of dAb in the region of the KD.

- 5 dAbs with a range of different affinities to serum albumin were identified. Included in the range 10-100nM, were the affinities of DOM7h-8 for HSA, DOM7h-2 for HSA and DOM7r-1 for RSA. Included in the range 100nM to 500nM were the affinities of DOM7h-7 for HSA, DOM7h-8 for RSA and DOM7h-26 for HSA. Included in the range 500nM to 5µM were the affinities of DOM7h-23 for HSA and
- 10 DOM7h-1 for HSA. Example traces are included in FIGS. 6A-6C.

Example 2. Formatting anti-serum albumin antibodies as a fusion with IL-1 receptor antagonist (IL-1ra)

- This example describes a method for making a fusion protein comprising IL-1ra and a dAb that binds to serum albumin. Two fusions were made, one with the
- 15 dAb N-terminal of the IL-1ra (MSA16IL1-ra) and one with the dAb C-terminal of the IL-1ra (IL1-raMSA 16). The sequences of the fusions and the vector are shown in FIG. 2C and 2D. A control fusion that did not bind MSA was also produced, and its sequence is shown in FIG. 2E.

- 20 KINERET (anakinra, Amgen Inc) has a short half-life of 4-6 hours, and the recommended dosing regime calls for daily injections. This regime lead to injection site reaction in 14-28 days in 71% of cases. Therefore a form of human IL-1ra that has a longer serum half-life would be beneficially and could increase efficacy and reduce dosing frequency. These are both desirable properties for a pharmaceutical.

25

Cloning

Briefly, two multiple cloning sites (MCSs) were designed as detailed below and inserted into an expression vector with a T7 promotor. The restriction sites were designed for the insertion of IL1-ra, dAb, GAS leader and linker. One (MCS 1+3)

30 encodes a protein with the dAb N terminal of the IL-1ra and the other (MCS 2 + 4) encode a protein with the dAb C terminal of the IL-1ra.

- 73 -

Cloning site 1+3 for dAbIL1-ra fusion

NdeI, stuffer, SalI, NotI, stuffer, XhoI, BamHI

gcgcatatgttagtcgctgcacgtcaaaaggccatagcggcgccgctgcaggtctcgagtgcgatggatcc

5 (SEQ ID NO:35)

Cloning site 2+4 for IL1-radAb fusion

NdeI, stuffer, StuI, SacI, stuffer, SalI, NotI, TAA TAA BamHI

10 gcgcatatgttaagcgaggccttctggagagagctcaggagtgctgcacggacatccagatgacccaggcgccgctaa
taaggatccaatgc (SEQ ID NO:36)

The GAS leader was then inserted into each vector by digesting the MCS using the appropriate restriction enzymes and ligating annealed primers coding for the leader. Next, linker DNA coding for the linker was inserted in a similar manner. DNA coding for IL-1ra was obtained by PCR (using primers designed to add the required restriction sites) from a cDNA clone and inserted into a TOPO cloning vector. After confirming the correct sequence by nucleic acid sequencing, DNA coding for IL-1ra was excised from the TOPO vector and ligated into the vectors containing leader and linker. Lastly, DNA coding for the dAb was excised from the dAb expression vector and inserted into the vectors by SalI/NotI digest of insert (purified by gel purification) and vector.

Expression and purification

25 MSA16IL1-ra, IL1-raMSA16 and dummyIL-1ra were expressed in the periplasm of *E. coli* and purified from the supernatant using batch absorption to protein L-agarose affinity resin (Affitech, Norway) followed by elution with glycine at pH 2.2. The purified dAbs were then analysed by SDS-PAGE gel electrophoresis followed by coomassie staining. For one of the proteins (IL-1raMSA 16), > 90% of the protein was of the expected size and therefore was analysed for activity without further purification. The other proteins (MSA16IL1-ra and dummy IL-1ra) were contaminated by a smaller band and were therefore further purified by FPLC ion

- 74 -

exchange chromatography on the RESOURCEQ ion exchange column at pH 9. Protein was eluted using a linear salt gradient from 0-500 mM NaCl. After analysis by SDS-PAGE gel electrophoresis, fractions containing a protein of the expected size were combined yielding a combined fraction of >90% purity. This protein was
5 used for further analysis

Example 3. Determination of activity of dAb IL1-ra fusion *in vitro*

MRC-5 IL-8 assay

MSA16IL-1ra fusions were tested for the ability to neutralise the induction
10 of IL-8 secretion by IL-1 in MRC-5 cells (ATCC Accession No. CCL-171; American Type Culture Collection, Manassas, VA). The method is adapted from Akeson, L. et al (1996) Journal of Biological Chemistry 271, 30517-30523, which describes the induction of IL-8 by IL-1 in HUVEC, MRC-5 cells were used instead of the HUVEC cell line. Briefly, MRC-5 cells plated in microtitre plates were
15 incubated overnight with dAbIL-1ra fusion proteins or IL-1ra control, and IL-1 (100 pg/mL). Post incubation the supernatant was aspirated off the cells and IL-8 concentration measured via a sandwich ELISA (R&D Systems).

The activity of IL-1ra in the fusion proteins led to a reduction in IL-8 secretion. The reduction of IL-8 secretion resulting from activity of the MSA16IL-1-
20 ra fusion and from activity of the IL-1raMSA16 fusion was compared to the reduction seen with the IL-1ra control (recombinant human IL-1ra, R&D systems). The neutralizing dose 50 (ND₅₀) of each of the tested proteins was determined and is presented in Table 2.

25 Table 2

Protein	ND ₅₀
IL-1ra	0.5 nM
MSA16IL-1ra	2 nM
IL-1raMSA16	8 nM

- 75 -

The results demonstrate that IL-1ra remained active as part of a fusion construct with an anti-serum albumin dAb. The MSA16IL-1ra protein was further studied to assess its pharmacokinetics (PK study).

5 Serum Albumin, anti IL-1ra sandwich ELISA

Three dAb/IL-1ra fusions were tested for the ability to bind serum albumin and simultaneously be detected by a monoclonal anti-IL1ra antibody. The fusions tested were MSA16IL-1ra, IL-1raMSA16 and dummyIL-1ra. Briefly, ELISA plate was coated overnight with mouse serum albumin at 10 µg/ml, washed 5 x with
10 0.05% Tween PBS and then blocked for 1 hour with 4% Marvel PBS. After blocking, the plate was washed 5 x with 0.05% Tween PBS and then incubated for 1 hour with each dAb, IL-1ra fusion diluted in 4% MPBS. Each fusion was incubated at 1 µM concentration and at 7 sequential 4-fold dilutions (ie down to 60pM). After the incubation, plates were washed 5 x with 0.05% Tween PBS and then incubated
15 for 1 hour with the manufacturers recommended dilution of a rabbit polyclonal antibody (ab-2573) to human IL-1 receptor antagonist (Abcam, UK) diluted in 4% MPBS. After this incubation, plates were washed 5 x with 0.05% Tween PBS and then incubated for 1h with a 1/2000 dilution of secondary antibody (anti-rabbit IgG-HRP) diluted in 4% MPBS. Following incubation with the secondary antibody,
20 plates were washed 3 x with 0.05% Tween PBS and 2 x with PBS and then developed with 50 µl per well of TMB microwell peroxidase substrate (KPL, MA) and the reaction stopped with 50 µl per well of HCL. Absorbtion was read at 450 nM.

Both the MSA16IL-1ra and IL-1raMSA16 proteins were detected at more
25 than 2 x background level at 1 µM concentration in the sandwich ELISA. The MSA16IL-1ra protein was detected at 2 x background or higher at dilutions down to 3.9 nM, whereas the IL-1raMSA16 protein was detected at 2 x background only down to 500 nM. Binding of the MSA16IL-1ra fusion to serum albumin was shown to be specific for serum albumin as the control construct (dummyIL-1ra) did not
30 bind serum albumin.

Example 4. Determination of serum half-life of drug fusions in mouse PK studies.

- 76 -

A. Determination of the serum half-life in mouse of a MSA binding dAb/HA epitope tag fusion protein.

The MSA binding dAb/HA epitope tag fusion protein was expressed in the periplasm of *E. coli* and purified using batch absorption to protein L-agarose affinity resin (Affitech, Norway) followed by elution with glycine at pH 2.2. Serum half-life of the fusion protein was determined in mouse following a single intravenous (i.v.) injection at approx 1.5 mg/kg into CD1 strain male animals. Analysis of serum levels was by ELISA using goat anti-HA (Abcam, UK) capture and protein L-HRP (Invitrogen, USA) detection which was blocked with 4% Marvel. Washing was with 0.05% Tween-20, PBS. Standard curves of known concentrations of MSA binding dAb/HA fusion were set up in the presence of 1x mouse serum to ensure comparability with the test samples. Modelling with a 1 compartment model (WinNonlin Software, Pharsight Corp., USA) showed the MSA binding dAb/HA epitope tag fusion protein had a terminal phase $t_{1/2}$ of 29.1 hours and an area under the curve of 559 hr. μ g/ml. This demonstrates a large improvement over the predicted half-life for a HA epitope tag peptide alone which could be as short as only several minutes.

The results of this study using the HA epitope tag as a drug model, demonstrate that the *in vivo* serum half-life of a drug can be extended when the drug is prepared as a drug fusion or drug conjugate with an antigen-binding fragment of (e.g., dAb) of an antibody that binds serum albumin.

The *in vivo* half-life in mice of the anti-MSA dAbs DOM7m-16 and DOM7m-26, and a control dAb that does not bind MSA were also assessed. Again, DOM7m-16, DOM7m-26 and the control dAb contained an HA epitope tag, which serves as a model for a drug (e.g., a protein, polypeptide or peptide drug). In this study, the control dAb, that does not bind MSA, had an *in vivo* half-life of 20 minutes, whereas the *in vivo* half-lives of DOM7m-16 and DOM7m-26 were significantly extended. (FIG. 12) DOM7m-16 was found to have an *in vivo* half-life in mice of 29.5 hours in further studies.

~~In another study, the *in vivo* half-life ($t_{1/2}$) of DOM7h-8 which contained an~~
HA epitope tag was evaluated in mice. Modelling with a 2 compartment model

- 77 -

(WinNonlin Software, Pharsight Corp., USA) showed that DOM7h-8 had a $t_{1/2\beta}$ of 29.1 hours.

The results of each of these study using the HA epitope tag as a model for a drug (*e.g.*, a protein, polypeptide or peptide drug), demonstrate that the *in vivo* serum half-life of a drug can be dramatically extended when the drug is prepared as a drug fusion or drug conjugate with an antigen-binding fragment of (*e.g.*, dAb) of an antibody that binds serum albumin.

B. Determination of the serum half-life in mouse of MSA binding dAb/IL-1ra fusion protein.

The MSA binding dAb/IL-1ra fusion protein (MSA16IL-1ra) was expressed in the periplasm of *E. coli* and purified using batch absorbtion to protein L-agarose affinity resin (Affitech, Norway) followed by elution with glycine at pH 2.2. Serum half-life of the MSA16IL-1ra (DOM7m-16/IL-1ra), an IL-1ra fusion with a dAb that does not bind MSA (Dummy dAb/IL-1ra), and an anti-MSA dAb fused to the HA epitope tag (DOM7m-16 HA tag) was determined in mice following a single i.v. injection at approximately 1.5 mg/kg into CD1 strain male animals.

Analysis of serum levels was by IL-1ra sandwich ELISA (R&D Systems, USA). Standard curves of known concentrations of dAb/IL-1ra fusion were set up in the presence of 1x mouse serum to ensure comparability with the test samples. Modelling was performed using the WinNonlin pharmacokinetics software (Pharsight Corp., USA).

It was expected that the IL-1ra fusion with the anti-MSA dAb would increase the serum half-life considerably when compared with the control which was a fusion of a non-MSA binding dAb with IL-1ra. The control non-MSA binding dAb/IL-1ra fusion was predicted to have a short serum half-life.

The results of the study are presented in Table 3, and show that the IL-1ra fusion with anti-MSA dAb (DOM7m-16/IL-1ra had a serum half-life that was about 10 times longer than the IL-1ra fusion with a dAb that does not bind MSA (Dummy dAb/IL-1ra). The results also revealed that there was a > 200 fold improvement (increase) in the area under the concentration time curve for DOM7m-16/IL-1ra (AUC: 267 hr. μ g/ml) as compared to dummy/IL-1ra (AUC: 1.5 hr. μ g/ml)

Table 3

Agent	Serum Half-life
DOM7m-16/IL-1ra	4.3 hours
dummy/IL-1ra	0.4 hours
DOM7m-16 HA tag	29 hours

5 The results of these studies demonstrate that the *in vivo* serum half-life and AUC of a drug can be significantly extended when the drug is prepared as a drug fusion or drug conjugate with an antigen-binding fragment of (*e.g.*, dAb) of an antibody that binds serum albumin.

10 Example 5. Determination of the serum half-life in rats of RSA binding dAb/HA epitope tag fusion proteins.

 Anti-rat serum albumin dAbs were expressed with C-terminal HA tags in the periplasm of *E. coli* and purified using batch absorbtion to protein L-agarose affinity resin (Affitech, Norway) for V κ dAbs and batch absorbtion to protein A affinity
15 resin for V H dAbs, followed by elution with glycine at pH 2.2. In order to determine serum half-life, groups of 4 rats were given a single i.v. injection at 1.5 mg/Kg of DOM7r-27, DOM7r-31, DOM7r-16, DOM7r-3, DOM7h-8 or a control dAb (HEL4) that binds an irrelevant antigen. Serum samples were obtained by serial bleeds from a tail vein over a 7 day period and analyzed by sandwich ELISA
20 using goat anti-HA (Abcam, cambridge UK) coated on an ELISA plate, followed by detection with protein A-HRP (for the V H dAbs) or protein L-HRP (for V κ dAbs). Standard curves of known concentrations of dAb were set up in the presence of 1x rat serum to ensure comparability with the test samples. Modelling with a 2 compartment model (using WinNonlin pharmacokinetics software (Pharsight Corp.,
25 USA)) was used to calculate t $_{1/2\beta}$ and area under the curve (AUC) (Table 4). The t $_{1/2\beta}$ for HEL4 control in rats is up to 30 minutes, and based on the data obtain the AUC for DOM7h-8 is expected to be between about 150 hr. μ g/mL and about 2500 hr. μ g/mL.

Table 4

Agent	Scaffold	Affintity (KD) for rat serum albumin	t _{1/2} β	AUC (hr.µg/mL)
DOM7r-3	V _κ	12 nM	13.7 hours	224
DOM7r-16	V _κ	1 µM	34.4 hours	170
DOM7r-27	V _H	250 nM	14.8 hours	78.9
DOM7r-31	V _H	5 µM	5.96 hours	71.2

The results of this rat study using the HA epitope tag as a model for a drug (e.g., a protein, polypeptide or peptide drug), demonstrate that the *in vivo* serum half-life of a drug can be dramatically extended when the drug is prepared as a drug fusion or drug conjugate with an antigen-binding fragment of (e.g., dAb) of an antibody that binds serum albumin.

10 Prediction of half-life in humans.

The *in vivo* half-life of a dAb, drug fusion or drug conjugate in humans can be estimated from half-life data obtained in animals using allometric scaling. The log of the *in vivo* half-lives determined in 3 animals is plotted against the log of the weight of the animal. A line is drawn through the plotted points and the slope and y-intercept of the line are used to calculate the *in vivo* half-life in humans using the formula $\log Y = \log(a) + b \log(W)$, in which Y is the *in vivo* half-life in humans, log(a) is the y-intercept, b is the slope, and W is the weight of a human. The line can be produced using *in vivo* half-life data obtain in animals that weigh about 35 grams (e.g., mice), about 260 grams (e.g., rats) and about 2,710 grams. For this calculation, the weight of a human can be considered to be 70,000 grams. Based on half-life values obtained in mice and rats, dAbs that bind human serum albumin, such as DOM7h-8, are expected to have t_{1/2}β of about 5.5 hours to about 40 hours and AUC of about 150 hr.µg/mL to about 2500 hr.µg/mL, in humans.

Example 6. Efficacy of anti-SA dAb/IL-1ra drug fusion in mouse collagen induced arthritis model of rheumatoid arthritis.

Efficacy of the fusion DOM7m-16/IL-1ra and efficacy of IL-1ra in a recognized mouse model of rheumatoid arthritis (type II collagen induced arthritis (CIA) in DBA/1 mice) was assessed. Throughout the study, mice were maintained in a test facility in standard type 2 cages that were housed in a HEPA-filtered Scantainer at 20-24°C with a 12-hours light, 12-hours dark cycle. Food (Harlan-Teklad universal diet 2016) and UV sterilized water were provided *ad libitum*. The mice were imported to the test facility at least 7 days before the start the study to assure proper acclimatization.

DBA/1 mice at 7-8 weeks of age (obtained from Taconic M and B, Domholtveg, Denmark) were injected once with an emulsion of Arthrogen-CIA adjuvant and Arthrogen-CIA collagen (both MD biosciences) emulsified at a 1:1 ratio until the emulsion was stable. The emulsion was considered to be stable when a drop of the emulsion added to a beaker of water formed a solid clump. The mice were then injected with the emulsion.

Twenty-one days after the emulsion was injected, the 20 animals with the most advanced arthritic disease were eliminated from the study, and the remaining mice were divided into groups of 10 animals (each group contained 5 males and 5 females). The mice were treated as shown in Table 5, and all treatments were delivered at a concentration calculated so that 10 ml/Kg were administered.

25

Table 5

Group	Treatment
1	IL-1ra, 1 mg/Kg (intrapertoneal (ip.) bolus)
2	IL-1ra, 10 mg/Kg (ip. bolus)
3	DOM7m-16/IL-1ra, 1 mg/Kg (ip. bolus)
4	DOM7m-16/IL-1ra, 10 mg/Kg (ip. bolus)

5	ENBREL® (entarecept; Immunex Corporation), 5 mg/Kg (ip. bolus)
6	saline (negative control), 10 ml/Kg (ip. bolus)
7	Dexamethasone (positive control), 0.4 mg/Kg (subcutaneous injection)

Clinical scores for the severity of arthritis were recorded 3 times a week from day 21 to day 49. Mice were euthanized at day 49. Individual mice were euthanized earlier if they presented an arthritic score of 12 or more, or had serious problems moving.

For clinical scoring, each limb was scored according to the criteria below and the scores for all four limbs were added to produce the total score for the mouse. This method resulted in a score of 0 to 16 for each mouse. Scoring criteria were: 0 = normal; 1 = mild but definite redness and swelling of the ankle or wrist, or apparent redness and swelling limited to individual digits, regardless of the number of affected digits; 2 = moderate redness and swelling of ankle and wrist; 3 = severe redness and swelling of the entire paw including digits; 4 = maximally inflamed limb with involvement of multiple joints.

Group average arthritic scores were calculated for each treatment group on every treatment day using clinical scores from individual mice. Any animals that had been removed from the study for ethical reasons were allocated the maximum score of 16. The group average arthritic scores were plotted against time (FIG. 13).

Statistical analysis of the group average arthritic scores on day 49 were performed using the Wilcoxon test. This statistical analysis revealed that the two groups treated with DOM7m-16/IL-1ra (at 1 mg/Kg or 10 mg/Kg (Groups 3 and 4)) had significantly improved arthritic scores at day 49 (at the $P < 1\%$ and $P < 0.05\%$ significance levels respectively) when compared to the saline control group (Group 6). In contrast, treatment with IL-1ra at 1 mg/Kg (Group 1) did not result in statistically significant improvement in the arthritic score at day 49, while treatment with IL-1ra at 10 mg/Kg (Group 2) resulted in a significant improvement at the $P < 5\%$ significance level. Treatment with ENBREL® (entarecept; Immunex Corporation) (Group 5) resulted in significant improvement in the arthritic score at day 49 at the $P < 10\%$ significance level.

Treatment with DOM7m-16/IL-1ra at the 10 mg/Kg dose (Group 4), was effective at improving the arthritic score at day 49 (significant at the $P < 0.5\%$ level) when compared to standard treatment with ENBREL® (entarecept; Immunex Corporation) at 5mg/Kg (Group 5). In addition, treatment with DOM7m-16/IL-1ra at the lower 1mg/Kg dose (Group 3), was more efficacious at improving the arthritic score at day 49 than treatment with IL-1ra alone at the same dosage (Group 1) (significant at the $P < 10\%$ level).

The results of the study show that at certain doses DOM7m-16/IL-1ra was more effective than IL-1ra or ENBREL® (entarecept; Immunex Corporation) in this study. The response to IL-1ra was dose dependent, as expected, and the response to DOM7m-16/IL-1ra was also dose dependent. The average scores for treatment with DOM7m-16/IL-1ra at 1mg/Kg were consistently lower than the average scores obtained by treatment with IL-1ra at 10 mg/kg. These plotted results (FIG. 13) indicate that treatment with DOM7m-16/IL-1ra was about 10 times more effective than IL-1ra in this study.

This superior efficacy of DOM7m-16/IL-1ra was observed even though the DOM7-16/IL-1ra fusion protein contains about half the number of IL-1 receptor binding epitopes as IL-1ra on a weight basis (*e.g.*, 1 mg of DOM7m-16/IL-1ra (MW \approx 31.2 kD) contains about half the number of IL-1 receptor binding epitopes as 1 mg of IL-1ra (MW \approx 17.1 kD).

The results of this study demonstrate that a dAb that binds serum albumin can be linked to IL-1ra (a clinically proven therapy for RA) and that the resulting drug fusion has both long serum half-life properties (conferred by the dAb) and IL-1 receptor binding properties (conferred by the IL-1ra). Due to the serum residence time of the drug fusion, the dose of DOM7-16/IL-1ra that was effective for treating CIA was dramatically reduced relative to IL-1ra.

The results of this study demonstrate that in addition to the benefits of extended half-life and increased AUC, drugs prepared as drug fusions or drug conjugates with an antigen-binding fragment of (*e.g.*, dAb) of an antibody that binds serum albumin are highly effective therapeutic agents that provide advantages over drug alone. For example, as demonstrated in the mouse CIA model, a lower dose of drug fusion was effective and inhibited the joint inflammation and joint damage

caused by IL-1 over a longer period of time in comparison to IL-1ra alone, and provided greater protection against disease progression.

Example 7. Anti-SA dAb/Saporin noncovalent drug conjugate

5 The ribosome-inactivating protein Saporin (an anti-cancer drug) is highly stable to denaturants and proteases and has been used as a targeted toxin to T lymphocytes. A non-covalent drug conjugate was prepared by coupling Saporin to DOM7h-8 via a biotin-streptavidin link. Results obtained with this non-covalent drug conjugate demonstrates that the DOM7h-8 retains its serum albumin binding
10 characteristics when coupled to a drug.

A variant DOM7h-8 referred to as DOM7h-8cys, in which the C-terminal arginine at position 108 (amino acid 108 of SEQ ID NO:24) was replaced with a cysteine residue was prepared by expression of a recombinant nucleic acid in HB2151 cells. The cells were grown and induced at 30°C in overnight expression
15 autoinduction TB readymix (Merck KGa, Germany) for 72 hours before recovery of the supernatant by centrifugation. DOM7h-8cys was purified from the supernatant using affinity capture on protein L-agarose. The resin was then washed with 10 column volumes of 2 x PBS and DOM7h-8cys was eluted with 0.1 M glycine pH2. Eluted DOM7h-8cys was neutralized with 0.2 x volume of Tris pH8 and
20 concentrated to 1mg/ml (using a CENTRICON 20 ml concentrator (Millipore Corp., MA).

Concentrated DOM7h-8cys was buffer exchanged to PBS using a NAP5 desalting column (GE Healthcare/Amersham Biosciences, NJ) and concentration determined. The dAb was then biotinylated (via primary amines) using EZ-LINK
25 sulfo-NHS-LC-biotin (Pierce Biotechnology Inc., IL). The biotinylated dAb was mixed with streptavidin-saporin (Advanced Targeting Systems, San Deigo) in a 1:1 molar ratio.

In order to confirm that the dAb/saporin complex was formed, a sandwich ELISA was used to detect intact complexes. Human serum albumin (HSA) was
30 coated onto half of the wells of an ELISA plate (Nunc, NY) overnight at 10 µg/ml in a volume of 100 µl per well. After overnight incubation, the plate was washed 3 times with PBS, 0.05% Tween and then the whole plate was blocked for 2 hours

- 84 -

with 2% PBS. After blocking, the plate was washed 3 times with PBS, 0.05% Tween and then incubated for 1 hour with DOM7h-8/saporin non-covalent conjugate diluted to 0.5 μ M in 2% Tween PBS. As controls on the same ELISA plate, uncoupled saporin at 0.5 μ M and uncoupled DOM7h8 at 0.5 μ M were

5 incubated in 2% Tween PBS. Additional controls were the same three diluted proteins incubated on wells of the ELISA plate not coated with HAS and blocked with 2% Tween. After the incubation, the plate was washed 3 times with PBS, 0.05% Tween and then incubated for 1 hour with 1/2000 dilution of goat anti-saporin polyclonal antibody (Advanced Therapeutic Systems) diluted in 2% Tween

10 PBS. After the incubation, the plate was washed 3 times with PBS, 0.05% Tween and then incubated for 1 hour with the secondary detection antibody (of 1/2000 anti-goat Ig HRP conjugate). After the incubation, the plate was washed 3 times with PBS, 0.05% Tween and once with PBS and tapped dry on paper. The ELISA was developed with 100 μ l 3,3',5,5'-tetramethylbenzidine as substrate and the reaction

15 stopped with 50 μ l 1M hydrochloric acid. The presence of non-covalent conjugates of DOM7h-8 and saporin was confirmed by comparing the OD600 of the conjugate with that of either of the unconjugated parts.

Table 6

	DOM7h-8/Saporin	DOM7h-8 alone	Saporin alone
OD600 (plate coated with HAS)	0.311	0.060	0.079
OD600 (plate blocked with 2% Tween PBS)	0.078	0.068	0.075

20

The results of this study demonstrate that a drug can be conjugated to an antigen-binding fragment of an antibody that binds serum albumin, and that the conjugated antigen-binding fragment retains serum albumin-binding activity. In addition, due to the stability and strength of the biotin-streptavidin interaction, the

25 ~~results show that covalently bonded and noncovalently bonded conjugates can be~~

- 85 -

prepared that retain the serum albumin-binding activity of the antigen-binding fragment of an antibody that binds serum albumin.

Example 8. Anti-SA dAb/Fluorescein conjugate

5 Fluorescein isothiocyanate (FITC) can be cross linked with amino, sulfhydryl, imidazolyl, tyrosyl or carbonyl groups on a protein. It has a molecular weight of 389 Da which is comparable in size to many small molecule drugs. Results obtained with this conjugate demonstrate that the anti-SA dAb maintains its serum albumin binding characteristics when coupled to a small chemical entity, and
10 indicate that small molecule drugs can be conjugated to anti-SA dAbs.

Concentrated DOM7h-8cys was prepared as described in Example 7. The concentrated dAb was buffer exchanged to 50 mM Borate pH 8 (coupling buffer) using a NAP5 desalting column (GE Healthcare/Amersham Biosciences, NJ) and then concentrated to 2.3 mg/ml using a 2 ml CENTRICON concentrator (Millipore
15 Corp., MA). The FITC (Pierce Biotechnology Inc.) was diluted to 10 mg/ml in dimethyl formamide (DMF) according to the manufacturer's instructions and then mixed with the dAb in coupling buffer at a molar ratio of 24:1 FITC:dAb. The reaction was allowed to proceed for 30 minutes. At this point, excess unreacted FITC was removed from the reaction using a PD10 desalting column (GE
20 Healthcare/Amersham Biosciences, NJ) that was pre-equilibrated with PBS, and the DOM7h-8cys/FITC conjugate was eluted with PBS.

In order to confirm that the FITC/dAb coupling reaction was successful, a sandwich ELISA was used to detect coupled dAb. Human serum albumin (HSA) was coated onto half of the wells of an ELISA plate (Nunc, NY) overnight at 10
25 µg/ml in a volume of 100 µl per well. After overnight incubation, the whole plate was washed 3 times with PBS, 0.05% Tween and then all the wells were blocked for 2 hours with 2% Tween PBS. After blocking, the plate was washed 3 times with PBS, 0.05% Tween and then incubated for 1 hour with DOM7h-8cys/FITC diluted to 1 µM in 2% Tween PBS. As controls on the same ELISA plate, a control FITC
30 coupled antibody at 1 µM and uncoupled DOM7h-8 at 1 µM were incubated in 2% Tween PBS. Additional controls were the same three diluted proteins incubated on
wells of the ELISA plate not coated with HSA and blocked with 2% Tween. After

the incubation, the plate was washed 3 times with PBS, 0.05% Tween and then incubated for 1 hour with 1/500 dilution of rat anti FITC antibody (Serotec) diluted in 2% Tween PBS. After the incubation, the plate was washed 3 times with PBS, 0.05% Tween, and then incubated for 1 hour with the secondary detection antibody diluted in 2% Tween PBS (1/5000 anti-rat Ig HRP conjugate). After the incubation, the plate was washed 3 times with PBS, 0.05% Tween and once with PBS and tapped dry on paper. The ELISA was developed with 100 μ l per well 3,3',5,5'-tetramethylbenzidine as substrate and the reaction stopped with 50 μ l per well 1M hydrochloric acid. The presence of conjugates of DOM7h-8 and FITC was confirmed by comparing the OD600 of the conjugate with that of either of the unconjugated parts.

Table 7

	DOM7h-8/FITC	DOM7h-8 alone	FITC coupled antibody (negative control)
OD600 (plate coated with HSA)	0.380	0.042	0.049
OD600 (plate blocked with 2% Tween PBS)	0.041	0.041	0.045

15

Example 9. anti-SA dAb/peptide conjugates.

Many peptides have therapeutic effects. Model peptides with an N- or C-terminal cysteine can be coupled to an anti-serum albumin dAb.

In this case, four different peptides will be used: peptide 1

20 YPYDVPDYAKKKKKKC (SEQ ID NO:68); peptide 2 CKKKKKKYPYDVPDYA (SEQ ID NO:69); peptide 3 HHHHHHKKKKKKKC (SEQ ID NO:70) and peptide 4: CKKKKKKHHHHHH (SEQ ID NO:71). Peptides 1 and 2 include the sequence of the hemagglutinin tag (HA tag) and peptides 3 and 4 include the sequence of the His tag. Concentrated DOM7h-8cys will be prepared as described in Example 7.

The concentrated dAb will be reduced with 5 mM dithiothreitol and then
buffer exchanged to coupling buffer (20 mM BisTris pH 6.5, 5 mM EDTA, 10%
glycerol) using a NAP5 desalting column (GE Healthcare/Amersham Biosciences,
NJ). Cysteines will be blocked (to prevent the dAb dimerizing with itself) using a
5 final concentration of 5 mM dithiodipyridine which will be added to the dAb
solution from a stock of 100 mM dithiodipyridine in DMSO. The dAb and
dithiodipyridine will be left to couple for 20-30 minutes. Unreacted dithiodipyridine
will then be removed using a PD10 desalting column and the dAb will be eluted in
coupling buffer (20 mM BisTris pH 6.5, 5 mM EDTA, 10% glycerol). The resulting
10 protein will then be frozen until required.

Peptides 1-4 will be individually dissolved in water at a concentration of 200
 μ M, will be reduced using 5 mM DTT and then will be desalted using a NAP5
desalting column (GE Healthcare/Amersham Biosciences, NJ). Each peptide will
then be added to a solution of reduced and blocked dAb at a 20:1 ratio, for the
15 peptide-dAb coupling to occur. In order to confirm success of the peptide, dAb
coupling reactions, a sandwich ELISA will be used to detect anti-SA dAb/peptide
conjugates.

Human serum albumin will be coated onto an ELISA plate (Nunc, NY)
overnight at 10 μ g/ml in a volume of 100 μ l per well. After overnight incubation,
20 the plate will be washed 3 times with PBS, 0.05% Tween and then will be blocked
for 2 hours with 4% Marvel PBS. After blocking, the plate will be washed 3 times
with PBS, 0.05% Tween and then will be incubated for 1 hour with DOM7h-
8/peptide conjugates diluted to 1 μ M in 4% Marvel PBS. As controls on the same
ELISA plate, uncoupled peptide at 20 μ M and uncoupled DOM7h-8 at 1 μ M will be
25 incubated in 4% MPBS. After the incubation, the plate will be washed 3 times with
PBS, 0.05% Tween and then will be incubated for 1 hour with 1/2000 dilution of
goat anti-HA antibody (Abcam) for peptides 1 and 2, and a 1/2000 dilution of Ni
NTA-HRP (for peptides 3 and 4) diluted in 4% Marvel PBS. After incubation, the
plate will be washed 3 times with PBS, 0.05% Tween and the wells with the goat
30 anti HA antibody will be incubated for 1h with secondary anti-goat HRP antibody
diluted 1/2000 in 4% MPBS (other wells were blocked for 1h). After the incubation,
the plate will be washed 3 times with PBS, 0.05% Tween and once with PBS and

will then be tapped dry on paper. The ELISA will be developed with 3,3',5,5'-

tetramethylbenzidine as substrate and the reaction will be stopped with 1M

hydrochloric acid. The presence of conjugates of DOM7h-8/peptide conjugate will be confirmed by comparing the OD600 of the conjugate with that of either of the

5 unconjugated parts.

Table 8 Anticancer Peptides		
Peptide Category	Peptide Sequence	Action/Application
LH-RH Agonists and Antagonists	p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 SEQ ID NO:89	Treatment of sex hormone dependent malignant diseases
Gastrin Releasing Peptide	p-Glu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 SEQ ID NO:90	Small Cell Lung Carcinoma
Somatostatin	p-Ala-Gly-Cys-Lys-Asn-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys SEQ ID NO:91	Tumors (general)
GH-RH	Gln-Trp-Ala-Val-Gly-His-Leu-psi(CH2-NH)-Leu-NH2 (RC-3094) SEQ ID NO:92	Glioblastoma Tumor, Prostate Tumor
VEGF	Arg-Arg-Lys-Arg-Arg-Arg SEQ ID NO:93	Human Colon Carcinoma
	Ala-Thr-Trp-Leu-Pro-Pro-Arg SEQ ID NO:94	Tumor Cell Proliferation
	Arg-Thr-Glu-Leu-Asn-Val-Gly-Ile-Asp-Phe-Asn-Trp-Glu-Tyr-Pro-Ala-Ser-Lys SEQ ID NO:95	Tumor Cell Proliferation and Migration
	His-His-Glu-Val-Val-Lys-Phe-Mel-Asp-Val-Tyr-Gln SEQ ID NO:96	Inhibits endothelial cell responses
	Asn-Ile-Thr-Val-Thr-Leu-Lys-Lys-Phe-Pro-Leu SEQ ID NO:97	Angiogenesis Inhibitor
EGF	Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys SEQ ID NO:98	Inhibits EGF based cell proliferation

	Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val-NH ₂ SEQ ID NO:99	Binds to HER2
IL-6	Gly-Gly-Cys-Lys-Leu-Trp-Thr-Ile-Pro-Glu-Cys-Gly-Gly SEQ ID NO:100	Inhibits cellular growth
IL-8	Ala-Val-Leu-Pro-Arg SEQ ID NO:101	Apoptosis induction and antitumor effect <i>in vivo</i>
PDGF	Tyr-Gly-Arg-Pro-Arg-Glu-Ser-Gly-Lys-Lys-Arg-Lys-Arg-Lys-Arg-Leu-Lys-Pro-Thr SEQ ID NO:102	Inhibits growth of malignant glioma
TNF	AcCys-Pro-Ser-Glu-Gly-Leu-Cys-NH ₂ SEQ ID NO:103	Inhibits Tumor Growth
	Ac-Cys-Pro-Ser-Glu-Gly-Thr-Pro-Ser-Thr-His-Val-Leu-Cys-NH ₂ SEQ ID NO:104	
	Ac-Leu-Ala-Asn-Gly-Val-Glu SEQ ID NO:105	
	Pro-Gln-Ala-Glu-Gly-Gln-Leu-NH ₂ SEQ ID NO:106	
	Val-Ala-Asn-Pro-Gln-Ala-Glu-Gly-Gln-Leu SEQ ID NO:107	
	Cyclic Lys-Gly-Asp-Gln-Leu-Ser SEQ ID NO:108	
	Cyclic Tyr-Ser-Cln-Val-Leu-Phe-Lys-Gly SEQ ID NO:109	
Alpha-feto Protein	Glu-Met-Thr-Pro-Val-Asn-Pro-Gly SEQ ID NO:110	Inhibits Estrogen Dependent Breast Cancer Cells
Sialyl-Lewis mimics	Ile-Glu-Leu-Leu-Gln-Ala-Arg SEQ ID NO:111	Inhibits lung colonization of tumor cells
Urokinase-type Plasminogen activator	Cys-Val-Ser-Asn-Lys-Tyr-Phe-Ser-Asn-Ile-His-Trp-Cys SEQ ID NO:112	Antagonist for uPA/uPAR
	Phe-X-X-Tyr-Lys-Trp SEQ ID NO:113	Antagonist for uPA/uPAR
	Lys-Trp-X-X-Ar SEQ ID NO:114	Antagonist for uPA/uPAR
	Leu-Asn-Phe-Ser-Gln-Tyr-Leu-Trp-Tyr-Thr-NH ₂ SEQ ID NO:115	Antagonist for uPA/uPAR
	Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-NH ₂	Inhibits tumor progression and

	SEQ ID NO:116	angiogenesis
p53	Ac-Met-Pro-Arg-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-Asn-NH2 SEQ ID NO:117	Inhibits Hdm2 and p53 binding
	Met-Val-Arg-Arg-Phe-Leu-Val-Thr-Leu-Arg-Ile-Arg-Arg-Ala-Cys-Gly-Pro-Pro-Arg-Val SEQ ID NO:118	Prevents p53 ubiquitination
	Gly-Ser-Arg-Ala-His-Ser-Ser-His-Leu-Lys-Ser-Lys-Gly-Gln-Ser-Thr-Ser-Arg-His-Lys-Lys-Leu SEQ ID NO:119	Activates p53
p34cdc2	Cys-Ala-Phe-Tyr-Ile SEQ ID NO:120	Inhibits interaction between p34/p33 and pRb2 and p107
	Leu-Cys-Ala-Phe-Tyr-Ile-Met-Ala-Lys SEQ ID NO:121	
	Met-Cys-Ser-Met-Tyr-Gly-Ile-Cys-Lys SEQ ID NO:122	
Cdk2	Tyr-Ser-Phe-Val-His-Gly-Phe-Phe-Asn-Phe-Arg-Val-Ser-Trp-Arg-Glu-Met-Leu-Ala SEQ ID NO:123	Inhibits interaction between Cdk2 and histone H1
p21WAF1	Lys-Arg-Arg-Gln-Thr-Ser-Met-Thr-Ala-Phe-Tyr-His-Ser-Lys-Arg-Arg-Leu-Ile-Phe-Ser SEQ ID NO:124	Induces G1/S growth arrest
	Lys-Arg-Arg-Leu-Ile-Phe-Ser-Lys SEQ ID NO:125	
	Phe-Leu-Asp-Thr-Leu-Val-Val-Leu-His-Arg SEQ ID NO:126	
E2F/DP transcription	Arg-Cys-Val-Arg-Cys-Arg-Phe-Val-Val-Trp-Ile-Gly-Leu-Arg-Val-Arg-Cys-Leu-Val SEQ ID NO:127	Inhibits E2F function in vitro
	Leu-Asn-Trp-Ala-Trp-Ala-Ala-Glu-Val-Leu-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-Ile-Thr-Asn-Val SEQ ID NO:128	
	Leu-Glu-Gly-Ile-Gln-Leu-Ile-Ala-NH2 SEQ ID NO:129	
	Phe-Trp-Leu-Arg-Phe-Thr SEQ ID NO:130	
	Trp-Val-Arg-Trp-His-Phe	

	SEQ ID NO:131	
	Trp-Val-Arg-Trp-His SEQ ID NO:132	
	Trp-His-Phe-Ile-Phe-Trp SEQ ID NO:133	
	Ile-Trp-Leu-Ser-Gly-Leu-Ser-Arg-Gly- Val-Trp-Val-Ser-Phe-Pro SEQ ID NO:134	
	Gly-Ser-Arg-Ile-Leu-Thr-Phe-Arg-Ser- Gly-Ser-Trp-Tyr-Ala-Ser SEQ ID NO:135	
	Asp-Glu-Leu-Lys-Arg-Ala-Phe-Ala-Ala- Leu-Arg-Asp-Gln-Ile SEQ ID NO:136	
Bcl2	Lys-Lys-Leu-Ser-Glu-Cys-Leu-Lys-Lys- Arg-Ile-Gly-Asp-Glu-Leu-Asp-Ser SEQ ID NO:137	Triggers apoptosis in a cell free system
	Gly-Gln-Val-Gly-Arg-Gln-Leu-Ala-Ile- Ile-Gly-Asp-Asp-Ile-Asn-Arg SEQ ID NO:138	
	Arg-Asn-Ile-Ala-Arg-His-Leu-Ala-Gln- Val-Gly-Asp-Ser-Met-Asp-Arg SEQ ID NO:139	
Integrins	Tyr-Ile-Gly-Ser-Arg-NH ₂ SEQ ID NO:140	Inhibits tumor cell binding to ECMs
	Ac-Tyr-Ile-Gly-Ser-Arg-NH ₂ SEQ ID NO:141	
	Ac-Tyr-Ile-Gly-Ser-Arg-NHCH ₃ SEQ ID NO:142	
	Ac-Tyr-Ile-Gly-Ser-Arg-N(CH ₃) ₂ SEQ ID NO:143	
	Phe(pNH ₂)-Ile-Gly-Ser-Arg-NH ₂ SEQ ID NO:144	
	Ac-Tyr-Ile-Gly-Ser-Arg-NHCH(CH ₃) ₂ SEQ ID NO:145	
	CO(Asp-Tyr-Ile-Gly-Ser-Arg-NHPr) ₂ SEQ ID NO:146	
	Arg-Gly-Asp SEQ ID NO:147	
	Tyr-Ile-Gly-Ser-Arg SEQ ID NO:148	
	Ile-Pro-Cys-Asn-Asn-Lys-Gly-Ala-His- Ser-Val-Gly-Leu-Met-Trp-Trp-Met-Leu- Ala-Arg SEQ ID NO:149	
Angiostatin	Ser-Pro-His-Arg-Pro-Arg-Phe-Ser-Pro-	

Analogues	Ala	
	SEQ ID NO:150	
	Ser-Pro-His-Ala-His-Gly-Tyr-Ile-Pro-Ser SEQ ID NO:151	
	Thr-Pro-His-Thr-His-Asn-Arg-Thr-Pro-Glu SEQ ID NO:152	
	Thr-Pro-His-Arg-His-Gln-Lys-Thr-Pro-Glu SEQ ID NO:153	
	Glu-Pro-His-Arg-His-Ser-Ile-Phe-Thr-Pro-Glu SEQ ID NO:154	
Cadherins	Ac-Cys-His-Ala-Val-Cys-NH ₂ SEQ ID NO:155	Inhibits Angiogenesis
Histone Deacetylase	Cys-Glu-Lys-His-Ile-Met-Glu-Lys-Ile-Gln-Gly-Arg-Gly-Asp-Asp-Asp-Asp SEQ ID NO:156	Leukemia Inhibition
MMP2	Cys-Thr-Thr-His-Trp-Gly-Phe-Thr-Leu-Cys SEQ ID NO:156	Tumor Metastasis

While this invention has been particularly shown and described with
5 references to preferred embodiments thereof, it will be understood by those skilled
in the art that various changes in form and details may be made therein without
departing from the scope of the invention encompassed by the appended claims.

CLAIMS

What is claimed is:

1. A drug fusion having the formula:
5 $a-(X)_{n1}-b-(Y)_{n2}-c-(Z)_{n3}-d$ or $a-(Z)_{n3}-b-(Y)_{n2}-c-(X)_{n1}-d$,
wherein
X is a polypeptide drug that has binding specificity for a first target;
Y is an immunoglobulin heavy chain variable domain (V_H) that has
binding specificity for serum albumin, or an immunoglobulin light chain
10 variable domain (V_L) that has binding specificity for serum albumin;
Z is a polypeptide drug that has binding specificity for a second
target;
a, b, c and d are independently a polypeptide comprising one to about
100 amino acid residues or absent;
15 $n1$ is one to about 10;
 $n2$ is one to about 10; and
 $n3$ is zero to about 10,
with the proviso that when $n1$ and $n2$ are both one and $n3$ is zero, X does not
comprise an antibody chain or a fragment of an antibody chain.
20
2. The drug fusion of Claim 1, wherein $n1$ and $n3$ are both one, and $n2$ is two to
about 10.
3. The drug fusion of Claim 1, wherein Y comprises an amino acid sequence
25 selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ
ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24,
SEQ ID NO:25 and SEQ ID NO:26.
4. The drug fusion of Claim 1, wherein Y comprises an amino acid sequence
30 selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ
ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22
and SEQ ID NO:23.

-
5. The drug fusion of Claim 1, wherein X is IL-1ra or a functional variant of IL-1ra.
- 5 6. The drug conjugate of Claim 1, wherein X is an analgesic agent, an anti-cancer agent, a hormone or an antimicrobial polypeptide or peptide.
7. The drug conjugate of Claim 1, wherein X is an immunosuppressive agent, an antiviral agent, an antibiotic, an anti-inflammatory agent, a cytotoxin or
10 cytotoxic agent.
8. The drug conjugate of Claim 1, wherein X is a protease inhibitor.
9. A drug fusion comprising moieties X' and Y', wherein
15 X' is a polypeptide drug, with the proviso that X does not comprise an antibody chain or a fragment of an antibody chain; and
Y' is an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin.
20
10. The drug fusion of Claim 9, wherein X' is located amino terminally to Y'.
11. The drug fusion of Claim 9, wherein Y' is located amino terminally to X'.
- 25 12. The drug fusion of Claim 9, wherein said V_H and V_L have binding specificity for human serum albumin.
13. The drug fusion of Claim 12, wherein Y' comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ
30 ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26.

-
14. The drug fusion of Claim 12, wherein Y' comprises an amino acid sequence
selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ
ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22
and SEQ ID NO:23.
- 5
15. The drug fusion of Claim 9, wherein X' is IL-1ra or a functional variant of
IL-1ra.
16. A drug conjugate comprising an immunoglobulin heavy chain variable
10 domain (V_H) that has binding specificity for serum albumin, or an
immunoglobulin light chain variable domain (V_L) that has binding specificity
for serum albumin, and a drug that is covalently bonded to said V_H or V_L.
17. The drug conjugate of Claim 16, wherein the drug conjugate comprises a
15 single V_H.
18. The drug conjugate of Claim 16, wherein the drug conjugate comprises a
single V_L.
- 20 19. The drug conjugate of Claim 16, wherein said drug is covalently bonded to
said V_H or V_L through a linker moiety.
20. The drug conjugate of Claim 16, wherein two or more different drugs are
covalently bonded to said V_H or V_L.
- 25
21. The drug conjugate of Claim 16, wherein the drug is a polypeptide.
22. The drug conjugate of Claim 21, wherein said polypeptide is IL-1ra or a
functional variant of IL-1ra.
- 30
23. The drug conjugate of Claim 16, wherein the drug is an analgesic agent, an
anti-cancer agent, a hormone or an antimicrobial polypeptide or peptide.

-
24. The drug conjugate of Claim 16, wherein the drug is an immunosuppressive agent, an antiviral agent, and antibiotic, an anti-inflammatory agent, a cytotoxin or cytotoxic agent, an antimetabolite, an alkylating agent, an anthacycline, or a radionuclide.
25. The drug conjugate of Claim 16, wherein the drug is a protease inhibitor.
26. The drug conjugate of Claim 16, wherein said immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.
27. A recombinant nucleic acid encoding the drug fusion of Claim 1 or Claim 9.
28. A nucleic acid construct comprising the recombinant nucleic acid of Claim 27.
29. A host cell comprising the recombinant nucleic acid of Claim 27.
30. A method for producing a drug fusion comprising maintaining the host cell of Claim 29 under conditions suitable for expression of said recombinant nucleic acid, whereby a drug fusion is produced.
31. A pharmaceutical composition comprising a drug fusion of Claim 1 or Claim 9 and a physiologically acceptable carrier.

-
32. A pharmaceutical composition comprising a drug conjugate of Claim 16 and a physiologically acceptable carrier.
33. A method for treating an individual having an inflammatory disease,
5 comprising administering to said individual a therapeutically effective amount of a drug conjugate or drug fusion of any one of Claims 5, 15 and 22.
34. The method of Claim 33, wherein said inflammatory disease is arthritis.
- 10 35. The drug conjugate or drug fusion of any one of Claims 3, 4, 13, 14 and 26 for use in therapy, diagnosis or prophylaxis
36. The drug conjugate or drug fusion of any one of Claims 5, 15 and 22 for use in therapy, diagnosis or prophylaxis.
- 15 37. Use of a drug conjugate or drug fusion of any one of Claims 5, 15 and 22 for the manufacture of a medicament for treatment of an inflammatory disease.
38. The use of Claim 37, wherein said inflammatory disease is arthritis.
- 20 39. A noncovalent drug conjugate comprising an immunoglobulin heavy chain variable domain (V_H) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (V_L) that has binding specificity for serum albumin, and a drug that is noncovalently bonded to said V_H or V_L .
- 25 40. The noncovalent drug conjugate of Claim 39, wherein said V_H or V_L and said drug are noncovalently bonded through complementary binding partners.
41. The noncovalent drug conjugate of Claim 40, wherein said complementary
30 binding partners are biotin and avidin, or biotin and streptavidin.

-
42. Use of a polypeptide binding moiety having a binding site that has binding
specificity for a polypeptide that enhances serum half-life *in vivo* for the
manufacture of medicament, the medicament comprising a drug composition
in which a drug is bonded to said polypeptide binding moiety, for increasing
5 *in vivo* serum half-life of the drug without reducing the activity of the drug
by more than about 10%.
43. Use of a polypeptide binding moiety having a binding site that has binding
specificity for a polypeptide that enhances serum half-life *in vivo* for the
10 manufacture of medicament, the medicament comprising a drug composition
in which a drug is bonded to said polypeptide binding moiety, for increasing
the *in vivo* serum half-life of the drug and reducing immunogenicity of the
drug.
- 15 44. Use of a polypeptide binding moiety having a binding site that has binding
specificity for a polypeptide that enhances serum half-life *in vivo* for the
manufacture of medicament, the medicament comprising a drug composition
in which a drug is bonded to said polypeptide binding moiety, for reducing
immunogenicity of the drug without reducing the activity of the drug by
20 more than about 10%.
45. Use of a polypeptide binding moiety having a binding site that has binding
specificity for a polypeptide that enhances serum half-life *in vivo* for the
manufacture of medicament, the medicament comprising a drug composition
25 in which a drug is bonded to said polypeptide binding moiety, for increasing
the *in vivo* serum half-life of the drug and reducing immunogenicity of the
drug without reducing the activity of the drug by more than about 10%.
- 30 46. The use of any one of Claims 42-45, wherein the medicament comprises a
drug composition in which a drug is covalently bonded to said polypeptide
binding moiety.

-
47. The use of Claim 46, wherein the drug composition is a drug fusion or drug conjugate.
48. The use of any one of Claims 42-45, wherein the medicament comprises a drug composition in which a drug is noncovalently bonded to said polypeptide binding moiety.
49. The use of Claim 48, wherein the drug composition is a noncovalent drug conjugate.
50. The use of any one of Claims 42-49, wherein said polypeptide binding moiety has binding specificity for serum albumin.
51. The use of Claim 50, wherein said polypeptide binding moiety is an antigen-binding fragment of an antibody that has binding specificity for serum albumin.
52. The use of any one of Claims 42-51, wherein the medicament comprises a drug composition that has greater activity than said drug.
53. A method for increasing the *in vivo* serum half-life of a drug without substantially reducing the activity of the drug, comprising bonding a drug to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, whereby a drug composition is produced,
wherein said drug composition has a longer *in vivo* serum half-life relative to said drug, and has at least about 90% of the activity of said drug.
54. A method for increasing the *in vivo* serum half-life of a drug and reducing the immunogenicity of the drug, comprising bonding a drug to a polypeptide binding moiety having a binding site that has binding specificity for a

polypeptide that enhances serum half-life *in vivo*, whereby a drug composition is produced,

wherein said drug composition has a longer *in vivo* serum half-life relative to said drug, and is less immunogenic than said drug.

5

55. A method for decreasing the immunogenicity of a drug without substantially reducing the activity of the drug, comprising bonding a drug to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, whereby a drug composition is produced,

10

wherein said drug composition is less immunogenic than said drug, and has at least about 90% of the activity of said drug.

56. A method for increasing the *in vivo* serum half-life of a drug and reducing the immunogenicity of the drug without substantially reducing the activity of the drug, comprising bonding a drug to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*, whereby a drug composition is produced,

15

wherein said drug composition has a longer *in vivo* serum half-life relative to said drug, is less immunogenic than said drug, and has at least about 90% of the activity of said drug.

20

57. The method of any one of Claims 53-56, comprising covalently binding said drug to said polypeptide binding moiety.

25

58. The method of Claim 57, wherein the drug composition is a drug fusion or drug conjugate.

59. The method of any one of Claims 53-56, comprising noncovalently binding said drug to said polypeptide binding moiety.

30

60. The method of Claim 59, wherein the drug composition is a noncovalent drug conjugate.
61. The method of any one of Claims 53-60, wherein the method further
5 comprises selecting said polypeptide binding moiety from one or more polypeptides, wherein the selected polypeptide binding moiety binds a polypeptide that enhances serum half-life *in vivo* with a KD of at least about 5 mM.
- 10 62. The method of any one of Claims 53-61, wherein said polypeptide binding moiety has binding specificity for serum albumin.
63. The method of Claim 62, wherein said polypeptide binding moiety is an
15 antigen-binding fragment of an antibody that has binding specificity for serum albumin.
64. The method of any one of Claims 53-63, wherein the drug composition has greater activity than said drug.
- 20 65. A drug composition comprising a drug that is bonded to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*,
wherein said drug composition has a longer *in vivo* serum half-life relative to drug, and has at least about 90% of the activity of the drug.
- 25 66. A drug composition comprising a drug that is bonded to a polypeptide binding moiety having a binding site that has binding specificity for a polypeptide that enhances serum half-life *in vivo*,
wherein said drug composition has a longer *in vivo* serum half-life
30 relative to said drug, and is less immunogenic than said drug.

67. A drug composition comprising a drug that is bonded to a polypeptide
binding moiety having a binding site that has binding specificity for a
polypeptide that enhances serum half-life *in vivo*,
wherein said drug composition is less immunogenic than said drug,
5 and has at least about 90% of the activity of said drug.
68. A drug composition comprising a drug that is bonded to a polypeptide
binding moiety having a binding site that has binding specificity for a
polypeptide that enhances serum half-life *in vivo*,
10 wherein said drug composition has a longer *in vivo* serum half-life
relative to said drug, is less immunogenic than said drug, and has at least
about 90% of the activity of said drug.
69. The drug composition of any one of Claims 65-68, wherein the drug is
15 covalently bonded to said polypeptide binding moiety.
70. The drug composition of Claim 69, wherein said drug composition is a drug
fusion or drug conjugate.
- 20 71. The drug composition of any one of Claims 65-68, wherein the drug is
noncovalently bonded to said polypeptide binding moiety.
72. The drug composition of Claim 71, wherein said drug composition is a
noncovalent drug conjugate.
25
73. The drug composition of any one of Claims 65-72, wherein said polypeptide
binding moiety has binding specificity for serum albumin.
74. The drug composition of Claim 73, wherein said polypeptide binding moiety
30 is an antigen-binding fragment of an antibody that has binding specificity for
serum albumin.

75. The drug composition of any one of Claims 65-74, wherein the drug
composition has greater activity than said drug.

1/36

FIG. 1A

VKs selected vs MSA

Kabat_Numbering	5	10	15	20	25	30	35
MSA16	DIQM	TQSP	SSL	LSAS	VGDRV	TITCR	ASQSI I KHLK W
MSA 12	DIQM	TQSP	SSL	LSAS	VGDRV	TITCR	ASQSI F RHLK W
MSA 26	DIQM	TQSP	SSL	LSAS	VGDRV	TITCR	ASQSI Y YHLK W

Kabat_Numbering	40	45	50	55	60	65	70
MSA16	YQQK	PGKAP	KLLIY	GASRL	QSGVP	SRFSG	S GSGT D
MSA 12	YQQK	PGKAP	KLLIY	AASRL	QSGVP	SRFSG	S GSGT D
MSA 26	YQQK	PGKAP	KLLIY	KASTL	QSGVP	SRFSG	S GSGT D

Kabat_Numbering	75	80	85	90	95	100	105
MSA16	FTLT	ISLQ	PEDFA	TYCQ	Q GARW	PQTFG	Q GTKV E
MSA 12	FTLT	ISLQ	PEDFA	TYCQ	Q VALY	PKTFG	Q GTKV E
MSA 26	FTLT	ISLQ	PEDFA	TYCQ	Q VRKV	PRTFG	Q GTKV E

Kabat_Numbering	
MSA16	I KR
MSA 12	I KR
MSA 26	I KR

2/36
FIG. 1B

VKs selected vs RSA

Kabat_Numbering	5	10	15	20	25	30	35
<u>DOM7r-1</u>	DIQT	TQSP	SSL	ASV	GDRV	TITCR	ASQYI G RYLR W
<u>DOM7r-3</u>	DIQM	TQSP	SSL	ASV	GDRV	TITCR	ASQYI G RYLR W
<u>DOM7r-4</u>	DIQM	TQSP	SSL	ASV	GDRV	TITCR	ASQWI G RYLR W
<u>DOM7r-5</u>	DIQM	TQSP	SSL	ASV	GDRV	TITCR	ASQYI S RQLR W
<u>DOM7r-7</u>	DIQM	TQSP	SSL	ASV	GDRV	TITCR	ASQYI G RYLR W
<u>DOM7r-8</u>	DIQM	TQSP	SSL	ASV	GDRV	TITCR	ASQWI H RQLK W

Kabat_Numbering	40	45	50	55	60	65	70
<u>DOM7r-1</u>	YQQK	PGKAP	KLLIY	DSSVL	QSGVP	SRFSG	S GSGT D
<u>DOM7r-3</u>	YQQK	PGKAP	KLLIY	DSSVL	QSGVP	SRFSG	S GSGT D
<u>DOM7r-4</u>	YQQK	PGKAP	KLLIY	NGSQL	QSGVP	SRFSG	S GSGT D
<u>DOM7r-5</u>	YQQK	PGKAP	RLLIY	GA SVL	QSGIP	SRFSG	S GSGT D
<u>DOM7r-7</u>	YQQK	PGKAP	KLLIY	DSSVL	QSGVP	SRFSG	S GSGT D
<u>DOM7r-8</u>	YQQK	PGKAP	KLLIY	YASIL	QSGVP	SRFSG	S GSGT D

Kabat_Numbering	75	80	85	90	95	100	105
<u>DOM7r-1</u>	FTLT	ISLQ	PEDFA	TYYCQ	QRYRM	PYTFG	Q GTRV E
<u>DOM7r-3</u>	FTLT	ISLQ	PEDFA	TYYCQ	QRYMQ	PFTFG	Q GTKV E
<u>DOM7r-4</u>	FTLT	ISLQ	PEDFA	TYYCQ	QRYLQ	PYTFG	Q GTKV E
<u>DOM7r-5</u>	FTLT	ISLQ	PEDFA	TYYCQ	QRYIT	PYTFG	Q GTKV E
<u>DOM7r-7</u>	FTLT	ISLQ	PEDFA	TYYCQ	QRYSS	PYTFG	Q GTKV E
<u>DOM7r-8</u>	FTLT	ISLQ	PEDFA	TYYCQ	QTF SK	PSTFG	Q GTKV E

Kabat_Numbering	
<u>DOM7r-1</u>	I K R
<u>DOM7r-3</u>	I K R
<u>DOM7r-4</u>	I K R
<u>DOM7r-5</u>	V K R
<u>DOM7r-7</u>	I K R
<u>DOM7r-8</u>	I K R

3/36

FIG. 1C

VKs selected vs HSA

Kabat_Numbering	5	10	15	20	25	30	35
<u>DOM7h-2</u>	DIQM	TQSP	SLSA	VGDR	VTIT	CRAS	SQKIATYLNW
<u>DOM7h-3</u>	DIQM	TQSP	SLSA	VGDR	VTIT	CRAS	SQWIDTGLAW
<u>DOM7h-4</u>	DIQM	TQSP	SLSA	VGDR	VTIT	CRAS	SQEIYSWLAW
<u>DOM7h-6</u>	DIQM	TQSP	SLSA	VGDR	VTIT	CRAS	SQSISSSYLNW
<u>DOM7h-1</u>	DIQM	TQSP	SLSA	VGDR	VTIT	CRAS	SQSISSSYLNW
<u>DOM7h-7</u>	DIQM	TQSP	SLSA	VGDR	VTIT	CRAS	SQSISSSYLNW

Kabat_Numbering	40	45	50	55	60	65	70
<u>DOM7h-2</u>	YQQK	PGKAP	KLLIY	RSSSL	QSAVP	SRFSG	SGSGTV
<u>DOM7h-3</u>	YQQK	PGKAP	RLLIY	NVSRL	QSGVP	SRFSG	SGSGTD
<u>DOM7h-4</u>	YQQR	PGKAP	KLLIY	NASHL	QSGVP	SRFSG	SGSGTD
<u>DOM7h-6</u>	YQQK	PGKAP	TLLIY	RLSVL	QSGVP	SRFSG	SGSGTD
<u>DOM7h-1</u>	YQQK	PGKAP	KLLIY	RNSFL	QSGVP	SRFSG	SGSGTD
<u>DOM7h-7</u>	YQQK	PGKAP	KLLIY	RNSQL	QSGVP	SRFSG	SGSGTD

Kabat_Numbering	75	80	85	90	95	100	105
<u>DOM7h-2</u>	FTLT	ISLQ	PEDFA	TYCQ	QTYAV	PPTFG	QGTKVE
<u>DOM7h-3</u>	FTLT	ISLQ	PEDFA	TYCQ	QYWGS	PPTFG	QGTKVE
<u>DOM7h-4</u>	FTLT	ISLQ	PEDFA	TYCQ	QVIGD	PVTFG	QGTKVE
<u>DOM7h-6</u>	FTLT	ISLQ	PEDFA	TYCQ	QTYNV	PPTFG	QGTKVE
<u>DOM7h-1</u>	FTLT	ISLQ	PEDFA	TYCQ	QTYTV	PPTFG	QGTKVE
<u>DOM7h-7</u>	FTLT	ISLQ	PEDFA	TYCQ	QTFAV	PPTFG	QGTKVE

Kabat_Numbering	
<u>DOM7h-2</u>	IKR
<u>DOM7h-3</u>	IKR
<u>DOM7h-4</u>	IKR
<u>DOM7h-6</u>	IKR
<u>DOM7h-1</u>	IKQ
<u>DOM7h-7</u>	IKR

4/36
FIG. 1D

VHs selected vs HSA

Kabat_Numbering	5	10	15	20	25	30	35
<u>DOM7h-22</u>	EVQL	L	ESGG	G	LVQP	G	GSLR L SCAAS GFTFS KYWM S
<u>DOM7h-23</u>	EVQL	L	ESGG	G	LVQP	G	GSLR L SCAAS GFTFY DYNM S
<u>DOM7h-24</u>	EVQL	L	ESGG	G	LVQP	G	GSLR L SCAAS GFTFH RYSM S
<u>DOM7h-25</u>	EVQL	L	ESGG	G	LVQP	G	GSLR L SCAAS GFTFW KYNM A
<u>DOM7h-26</u>	EVQL	L	ESGG	G	LVQP	G	GSLR L SCTAS GFTFD EYNM S
<u>DOM7h-21</u>	EVQL	L	ESGG	G	LVQP	G	GSLR L SCAAS GFTFD LYDM S
<u>DOM7h-27</u>	EVQL	L	ESGG	G	LVQP	G	GSLR L SCAAS GFTFS DYRM S
Consensus	<u>EVQL</u>	<u>L</u>	<u>ESGG</u>	<u>G</u>	<u>LVQP</u>	<u>G</u>	<u>GSLR L SCAAS GFTF X X YNM S</u>

Kabat_Numbering	40	45	50	54	59	64	69
<u>DOM7h-22</u>	WVRQ	A	PGKG	L	EWVS	S	IDFM G PHTY Y ADSV K GRFT I
<u>DOM7h-23</u>	WVRQ	A	PGKG	L	EWVS	T	ITHT G GVTY Y ADSV K GRFT I
<u>DOM7h-24</u>	WVRQ	A	PGKG	L	EWVS	T	ILPG G DVTY Y ADSV K GRFT I
<u>DOM7h-25</u>	WVRQ	A	PGKG	L	EWVS	T	ILGE G NNTY Y ADSV K GRFT I
<u>DOM7h-26</u>	WVRQ	A	PGKG	L	EWVS	T	ILPH G DRTY Y ADSV K GRFT I
<u>DOM7h-21</u>	WVRQ	A	PGKG	L	EWVS	S	IVNS G VRTY Y ADSV K GRFT I
<u>DOM7h-27</u>	WVRQ	A	PGKG	L	EWVS	T	IISNG KFTY Y ADSV K GRFT I

Kabat_Numbering	74	79	82b	86	91	96	100a
<u>DOM7h-22</u>	SRDN	S	KNTL	Y	LQMN	S	LRAED TAVY Y CAKGR TSML P
<u>DOM7h-23</u>	SRDN	S	KNTL	Y	LQMN	S	LRAED TAVY Y CAKQN PSYQ -
<u>DOM7h-24</u>	SRDN	S	KNTL	Y	LQMN	S	LRAED TAVY Y CAKQ T PDYM -
<u>DOM7h-25</u>	SRDN	S	KNTL	Y	LQMN	S	LRAED TAVY Y CAKTM DYK - -
<u>DOM7h-26</u>	SRDN	S	KNTL	Y	LQMN	S	LRAED TAVY Y CAKQ D PLYR -
<u>DOM7h-21</u>	SRDN	S	KNTL	Y	LQMN	S	LRAED TAVY Y CAKLN QSYH W
<u>DOM7h-27</u>	SRDN	S	KNTL	Y	LQMN	S	LRAED TAVY Y CAKQ D WMYM -

Kabat_Numbering	100o	105	110
<u>DOM7h-22</u>	MKGK	F	DYWG Q GTLV T VSS
<u>DOM7h-23</u>	- - - -	F	DYWG Q GTLV T VSS
<u>DOM7h-24</u>	- - - -	F	DYWG Q GTLV T VSS
<u>DOM7h-25</u>	- - - -	F	DYWG Q GTLV T VSS
<u>DOM7h-26</u>	- - - -	F	DYWG Q GTLV T VSS
<u>DOM7h-21</u>	D - - -	F	DYWG Q GTLV T VSS
<u>DOM7h-27</u>	- - - -	F	DYWG Q GTLV T VSS

5/36

FIG. 1E

VKs selected vs HSA and RSA

Kabat_Numbering	5	10	15	20	25	30	35																												
<u>DOM7h-8</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	S	I	S	S	Y	L	N	W
<u>DOM7r-13</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	H	I	H	R	E	L	R	W
<u>DOM7r-14</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	H	I	H	R	E	L	R	W

Kabat_Numbering	40	45	50	55	60	65	70																												
<u>DOM7h-8</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	R	N	S	P	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-13</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	Q	A	S	R	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-14</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	Q	A	S	R	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D

Kabat_Numbering	75	80	85	90	95	100	105																												
<u>DOM7h-8</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	Y	R	V	P	P	T	F	G	Q	G	T	K	V	E
<u>DOM7r-13</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	K	Y	L	P	P	Y	T	F	G	Q	G	T	K	V	E
<u>DOM7r-14</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	R	Y	R	V	P	Y	T	F	G	Q	G	T	K	V	E

Kabat_Numbering	
<u>DOM7h-8</u>	I K R
<u>DOM7r-13</u>	I K R
<u>DOM7r-14</u>	I K R

6/36

FIG. 2A

(i) vector diagrams





FIG. 2B



7/36

FIG. 2C

(ii) amino acid and nucleic acid sequence of human IL-1ra, dAb fusions

IL-1raMSA16

```
1   R P S G R K S S K M Q A F R I W D V N Q
1   AGGCCTTCTGGGAGAAAATCCAGCAAGATGCAAGCCTTCAGAATCTGGGATGTTAACCAG

21  K T F Y L R N N Q L V A G Y L Q G P N V
61  AAGACCTTCTATCTGAGGAACAACCACTAGTTGCCGGATACTTGCAAGGACCAAATGTC

41  N L E E K I D V V P I E P H A L F L G I
121 AATTTAGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGGGAATC

61  H G G K M C L S C V K S G D E T R L Q L
181 CATGGAGGGAAGATGTGCCTGTCTGTGTCAAGTCTGGTGATGAGACCAGACTCCAGCTG

81  E A V N I T D L S E N R K Q D K R F A F
241 GAGGCAGTTAACATCACTGACCTGAGCGAGAACAGAAAGCAGGACAAGCGCTTCGCCTTC

101 I R S D S G P T T S F E S A A C P G W F
301 ATCCGCTCAGACAGTGGCCCCACCACCAGTTTTGAGTCTGCCGCCTGCCCCGGTTGGTTC

121 L C T A M E A D Q P V S L T N M P D E G
361 CTCTGCACAGCGATGGAAGCTGACCAGCCCGTCAGCCTCACCAATATGCCTGACGAAGGC

141 V M V T K F Y F Q E D E S S G G G G S G
421 GTCATGGTCACCAAATTCTACTTCCAGGAGGACGAGAGCTCAGGTGGAGGCGGTTACGGC

161 G G G S G G G G S G G G G S G G G G S T
481 GGAGGTGGCAGCGGCGGTGGCGGGTCAGGTGGTGGCGGAAGCGCGGTGGCGGGTCGACG

181 D I Q M T Q S P S S L S A S V G D R V T
541 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCAAC

201 I T C R A S Q S I I K H L K W Y Q Q K P
601 ATCACTTGCCGGGCAAGTCAGAGCATTATTAAGCATTAAAGTGGTACCAGCAGAAACCA

221 G K A P K L L I Y G A S R L Q S G V P S
661 GGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCCCGGTTGCAAAGTGGGGTCCCATCA

241 R F S G S G S G T D F T L T I S S L Q P
721 CGTTTCAGTGGCAGTGGATCTGGGACAGATTCACCTCTACCATCAGCAGTCTGCAACCT
```

8/36

FIG. 2D

261 E D F A T Y Y C Q Q G A R W P Q T F G Q
781 GAAGATTTTGCTACGTACTACTGTCAACAGGGGGCTCGGTGGCCTCAGACGTTTCGGCCAA

281 G T K V E I K R A A A - -
841 GGGACCAAGGTGGAAATCAAACGGGCGGCCGCATAATAA

9/36

FIG. 2E

MSA16IL-1ra

1 S T D I Q M T Q S P S S L S A S V G D R
1 TCGACGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGT

21 V T I T C R A S Q S I I K H L K W Y Q Q
61 GTCACCATCACTTGCCGGGCAAGTCAGAGCATTATTAAGCATTTAAAGTGGTACCAGCAG

41 K P G K A P K L L I Y G A S R L Q S G V
121 AAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCCCGGTTGCAAAGTGGGGTC

61 P S R F S G S G S G T D F T L T I S S L
181 CCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTG

81 Q P E D F A T Y Y C Q Q G A R W P Q T F
241 CAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGGGGCTCGGTGGCCTCAGACGTTT

101 G Q G T K V E I K R A A A S G G G G S G
301 GGCCAAGGGACCAAGGTGGAATCAAACGGGCGGCCGCAAGCGGTGGAGGCGGTTACGGC

121 G G G S G G G G S G G G G S G G G G S R
361 GGAGGTGGCAGCGGCGGTGGCGGTCAGGTGGTGGCGGAAGCGGCGGTGGCGGCTCGAGG

141 P S G R K S S K M Q A F R I W D V N Q K
421 CCCTCTGGGAGAAAATCCAGCAAGATGCAAGCCTTCAGAATCTGGGATGTTAACCAGAAG

161 T F Y L R N N Q L V A G Y L Q G P N V N
481 ACCTTCTATCTGAGGAACAACCAACTAGTTGCCGATACTTGCAAGGACCAATGTCAAT

181 L E E K I D V V P I E P H A L F L G I H
541 TTAGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGGAATCCAT

201 G G K M C L S C V K S G D E T R L Q L E
601 GGAGGGAAGATGTGCCTGTCTGTCTCAAGTCTGGTGATGAGACCAGACTCCAGCTGGAG

221 A V N I T D L S E N R K Q D K R F A F I
661 GCAGTTAACATCACTGACCTGAGCGAGAACAGAAAGCAGGACAAGCGCTTCGCCTTCATC

241 R S D S G P T T S F E S A A C P G W F L
721 CGCTCAGACAGTGGCCCCACCAACAGTTTTGAGTCTGCCGCTGCCCGGTTGGTTCCTC

10/36

FIG. 2F

261 C T A M E A D Q P V S L T N M P D E G V
781 TGCACAGCGATGGAAGCTGACCAGCCCGTCAGCCTCACCAATATGCCTGACGAAGGCGTC

281 M V T K F Y F Q E D E - -
841 ATGGTCACCAAATTCTACTTCCAGGAGGACGAGTAATAA

11/36
FIG. 2G

DummyIL-1ra

1 S T D I Q M T Q S P S S L S A S V G D R
1 TCGACGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGT
21 V T I T C R A S Q S I S S Y L N W Y Q Q
61 GTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTACCAGCAG
41 K P G K A P K L L I Y A A S S L Q S G V
121 AAACCAGGGAAAGCCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTC
61 P S R F S G S G S G T D F T L T I S S L
181 CCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTG
81 Q P E D F A T Y Y C Q Q S Y S T P N T F
241 CAACCTGAAGATTTTGCTACGTACTACTGTCAACAGAGTTACAGTACCCCTAATACGTTT
101 G Q G T K V E I K R A A A S G G G G S G
301 GGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCCGCAAGCGGTGGAGGCGGTTTCAGGC
121 G G G S G G G G S G G G G S G G G G S R
361 GGAGGTGGCAGCGGCGGTGGCGGGTCAGGTGGTGGCGGAAGCGGCGGTGGCGGCTCGAGG
141 P S G R K S S K M Q A F R I W D V N Q K
421 CCCTCTGGGAGAAAATCCAGCAAGATGCAAGCCTTCAGAATCTGGGATGTTAACCAGAAG
161 T F Y L R N N Q L V A G Y L Q G P N V N
481 ACCTTCTATCTGAGGAACAACCAACTAGTTGCCGGATACTTGCAAGGACCAAATGTCAAT
181 L E E K I D V V P I E P H A L F L G I H
541 TTAGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGGAATCCAT
201 G G K M C L S C V K S G D E T R L Q L E
601 GGAGGGAAGATGTGCCTGTCTGTCAAGTCTGGTGATGAGACCAGACTCCAGCTGGAG
221 A V N I T D L S E N R K Q D K R F A F I
661 GCAGTTAACATCACTGACCTGAGCGAGAACAGAAAGCAGGACAAGCGCTTCGCCTTCATC
241 R S D S G P T T S F E S A A C P G W F L
721 CGCTCAGACAGTGGCCCCACCACAGTTTTGAGTCTGCCGCTGCCCGGTTGGTTCCTC

12/36

FIG. 2H

261 C T A M E A D Q P V S L T N M P D E G V
781 TGCACAGCGATGGAAGCTGACCAGCCCGTCAGCCTCACCAATATGCCTGACGAAGGCGTC

281 M V T K F Y F Q E D E - -
841 ATGGTCACCAAATCTACTTCCAGGAGGACGAGTAATAA

13/36

FIG. 3A


(i) *HeLa IL-8 assay*

FIG. 3B


(ii) *HeLa IL-8 bioassay results for MSAIL-1ra orientations***MRC-5/IL-8 bioassay MSA16/IL-1ra orientations**

FIG. 4A

MRC-5/IL-8 bioassay
MSA16/IL-1ra 0% MSA




FIG. 4B

MRC-5/IL-8 bioassay
MSA16/IL-1ra 5% MSA






FIG. 4C

MRC-5/IL-8 bioassay
MSA16/IL-1ra 10% MSA




15/36



16/36

FIG. 6A

Example biacore data for clone DOM7h-1

17/36

FIG. 6A(contd.)

Report

	ka (1/Ms)	kd (1/s)	Rmax (RU)	RI (RU)	Conc of analyte
12.05.04 offrate,onrat Fc=2 - 3	5.63e4	0.0539	12.7	160	2000n
12.05.04 offrate,onrat Fc=2 - 4	1.49e5	0.0523	39.3	117	1000n
12.05.04 offrate,onrat Fc=2 - 5	1.12e5	0.0481	80.1	58	500n
12.05.04 offrate,onrat Fc=2 - 6	5.01e4	0.0486	136	40.6	250n

	KA (1/M)	KD (M)	Req (RU)	kobs (1/s)	Chi2
					0.12
12.05.04 offrate,onrat Fc=2 - 3	1.05e6	9.57e-7	8.59	0.167	
12.05.04 offrate,onrat Fc=2 - 4	2.85e6	3.51e-7	29.1	0.201	
12.05.04 offrate,onrat Fc=2 - 5	2.33e6	4.29e-7	43.1	0.104	
12.05.04 offrate,onrat Fc=2 - 6	1.03e6	6.7e-7	27.8	0.0611	


Parameters

	ka	T(ka)	Rmax	T(Rmax)	Conc	t0	kd
12.05.04 offrate,onrat Fc=2 - 3	5.63E+04	10.7	12.7	28.9	2000n	91.5	0.0539
12.05.04 offrate,onrat Fc=2 - 4	1.49E+05	40.3	39.3	114	1000n	91.5	0.0523
12.05.04 offrate,onrat Fc=2 - 5	1.12E+05	35.1	80.1	68.1	500n	91.5	0.0481
12.05.04 offrate,onrat Fc=2 - 6	5.01E+04	5.32	136	6.21	250n	91.5	0.0486

	RI	T(RI)
12.05.04 offrate,onrat Fc=2 - 3	160	632
12.05.04 offrate,onrat Fc=2 - 4	117	442
12.05.04 offrate,onrat Fc=2 - 5	58	257
12.05.04 offrate,onrat Fc=2 - 6	40.6	198

18/36

FIG. 6B
Example biacore data for clone DOM7h-7
7h7 on HSA



19/36

FIG. 6B(contd.)


Report

	ka (1/Ms)	kd (1/s)	Rmax (RU)	RI (RU)	Conc of analyte
12.05.04 offrate,onra Fc=2 - 41	11	0.107	6.32e3	196	5000n
12.05.04 offrate,onra Fc=2 - 42	2.35e3	0.106	60.9	185	3000n
12.05.04 offrate,onra Fc=2 - 43	2.51e5	0.108	39	140	2000n
12.05.04 offrate,onra Fc=2 - 44	6.23e5	0.105	46.2	132	1000n
12.05.04 offrate,onra Fc=2 - 45	3.02e5	0.103	106	57.8	500n
12.05.04 offrate,onra Fc=2 - 46	2.83e5	0.0998	122	44	250n
12.05.04 offrate,onra Fc=2 - 47	1.43e5	0.0946	181	29	125n
12.05.04 offrate,onra Fc=2 - 48	5.01e5	0.1	62.8	26	62.5n

	KA (1/M)	KD (M)	Req (RU)	kobs (1/s)	Chi2
					0.542
12.05.04 offrate,onrat Fc=2 - 41	103	9.71e-3	3.25	0.107	
12.05.04 offrate,onrat Fc=2 - 42	2.21e4	4.51e-5	3.79	0.113	
12.05.04 offrate,onrat Fc=2 - 43	2.33e6	4.3e-7	32.1	0.61	
12.05.04 offrate,onrat Fc=2 - 44	5.93e6	1.69e-7	39.6	0.728	
12.05.04 offrate,onrat Fc=2 - 45	2.93e6	3.41e-7	63	0.254	
12.05.04 offrate,onrat Fc=2 - 46	2.83e6	3.53e-7	50.7	0.171	
12.05.04 offrate,onrat Fc=2 - 47	1.51e6	6.62e-7	28.8	0.112	
12.05.04 offrate,onrat Fc=2 - 48	5.01e6	2e-7	15	0.131	

20/36

FIG. 6C
Example biacore data for clone DOM7r-1



21/36

FIG. 6C(contd.)

Report

	ka (1/Ms)	kd (1/s)	Rmax (RU)	RI (RU)	Conc of analyte
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -1	3.23e6	0.0345	40.8	53	25n
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -2	2.89e6	0.0344	45.1	39.9	20n
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -3	2.52e6	0.0331	52.8	34.8	15n
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -4	2.87e6	0.0316	53.5	30.5	10n
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -5	1.93e6	0.0316	79.8	27.1	5n

	KA (1/M)	KD (M)	Req (RU)	kobs (1/s)	Chi2
					0.0252
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -1	9.35e7	1.07e-6	28.5	0.115	
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -2	8.41e7	1.19e-6	28.3	0.0923	
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -3	7.62e7	1.31e-6	28.2	0.071	
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -4	9.07e7	1.4e-6	25.5	0.0603	
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -5	6.12e7	1.63e-6	18.7	0.0413	

Parameters

	ka	T(ka)	Rmax	T(Rmax)	Conc	t0	kd
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -1	3.23E+06	58.2	40.8	138	25n	87.5	0.0345
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -2	2.89E+06	42.9	45.1	82.9	20n	87.5	0.0344
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -3	2.52E+06	27.6	52.8	43	15n	87.5	0.0331
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -4	2.87E+06	18.3	53.5	25.6	10n	87.5	0.0316
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -5	1.93E+06	3.91	79.8	4.38	5n	87.5	0.0316

	RI	T(RI)
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -1	53	488
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -2	39.9	383
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -3	34.8	348
7r1, 7r3, 7r8, 7r13, 7 Fc=3 -4	30.5	312

22/36

FIG. 7

AFFINITIES OF ANTI-SA dAbs

dAB	Scaffo ld	Affinity (KD)		
		Mouse serum albumin	Rat serum albumin	Human serum albumin
DOM7h-1	V _K	+	+	800 nM
DOM7h-2	V _K	+	+	70 nM
DOM7h-7	V _K	+	+	400 nM
DOM7r-3	V _K	+	12 nM	-
DOM7h-8	V _K	200 nM	120 nM	70 nM
DOM7r-16	V _K	1 μ M	1 μ M	-
DOM7m-16	V _K	50 nM	ND	+
DOM7m-26	V _K	60 nM	ND	+
DOM7r-1	V _K	-	15 nM	-
DOM7r-8	V _K	40 nM	20 nM	-
DOM7r-13	V _K	-	80 nM	-
DOM7r-14	V _K	-	50 nM	-
DOM7r-27	V _H	250 nM	250 nM	-
DOM7r-31	V _H	1 μ M	5 μ M	+
				(10 μ M estimate)
DOM7h-22	V _H	-	-	60 nM
DOM7h-23	V _H	-	-	900 nM
DOM7h-26	V _H	-	-	300 nM

- No detectable binding

+ detectable binding but weak (estimated KD > 5 μ M)

ND not determined

23/36

FIG. 8A

```

1 atttctttat aaaccacaac tctgggcccg caatggcagt ccactgcctt gctgcagtea
61 cagaatggaa atctgcagag gcctccgcag tcacctaate acttctctcc tcttctgtt
121 ccattcagag acgatctgcc gaccctctgg gagaaaatcc agcaagatgc aagccttcag
181 aatctgggat gttaaccaga agaccttcta tctgaggaac aaccaactag ttgctggata
241 cttgcaagga ccaaattgtca atttagaaga aaagatagat gtggtaccca ttgagcctca
301 tgetctgttc ttgggaatcc atggagggaa gatgtgcctg tctgtgtca agtctggtga
361 tgagaccaga ctccagctgg aggcagttaa catcactgac ctgagcgaga acagaaagca
421 ggacaagcgc ttgccttca tccgctcaga cagcggcccc accaccagtt ttgagtctgc
481 cgcctgcccc gggtggttcc tctgcacagc gatggaagct gaccagcccc tcagcctcac
541 caatatgcct gacgaaggcg tcatggtcac caaattctac ttccaggagg acgagtagta
601 ctgcccaggc ctgcctgttc ccattcttgc atggcaagga ctgcagggac tgccagtcctc
661 cctgccccag ggtccccggc tatgggggca ctgaggacca gccattgagg ggtggaccct
721 cagaaggcgt cacaagaacc tggtcacagg actctgcctc ctcttcaact gaccagcctc
781 catgctgcct ccagaatggt ctttctaata tgtgaatcag agcacagcag cccctgcaca
841 aagcccttcc atgtcgcctc tgcattcagg atcaaacccc gaccacctgc ccaacctgct
901 ctctcttgc cactgcctct tctccctca ttccacctc ccatgccctg gatccatcag
961 gccacttgat gacccccaac caagtggctc ccacaccctg ttttacaaaa aagaaaagac
1021 cagtccatga gggagggttt taagggtttg tggaaaatga aaattaggat ttcatgattt
1081 ttttttttca gtccccgtga aggagagccc ttcatttgga gattatgttc tttcggggag
1141 aggctgagga cttaaaatat tcctgcattt gtgaaatgat ggtgaaagta agtggttagct
1201 tttcccttct ttttcttctt tttttgtgat gtcccaactt gtaaaaatta aaagttagg
1261 tactatgtta gcccataat ttttttttct cttttaaaac acttccataa tctggactcc
1321 tctgtccagg cactgctgcc cagcctcaa gctccatctc cactccagat tttttacagc
1381 tgcctgcagt actttacctc ctatcagaag tttctcagct cccaaggctc tgagcaaatg
1441 tggctcctgg gggttcttct tctctctgct gaaggaataa attgctcctt gacattgtag
1501 agcttctggc acttgagac ttgtatgaaa gatggctgtg cctctgcctg tctccccac
1561 cgggctggga gctctgcaga gcaggaaaca tgactcgtat atgtctcagg tccttcagc
1621 gccaagcacc tagcctcgtc cttggcagggt actcagcgaa tgaatgctgt atatgttggg
1681 tgcaaaagtc cctacttctt gtgacttcag ctctgtttta caataaatc ttgaaaatgc
1741 ctaaaaaaaaa aaaaaaaaaa

```


FIG. 8B

```

MEICRGLRSH LITLLLFLFH SETICRPSGR KSSKMQAFRI WDVNQKTFYL
RNNQLVAGYL QGPNVNLEEK IDVVPPIEPHA LFLGIHGGKM CLSCVKSGDE
TRLQLEAVNI TDLSENKQD KRFAFIRSDS GPTTSFESAA CPGWFLCTAM
EADQPVSLTN MPDEGVMVTK FYFQEDE

```

FIG. 9
Pharmacokinetics of the anti-MSA dAb/HA
epitope tag fusion following iv bolus dose



25/36

FIG. 10

Kabat_Numbering	5	10	15	20	25	30	35																												
<u>DOM7r-15</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	S	I	G	R	R	L	K	W
<u>DOM7r-16</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	K	I	Y	K	N	L	R	W
<u>DOM7r-17</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	K	I	Y	N	N	L	R	W
<u>DOM7r-18</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	W	I	Y	K	S	L	G	W
<u>DOM7r-19</u>	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	W	I	Y	R	H	L	R	W

Kabat_Numbering	40	45	50	55	60	65	70																												
<u>DOM7r-15</u>	Y	Q	Q	K	P	G	A	A	P	R	L	L	I	Y	R	T	S	W	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-16</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	N	S	S	I	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-17</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	N	T	S	I	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-18</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	Q	S	S	L	L	Q	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D
<u>DOM7r-19</u>	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	D	A	S	R	L	Q	S	G	V	P	T	R	F	S	G	S	G	S	G	T	D

Kabat_Numbering	75	80	85	90	95	100	105																												
<u>DOM7r-15</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	S	Q	W	P	H	T	F	G	Q	G	T	K	V	E
<u>DOM7r-16</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	R	Y	L	S	P	Y	T	F	G	Q	G	T	K	V	E
<u>DOM7r-17</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	R	W	R	A	P	Y	T	F	G	Q	G	T	K	V	E
<u>DOM7r-18</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	Y	H	Q	M	P	R	T	F	G	Q	G	T	K	V	E
<u>DOM7r-19</u>	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	T	H	N	P	P	K	T	F	G	Q	G	T	K	V	E

Kabat_Numbering	
<u>DOM7r-15</u>	I K R
<u>DOM7r-16</u>	I K R
<u>DOM7r-17</u>	I K R
<u>DOM7r-18</u>	I K R
<u>DOM7r-19</u>	I K R

26/36

FIG. 11A

Kabat_Numbering	5	10	15	20	25	30	35
<u>DOM7r-20</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-21</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-22</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-23</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-24</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-25</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-26</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-27</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-28</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-29</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-30</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-31</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-32</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						
<u>DOM7r-33</u>	E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F W P Y T M S						

27/36

FIG. 11A(contd.)

Kabat_Numbering	40	45	50	54	59	64	69
<u>DOM7r-20</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-21</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-22</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-23</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-24</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-25</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-26</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-27</u>	W V R Q A P G K G L E W V S T I S P F G S T T Y Y A D S V K G R F T I						
<u>DOM7r-28</u>	W V R Q A P G K G L E W V S T I H Q T G F S T Y Y A D S V K G R F T I						
<u>DOM7r-29</u>	W V R Q A P G K G L E W V S M I S S S G L W T Y Y A D S V K G R F T I						
<u>DOM7r-30</u>	W A R Q A P G K G L E W V S L I K P N G S P T Y Y A D S V K G R F T I						
<u>DOM7r-31</u>	W V R Q A P G K G L E W V S W I R P D G T F T Y Y A D S V K G R F T I						
<u>DOM7r-32</u>	W V R Q A P G K G L E W V S F I G R E G Y G T Y Y A D S V K G R F T I						
<u>DOM7r-33</u>	W V R Q A P G K G L E W V S S I S S W G T G T Y Y A D S V K G R F T I						


28/36


FIG. 11A(contd.)

Kabat_Numbering	74	79	82	86	91	96	10
<u>DOM7r-20</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K G G K D F .						
<u>DOM7r-21</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K G N L E P F .						
<u>DOM7r-22</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K K L S N G F .						
<u>DOM7r-23</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K V V K D N T F						
<u>DOM7r-24</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K N T G G K Q F						
<u>DOM7r-25</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K K T G P S S F						
<u>DOM7r-26</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K R T E N R G V						
<u>DOM7r-27</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K S D V L K T G						
<u>DOM7r-28</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K V R S M R P Y						
<u>DOM7r-29</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K G F R L F P R						
<u>DOM7r-30</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K G R G R F N V						
<u>DOM7r-31</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K S V M G D R F						
<u>DOM7r-32</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K S V A S F .						
<u>DOM7r-33</u>	S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K G G Q G S F .						

30/36

FIG. 12
PK of anti-SA dAbs mouse





32/36

FIG. 14A

1 MKIYVVATIA WILLQFSAWT TDAVTSITL DLVNPTAGQY SSFVDKIRNN VKDPNLKYGG
61 TDIavigpps Kdkflrinfq SSRGTVSLGL KRDLYVVAY LAMDNNTNVNR AYYFKSEITS
121 AELTALFPEA TTANQKALEY TedyQSIEKN AQITQGDksr KELGLGIDLL LTFMEAVNKK
181 ARVVKNEARF LLIAIQMTAE VARFRYIQNL VTKNFPNKFD SDNKVIQFEV SWRKISTAIY
241 GDAKNGVFNK DYDFGFGKVR QVKDLQMGLL MYLGKPKSSN EANSTAYATT VL

FIG. 14B

1 DPNLKYGGTD IAVIGPPSRD KFLRLNFQSS RGTVSLGLKR ENLYVVAYLA MDNANVNRAY
61 YFGTEITSAE LTTLPEATV ANQKALEYTE DYQSIEKNAK ITEGDKTRKE LGLGINLLST
121 LMDAVNKKAR VVKNEARFLL IAIQMTAEAA RFRYIQNLVT KNFPNKFENSE DKVIQFQVNW
181 SKISKAIYGD AKNGVFNKDY DFGFGKVRQV KDLQMGLLMY LGTTPNNAAD RYRAEL

33/36

FIG. 14C

1 MKIYVVATIA WILLQFSAWT TDAVTSITL DLVNPTAGQY SSFVDKIRNN VKDPNLKYGG
61 TDIavigpps KGFELRINFQ SSRGTVSLGL KRDNLVWAY LAMDNTNVNR AYYFRSEITS
121 AELTALFPEA TTANQKALEY TEDYQSIEKN AQITQED

FIG. 14D

1 VTSITLDLVN PTAGQYSSFV DKIRNNVKDP NLKYGGTDIA VIGPPSKEKF LRINFQSSRG
61 TVSLGLKRDN LYVVAYLAMD NTNVRAYYF RSEITSAELT ALFPEATAN QKALEYTEDY
121 QSIEKNAQIT QGDKSRKELG LGIDLLLTSM EAVNKKARVV KNEARFLIA IQMTAEVARF
181 RYIQNLVTKN FPNKFDS DNK VIQFEVSWRK ISTAIYGD AK NGVFNKDYDF GFGKVRQVKD
241 LQMGLLMYLG KPK

34/36

FIG. 14E

1 MKIYVVATIA WILLOFSAWT TDAVTSITL DLVNPTAGQY SSFVDKIRNN VKDPNLKYGG
61 TDIavigpps KEKFLRINFQ SSRGTVSLGL KRDNLVWAY LAMDNNTVNR AYYFRSEITS
121 AESTALFPEA TTANQKALEY TedyQsIEKn AQITQGDQSR KELGLGIDLL STSMEAVNKK
181 ARVVKDEARF LLIAIQMTAE AARFryIQNL VIKNFPNKFN SENKVIQFEV NWKKISTAIY
241 GDAKNGVFNK DYDFGFGKVR QVKDLQMGLL MYLGKPKSSN EANSTVRHYG PLKPTLLIT

FIG. 14F

1 VTSITLDLVN PTAGQYSSFV DKIRNMVKDP NLKYGGTDIA VIGPPSKEKF LRINFQSSRG
61 TVSLGLKRDN LYVWAYLAMD NTNvNRAYYF RSEITSaELT ALFPEATTAN QKALEYTEDY
121 QSIEKNAQIT QGDKSRKELG LGIDLLLTSM EAVNKKARVV KNEARFLLIA IQMTAEARF
181 RYIQNLVIK N FPNKFNSenk VIQFEVNWKK ISTAIYGDak NGVFNKDYDF GFGKVRQVKD
241 LQMGLLMYLG KPK

35/36

FIG. 14G

VTSITL DLVN PTAGQYSSFV DKIRNNVKDP NLKYGGTDIA VIGPPSK(E/D)KF LRINFQSSRG
TVSLGLKRDN LYVVAYLAND NTNVRAYYF (R/K)SEITSAE(S/L)T ALFPEATAN
QKALEYTEDY QSIEKNAQIT QGD(Q/K)SRKELG LGIDLL(S/L)T(S/F)M EAVNKKARVV
K(D/N)EARFLLIA IQMTAE(A/V)ARF RYIQNLV(I/T)KN FPNKF(N/D)S(E/D)NK
VIQPEV(N/S)W(K/R)K ISTAIYGDAL NGVFNKDYDF GFGKVRQVKD LQMGLLMYLG
KPKSSNEANS TVRHYGPLKP TLLIT

36/36

FIG.15

Sequence	
Anti-mouse serum albumin	
A	QVQLQESGGGLVQPGGSLPLSCEASGFTFSRFGMTWVRQAPGKGVVEWV SGISSLGDSSTLYADSVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYC TIGGSLNPGGQGTQVTVSS
B	QVQLQESGGGLVQPGNSLRLSCAASGFTFRNFGMSWVRQAPGKEPEWV SSISGSGENTIIYADSVKDRFTISRDNASTLYLQMNSLKPEDTAVYYC TIGGSLSRSSQGTQVTVSS
C	QVQLQESGGGLVQPGGSLRLTCTASGFTFSFGMSWVRQAPGKGLEWV SAISSDSGTSKNYADSVKGRFTISRDNAKMLFLQMNSLRPEDTAVYYC VIGRGSPSSQGTQVTVSS
D	QVQLQESGGGLVQPGGSLRLTCTASGFTFRSFGMSWVRQAPGKGLEWV SAISADGSDKRYADSVKGRFTISRDNKGKMLTLDMNSLKPEDTAVYYC VIGRGSPASQGTQVTVSS
E	AVQLVESGGGLVQAGDSLRLSCVVSGETTFSSAAMGWFRQAPGKEREFV GAIKWSGTSTYYTDSVKGRFTISRDNVKNVTYVLQMNMLKPEDTGVTYC AADRDYRDRMGPMTTTDFRFGQGTQVTVSS
F	QVKLEESGGGLVQTGGSLRLSCAASGRTFSSFAMGWFRQAPGREREFV ASIGSSGITTNADSVKGRFTISRDNAKNTVYLQMNSLKPEDTGLCYC AVNRYGIPYRSGTOYQNWQGTQVTVSS
G	EVQLEESGGGLVQPGGSLRLSCAASGLTFNDYAMGWYRQAPGKERDMV ATISIGGRTYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAIYYCV AHRQTVVRGPYLLWGQGTQVTVSS
H	QVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREFV AGSGRSNSYNYSDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYC AASTNLWPRDRNLAYWGQGTQVTVSS
I	EVQLVESGGGLVQAGDSLRLSCAASGRSLGIYRMGWFRQVPGKEREFV AAISWSGGTTRYLDSVKGRFTISRSTKNAVYLMNSLKPEDTAVYYC AVDSSGRLYWTLSTSYDYWGQGTQVTVSS
J	QVQLVEFGGGLVQAGDSLRLSCAASGRSLGIYKMAWFRQVPGKEREFV AAISWSGGTTRYIDSVKGRFTLSRDNTKNMVYLMNSLKPDDTAVYYC AVDSSGRLYWTLSTSYDYWGQGTQVTVSS
K	EVQLVESGGGLVQAGGSLRLSCAASGRTFSPYTMGWFRQAPGKEREFV AGVTWSGSSTFYGDSVKGRFTASRDSAKNTVTLEMNSLNPEDTAVYYC AAAYGGGLYRDPRESYDYWGRGTQVTVSS
L	AVQLVESGGGLVQAGGSLRLSCAASGFTLDAPWPIAWFRQAPGKEREGV SCIRDGTYYADSVKGRFTISSDNANNTVYLQTNLSLKPEDTAVYYCAA PSGPATGSSHTFGIYWNLRDDYDNWGQGTQVTVSS
M	EVQLVESGGGLVQAGGSLRLSCAASGFTFDHYTIGWFRQVPGKEREGV SCISSSDGSTYYADSVKGRFTISSDNANTVYLQMNTELPDDTAVYYC AAGGLLLRVEELQASDYDYWGQGIQVTVSS
N	AVQLVDSGGGLVQPGGSLRLSCTASGFTLDYYAIGWFRQAPGKEREGV ACISNSDGSSTYYGDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYC ATADRHYASASHPFADFANWGWQGTQVTVSS
O	EVQLVESGGGLVQAGGSLRLSCAAYGLTFWRAAMAFRRAPGKERELV VARINWGDGSTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYC AAVRTYGSATYDIWGQGTQVTVSS
P	EVQLVESGGGLVQDGGSLRLSCIFSGRTFANYAMGWFRQAPGKEREFV AAINRNGGTTNYADALGRFTISRDNKNTAFLOMNSLKPDDTAVYYC AAREWPFSTIPSGWRYWGQGTQVTVSS
Q	DVQLVESGGGWVQPGGSLRLSCAASGPTASSHAIGWFRQAPGKEREFV VGINRGGVTRDYADSVKGRFAVSRDNVKNVTYVLQMNRLKPEDSAIYIC AARPEYSFTAMSKGDMDYWGKGLTVTVSS